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Abbreviations
Aa amino acid NAT negative regulator of activated
AEV avian erythroblastosis virus transcription
AEL avian erythroleukemia NCoR nuclear receptor corepressor
AF-2 activation function-2 NF-k B nuclear factor-kappa B
AIB1 amplified in breast cancer 1 NR nuclear receptor
AP-1 activating protein-1 PAGE polyacrylamide gel
APL acute promyelocytic electrophoresis
leukemia P/CAF p300/CBP associating factor
CA II carbonic anhydrase II P/CIP p300/CBP interacting protein
CBP CREB binding protein PIC pol II transcription
CEF chicken embryonic preinitiation complex
fibroblasts PKA protein kinase A
CREB cyclic AMP element binding PLZF promyelocytic leukemia zinc
protein finger
GRIP-1 glucocorticoid recptor PML promyelocytic leukemia
interacting protein-1 Pol II RNA polymerase II
CRSP cofactor required for Sp1 PPAR peroxisome proliferator-
DBD DNA binding domain activator receptor
DR direct repeat PR progesterone receptor
DRIP VDR interacting proteins Pu purine
EGFR epidermal growth factor RA retinoic acid
receptor RAC3 receptor-associated
EKLF erythroid krüppel like factor coactivator
EMSA electrophoretic mobility shift RAR retinoic acid receptor
assay Rpd3 reduced phosphate
Epo erythropoietin dependency
ER estrogen receptor RXR retinoid X receptor
GR glucocorticoid receptor SCF stem cell factor
HAT histone acetyltransferase Sin3 Swi5p independent
HDAC histone deacetylase SMCC SRB/MED-containing
HRE hormone responsive element cofactor complex
HS DNase I hypersensitive site SMRT silencing mediator for retinoic
HSC hematopoietic stem cell acid and thyroid receptors
LBD ligand binding domain SRC-1 steroid receptor coactivator 1
LCR locus control region STAT signal transducer and
MAP kinase microtubule associated activator of transcription
protein T3 3,3’,5-triiodo-L-thyronine
MEL mouse erythroleukemia cells TAF TBP associated factor
MoMLV molony murine leukemia TBP TATA-box binding protein
virus td-359 transformation deficient 359
TFIIB transcription factor for pol II,
B
TGF transforming growth factor
TIF2 transcriptional intermediary
factor
TPA 12-O-tetradecanoylphorbol
13-acetate
TR thyroid receptor
TRAM-1 thyroid hormone receptor
activator molecule
TRAP thyroid receptor
associating proteins
TRE thyroid responsive element
TSA trichostatin A
TSH thyroid stimulating
hormone
VDR vitamin D3 receptor
VRE v-ErbA responsive
element
Chapter 1
Introduction
12 Chapter 1
Introduction
1. Nuclear hormone receptors in disease
2. Hematopoiesis and leukemia
3. Factors involved in hematopoiesis
3.1. Extracellular signals
3.2. Transcription factors
3.3. Translocation products and mutated nuclear receptors in leukemia
4. Nuclear hormone receptors (NR)
4.1 Classification of nuclear hormone receptors
4.2. General structure of Class II nuclear receptors
4.2.1 The DNA binding domain (DBD)
4.2.2 The ligand binding domain (LBD)
4.2.2.1. Dimerisation of nuclear receptors
4.2.3. The N-terminal part of nuclear receptors
4.3. Transcriptional regulation by NRs - Many actors on performance
4.3.1. Coactivators
4.3.2 Corepressors
4.3.3. Determinants of coactivator and corepressor binding
4.3.4. Transcription and chromatin structure
5. Why v-ErbA ?
6. Avian Erythroblastosis Virus (AEV)
7. The v-ErbA protein
7.1. Structure of the protein
7.2. Dimerization of v-ErbA and DNA binding properties
7.3. Phosphorylation
7.4. Binding of v-ErbA to cofactors
7.5. Models for v-ErbA-mediated transcriptional regulation
7.5.1. Binding site occlusion model
7.5.2. Sequestration of auxiliary factors required for TR/RAR activation 
function
7.5.3 Squelching of cofactors
7.5.4. HRE-independent model: The AP-1 case
7.5.5. Constitutive corepressors binding
8. Outline of this thesis
Chapiter 1
Chapter 1 13
1. Nuclear hormone receptors in disease
Nuclear hormone receptors (NRs) are transcriptions factors that play a major 
role in homeostasis, development and differentiation. Not surprisingly, malfunctioning 
forms of nuclear receptors underlie neoplasias as well as a variety of endocrine 
diseases. Generalised thyroid hormone resistance syndrome (TRS) and vitamin D- 
resistant rickets type II are caused by mutated nuclear hormone receptors (Hughes et 
al., 1988; Nagaya et al., 1992). Several types of breast and prostate cancer are 
associated with mutated nuclear receptors (Suzuki et al., 1996; Tilley et al., 1995) 
(reviewed in Tenbaum and Baniahmad, 1997). A glucocorticoid receptor (GR) mutant 
was detected in patients with Cushing syndrome (reviewed in Malchoff et al., 1993). 
Malignancies of the hematopoietic tissue, such as human acute promyelocytic 
leukemias (APL) or avian erythroleukemia (AEL) are also correlated with 
translocation products or heavily mutated, malfunctioning NRs (Kakizuka et al., 1991) 
(reviewed in He et al., 1999; Stunnenberg et al., 1999). The majority of the mutant 
receptors causing these diseases affect the balance between proliferation and 
differentiation of cells by interfering with the action of the normal receptor 
counterparts. However, the exact molecular mechanisms are not yet understood. The 
best studied leukemia is the avian erythroleukemia, which provides an excellent model 
system to unravel the molecular bases and the etiology of hematopoietic malignancies. 
A better understanding of the function(s) of v-ErbA, a causative agent of AEL, may 
lead to important findings that can be applied to other mutated transcription factors 
responsible for a variety of clinical situations.
INTRODUCTION
2. Hematopoiesis and leukemia
In vertebrates, hematopoiesis or blood formation occurs in distinct phases and 
anatomic sites during development. The origin of blood is the hematopoietic stem cell 
(HSC) defined as a cell competent to sustain long term hematopoiesis in a recipient 
individual (Figure 1). In mammals and avians the HSC is located in the blood islands
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of the yolk sac (reviewed in Orkin, 1996; Shivdasani and Orkin, 1996). Hematopoiesis 
occurs in two major steps: the primitive or embryonic and the definitive. Primitive 
hematopoiesis is a transient wave of cells emerging from mesoderm of the yolk sac. 
Definitive hematopoiesis is initiated in the aorta-gonad-mesonephros (AGM) region 
and the fetal liver, and after birth, it occurs in the bone marrow where stem cells are 
produced (Medvinsky and Dzierzak, 1996; de Bruijn et al., 2000). The cells arising 
from HSC, called pluripotent stem cells, are critical for the production of all 
hematopoietic cells in vertebrates. Their unique feature is their ability to self-renew i.e. 
they have the capacity to proliferate for many generations without entering a 
differentiation pathway. More importantly, the pluripotent stem cells are able to keep a 
delicate balance between proliferation and differentiation; they maintain their 
population as well as generate appropriate numbers of more mature cells that will 
differentiate into various lineages to generate erythrocytes, myeloid cells or 
lymphocytes. The arising so-called multipotent cells retain the ability to proliferate, 
but their differentiation spectra become gradually restricted, leading to the 
development of committed progenitors. Committed progenitors have only limited self­
renewal capacity and ultimately differentiate into mature cells of the various 
hematopoietic lineages (reviewed in Beug et al., 1996; Keller, 1992; Orkin, 1996) 
(Figure 1).
Leukemia is manifested by disturbance of the delicate balance between 
proliferation and differentiation. In leukemia, differentiation of stem cells is limited 
and cells proliferate aberrantly. Interestingly, several studies have shown that this 
misbalance can occur in all cell stages i.e. in pluripotent, multipotent and committed 
hematopoietic progenitors. All these cells, and in particular the committed progenitors, 
differentiate during their proliferation. Conceivably, it is thought that leukemia- 
associated mutated proteins function in such a way that they promote the ability of the 
progenitors to divide without further progress along the differentiation pathway 
(reviewed in Beug et al., 1996).
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Figure 1 Schema depicting the stages where selected transcription factors exhibit essential 
functions in erythroid differentiation of the hematopoietic stem cell (HSC). Positioning is 
based on the earliest block in differentiation resulting from absence of the designated factor. 
Only factors with a demonstrated role in hematopoietic development (as suggested by 
interference with cell-specific differentiation in knockout mice) are included. Adapted from 
(Shivdasani and Orkin, 1996).
3. Factors involved in hematopoiesis
3.1. Extracellular signals
The fate of a given cell depends on the signals that it receives as well as on its 
unique response to those signals. A number of polypeptide growth and differentiation 
factors transfer the extracellular signal into the cell and ultimately regulate the activity 
of several transcription factors. Factors specific for the hematopoietic tissue include 
erythropoietin (Epo), transforming growth factors (TGFa and TGFß), stem cell factor 
(SCF) and interleukines (ILs). These factors transmit their signal via binding to their 
cognate cellular receptors, which are mainly tyrosine kinases and interleukin receptors.
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In the absence of Epo receptor, lineage commitment of erythroid progenitors occurs 
but terminal differentiation into definitive erythrocytes is not attained because the cells 
undergo apoptosis (Lin et al., 1996). SCF, the ligand of c-Kit, regulates early 
hematopoiesis and provides short-term self-renewal capacity. SCF in collaboration 
with TGFa (the ligand for the tyrosine kinase receptor c-ErbB-1) can significantly 
prolong the self-renewal potential of erythroid progenitors even in the absence of Epo 
(Hayman et al., 1993). The signal of both tyrosine kinases and interleukin receptors is 
mediated through multiple pathways that include Ras, MAP kinase and Jak/Stat 
pathways. Receptor signalling culminates in the modification of transcription factors 
leading to activation or repression of key target genes (Beug et al., 1996). 
Consequently, ectopic expression of cytokines or constitutive activation of their 
receptors disturb the regulation of certain genes and are often implicated in leukemias 
( Li et al., 1990; reviewed in McCubrey et al., 2000; Touw et al., 2000).
3.2. Transcription factors
Ensuing research on the mechanisms governing differentiation of hematopoiteic 
cells revealed a number of widely-expressed as well as cell-specific transcription 
factors. In the following section I will mainly focus on transcription factors that play a 
critical role in the differentiation of the HSC into erythrocytes (Figure 1).
Tal-1/SCL, a basic helix-loop-helix (bHLH) transcription factor, has been 
identified in translocation products in human acute T-cell leukemias. Tal-1/SCL is 
detected among early hematopoietic progenitors. Tal-1/SCL expression in Xenopus  
embryos precedes that of any other known hematopoietic-specific gene in the earliest 
sites of blood formation. It has also been suggested that Tal-1/SCL plays a role in late 
erythroid differentiation (reviewed in Shivdasani and Orkin, 1996). Like Tal-1/SCL, 
the Lim-domain nuclear protein rbtn2/Ttg2/LMO2 is critical for the early stages of 
differentiation of the hematopoietic tissue. The rbtn2/Ttg2/LMO2 protein is 
misregulated in human T-cell acute leukemia. The rbtn2/Ttg2/LMO2 and Tal-1/SCL 
knockout phenotypes are similar and mice die from anemia due to lack of erythrocytes 
(Warren et al., 1994). The zinc-finger protein GATA-1 is a central regulator of 
erythroid-specific gene expression and differentiation, and binds to a GATA DNA
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sequence. Within hematopoietic cells, expression of GATA-1 occurs in the erythroid, 
megakaryocyte, eosinophil, mast cell lineages and multipotent progenitors (Evans and 
Felsenfeld, 1989; Martin et al., 1990; Romeo et al., 1990). Erythroid precursors 
lacking GATA-1 show a maturation arrest at the proerythroblast stage suggesting a 
major role for GATA-1 in survival and terminal erythroid differentiation of these cells 
(Pevny et al., 1995; Weiss et al., 1994). GATA-1 negative embryonic stem (ES) cells 
fail to contribute to mature red blood cells, but are fully able to develop into other 
hematopoietic lineages or other tissues (Pevny et al., 1991). Moreover, differences in 
the intracellular levels of GATA-1 have been shown to be critical for lineage selection 
and commitment within the hematopoietic cells (reviewed in Shivdasani and Orkin,
1996). GATA-2, another member of the GATA-family is also critical in the 
development of hematopoietic cells. It is detected in erythroid and other hematopoietic 
progenitors but its expression decreases as GATA-1 expression increases with 
erythroid differentiation (Yamamoto et al., 1990). In chicken erythroid precursors, 
forced expression of GATA-2 but not GATA-1 or GATA-3 (another member of the 
GATA-family), promotes proliferation and blocks differentiation (Briegel et al., 
1993). An erythroid specific CACCC-binding protein designated erythroid Kruppel- 
like factor (EKLF) is expressed at all stages of erythropoiesis and is critical for the 
transcription of erythroid-expressed genes and particularly globins (Miller and Bieker, 
1993; Nuez et al., 1995; Perkins et al., 1995). The transcription factor PU.1 has been 
suggested to play a critical role in lineage commitment (reviewed in Shivdasani and 
Orkin, 1996). The c-myb gene is highly expressed in progenitor cells of myeloid, 
erythroid and lymphoid lineages and is downregulated during maturation 
/differentiation of these cells. The AML-1 gene is frequently deregulated in leukemias. 
Both c-myb- and AML-1-lacking mice display normal primitive hematopoiesis, 
whereas definitive hematopoiesis is severely impaired (reviewed in Blobel, 2000). 
Thus, several transcription mechanisms with competing or synergistic activities 
operate to ultimately define lineage selection and hematopoietic development.
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3.3. Translocation products and m utated nuclear receptors in leukemias
Of particular interest for this thesis are mutated nuclear receptors and 
chromosomal translocation products. Fusions of a wide variety of genes with markedly 
distinct functions are now known to be involved in leukemogenesis. For example, the 
fusion products of Bcr-Abl, Dek-Can, AML-1-ETO or MLL transclocated to a number 
of chromosomes are signal transducers, nucleoporins, transcription factors or putative 
chromatin regulators (Fornerod et al., 1995; Kabarowski et al., 1994; Miyoshi et al., 
1993; Ridge and Wiedemann, 1994). Among these translocation products, the retinoic 
acid receptor (RARa) coupled to other transcription factors yielding PML-RARa or 
PLZF-RARa block differentiation of hematopoietic progenitors. PML-RARa and 
PLZF-RARa are involved in nearly 80% of the human acute promyelocytic leukemias 
(APLs) (Alcalay et al., 1991; Borrow et al., 1990; Chen et al., 1993b; de The et al., 
1990a; Grignani et al., 1993; Kakizuka et al., 1991; Rousselot et al., 1994). Nuclear 
receptors carrying point mutations or deletions are also involved in malignant 
transformation of hematopoietic cells. Murine bone marrow cells expressing a 
dominant negative RARa lacking its ligand-dependent activation function-2 (AF-2) 
(see paragraph 4.2.2), are blocked at the stage of lymphohematopoietic progenitors 
(Tsai et al., 1994; Tsai and Collins, 1993). v-ErbA, a viral variant of thyroid hormone 
receptor TRa produced by the Avian Erythroblastosis Virus (AEV), is a paradigm of a 
mutated nuclear receptor implicated in avian erythroleukemia (Graf and Beug, 1983).
The studies described in this thesis are focused on the role of v-ErbA in 
transcriptional regulation. In order to get more insight into the function of v-ErbA it is 
a prerequisite to understand in detail the principles that govern the physiological 
functions of TRa, the cellular counterpart of v-ErbA, and nuclear receptors in general.
4. Nuclear hormone receptors (NRs)
In 1913 a scientific report appeared claiming that ‘certain lipids’ are essential 
for growth (McCollum and Davis, 1913; Osborne and Mendel, 1913). Since then, a 
large number of small lipophilic molecules, referred to as hormones, have been
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discovered to play an important role in cell differentiation, homeostasis, development 
and organ physiology. These hormones, including steroids, retinoids, thyroid 
hormones and vitamin D3, were shown to translocate to the nucleus to regulate 
transcription. A milestone in hormone research was the discovery that these lipophilic 
molecules bind to their cognate nuclear hormone receptors. Consequently, the 
receptors undergo a conformational change and bind with high affinity to specific sites 
in chromatin to regulate transcription (reviewed in Mangelsdorf et al., 1995).
4.1. Classification of nuclear hormone receptors
The cloning of the glucocorticoid receptor (GR) and the estrogen receptor (ER), 
and the realisation that they were highly related to the protein product of the v-ErbA 
oncogene suggested that these proteins belong to the same family of transcription 
factors dubbed nuclear receptors (NR) (Evans, 1988; Green et al., 1986; Hollenberg et 
al., 1985; Miesfeld et al., 1984; Weinberger et al., 1985). At present, this family has 
grown to greater than 200 members. For the purpose of this thesis I will follow the 
classification of NRs based on the dimerisation and the DNA binding properties as 
proposed by Stunnenberg (reviewed in Stunnenberg, 1993). Accordingly, NRs are 
classified in three different subfamilies (Figure 2A): Class I includes the classical 
steroid receptors such as GR, ER, progesterone receptor (PR), mineralocorticoid 
receptor (MR) and androgen receptor (AR). Class I NRs form ligand induced 
homodimers and bind to hexameric DNA motifs, called half-sites, arranged as 
palindromic repeats (Figure 2A, B). Class II NRs, including TR, RAR, vitamin D3 
receptor (VDR), ecdysone receptor (EcR) and peroxisome proliferator-activator 
receptor (PPAR) heterodimerise with retinoid X receptor (RXR), which is itself a 
member of class II. Unlike class I NRs, class II receptors predominantly recognise 
DNA half-site motifs arranged as direct repeats (Figure 2A, B). Class III comprises, 
amongst many others, ROR, chicken ovalbumin upstream promoter-transcription 
factor (COUP-TF) and Rev-Erb that bind to direct repeats as homodimers or as 
monomers to extended DNA half-sites. The Class III NRs are also arbitrarily referred 
to as orphan receptors because either they are not likely to have ligand or their ligand
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has not been identified yet (Figure 2) (reviewed in Stunnenberg, 1993; Mangelsdorf et 
al., 1995).
A  Class I
Steroid Receptors
Class I
RXR Heterodimers
TR a, ß 
RAR a, ß, y 
VDR
RXR a, ß, y 
LXR a, ß 
FXR
PPAR a, ß, 5 
PPAR Y
Class II
OR
COUP/ARP
HNF-4
TR2
NGFI-B 
ELP/SF1 
ROR a,ß
Orphan Receptors
GR
MR
PR
AR
ER
Palindromic repeat
Direct repeat
Everted repeat
Figure 2 (A) Classification of the nuclear hormone receptors (NRs). Depending on their 
dimerisation and DNA binding properties NRs can be grouped into three classes: the steroid 
hormone receptors (I), the RXR heterodimers (II) and the orphan receptors (III). 
Representative receptors of each group are listed. (B) Schematic representation of DNA 
binding sites for NRs with half-sites orientation.
B
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Binding site Type Receptor
GGTTc A>NNN GGTTCA
g g g t c a > n n n n  a g g t c c
a g g a c a >|C N a g g t c a >
g g g t c a > n  g g t t c a >
a g g g c a|C A > n  a g g t c a >
a g t t c a > n n a g g t c a ;
GGTTc A>NNNNN AGTTc A >
DR 3
osteopontin
R X R -V D  R
DR 4
MoMLV
R X R -T  R
DR 1 R X R - P P A R
AcylCoA
DR 1
ApoAI
R X R - R X R
R A R - R X R
DR 1 R A R -R X  R
CRABP I
DR 2 R X R -R A  R
CRABP I
DR 5 R X R -R A  R
RAR ß2
Table 1 Class II nuclear receptors binding sites. Indicated are the promoters in which the 
binding sites are located and the receptor hetero-/homodimers that have been reported to bind 
and trans-activate through the respective binding sites. The binding sites are derived from the 
following promoters: the rat Cellular Retinoic Acid Binding Protein I (CRABP I) (Durand et 
al., 1992), Acyl CoA oxidase (Tugwood et al., 1992), Osteopontin (Noda et al., 1990), 
Moloney Murine Leukemia Virus LTR (MoMLV) (Sap et al., 1990), RAR-ß2 (de The et al., 
1990), Apo AI (Zhang et al., 1992b). Nucleotides deviating from the consensus sequence 
AGG/TTCA are highlighted.
4.2. G eneral structure of Class II  nuclear receptors
NRs, commonly, have a tripartite structure. A highly conserved DNA binding 
domain (DBD) separates the variable N-terminal region from the conserved C- 
terminal domain (Figure 3). The features that have provided the criteria to classify 
members of the NR superfamily are the DBD, which recognises similar DNA 
sequences and the C-terminal, ligand binding domain (LBD). On the basis of intron- 
exon boundaries and structure-function similarities, NRs consist of six regions referred
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to as A to F (reviewed in Evans, 1988; Green and Chambon, 1988; Mangelsdorf and 
Evans, 1995). In the following I will describe the structure and function of the class II 
NRs.
A/B
A F -1
DNA b i n d i n  g
D i m é r i s a t i o n
n u c l e u s
H orm one b i n d i n
D i m e r i s a t i a n
A F -2
S i l e n c i i g
C D E F
CN
Figure 3 Schematic representation of a typical nuclear hormone receptor with its functional 
domains. NRs are composed of a highly conserved DNA binding domain (DBD) or C-region, 
a variable amino-terminus (A/B) region and a conserved carboxy-terminus (D, E and F 
region). The DBD is responsible for sequence specific binding to DNA responsive elements 
and harbours dimerisation as well as nuclear localisation functions. The N-terminus harbours 
trans-activation function-1 (AF-1). The C-terminus contains multiple hormone-dependent 
functions including hormone binding, trans-activation function-2 (AF-), silencing function, 
dimerisation and nuclear localisation properties. The black bars show the localisation of each 
receptor function.
4.2.1. The DNA binding domain (DBD)
The central DNA binding domain (DBD) is the most conserved part between 
NRs and it targets the receptor to specific DNA sequences known as hormone 
responsive elements (HREs) (reviewed in Evans, 1988; Mangelsdorf and Evans, 1995; 
Mangelsdorf et al., 1995). The observation that class I NRs bind as homodimers to 
DNA half-site sequences arranged as palindromes invariably spaced by three 
nucleotides (Beato, 1989) was initially extrapolated to the class II NRs. However,
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subsequent studies revealed that the class II receptors recognise the same hexameric
A TDNA core-motif 5’- /gG /gTCA-3’, referred to as half-site, mostly arranged in a direct 
repeat configuration (Brent et al., 1989; de The et al., 1990b). Specificity in DNA 
binding of a class II receptor is achieved by varying the spacing between the half-sites 
(Table 1): Direct repeats spaced by 1 nucleotide (DR1) constitute binding sites for 
PPAR, DR3 is a binding site for the VDR and DR4 constitutes a thyroid hormone 
responsive element (TRE). The binding sites for RAR-RXR are directs repeats spaced 
by 1, 2 or 5 nucleotides (DR1, DR2 and DR5, respectively). Since DRs are 
asymmetric elements, heterodimer complexes are asymmetric units and the receptors 
DBDs are arranged in a head to tail fashion. On DR3, DR4, DR2 and DR5 elements, 
RXR occupies the 5’ half-site and the partner (VDR, TR and RAR respectively) 
occupies the 3’ half-site (Jin and Pike, 1996; Kurokawa et al., 1993; Mader et al., 
1993; Naar et al., 1991; Umesono et al., 1991; Vivanco Ruiz et al., 1991) (reviewed in 
Desvergne, 1994; Mangelsdorf and Evans, 1995). RXR can bind both as homodimer 
and as heterodimer with RAR on a DR1, but in contrast to its position on a DR2 and 
DR5, RXR occupies the downstream half-site (Kurokawa et al., 1995) (reviewed in 
(Leblanc and Stunnenberg, 1995).
Apart from the above-mentioned ‘classical’ HREs, other arrangements of the 
hexameric half-sites have been identified to constitute functional HREs for class II 
NRs, such as palindromic (PAL) or everted repeats-like elements (Figure 2B). It 
should be emphasised that many natural HREs deviate from the idealised consensus 
sequences (reviewed in Mangelsdorf and Evans, 1995).
The constraints for binding to a specifically spaced and/or oriented responsive 
element are dictated by the DBD (Mader et al., 1993; Perlmann et al., 1993). The 
DBD of NRs contains two highly conserved zinc-fingers with four cysteine residues 
co-ordinating the binding of one Zn2+-ion (Figure 4A). The first amino-terminal or 
proximal zinc-finger recognises specific bases of the half-sites. The C-terminal part of 
the first zinc-finger comprises helix 1 (C1). A part of the helix motif C1, designated P- 
box, makes direct contacts with the major groove of DNA (Figure 4A, B) (reviewed in 
Freedman and Luisi, 1993; Nelson et al., 1996; Nelson et al., 1995a).
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Figure 4 The DNA binding domain of hTRß. (A) Schematic diagram of TRß DNA 
binding domain (DBD). a-helices are boxed, the P-box amino acids are circled, amino acids 
involved in protein-DNA contacts are enclosed in shaded circles or squares, amino acids 
involved in specific protein interaction with RXR are enclosed in striped squares and amino 
acids contacting the sugar-phosphate backbone of the DNA are indicated with asterisks 
(Nelson et al., 1996). (B) Cocrystal structure of the DBDs of TRß and RXR on DNA. Helix 
C1 is perpendicular to C2 and contacts the major groove of DNA. D-box sequences are 
involved in dimerisation. TRß is sitting 5' to RXR (PDB Id: 2NLL; F.Rastinejad, T.Perlmann, 
R.M.Evans & P.B.Sigler; PDB Deposition: 20-Nov-1996).
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The P-box is defined by the five amino acids EGCKG and is conserved in all 
members of the class II receptors family. A short amino acid sequence located at the 
N-terminus of the second or distal zinc-finger was originally shown to be involved in 
protein-protein interactions of the steroid, class I NRs, hence termed dimerisation-box 
(D-box) (Figure 4A) (Umesono and Evans, 1989). However, for the class II NR 
heterodimers, the various spacing between the half-sites dictates that different parts of 
the proteins face each other to form the dimer interface (Perlmann et al., 1993; 
Rastinejad et al., 2000; Zechel et al., 1994a; Zechel et al., 1994b). The last four amino 
acids of the distal finger together with the eight downstream residues constitute helix 2 
(C2) (Figure 4A). The helices C1 and C2 are oriented nearly perpendicularly and form 
the core of the DBD. (Figure 4B). The T/A box which is a helix downstream of the C2 
contacts the minor groove (Luisi et al., 1991; Rastinejad et al., 1995; Schwabe et al., 
1993) (reviewed in Mangelsdorf and Evans, 1995; Rascle et al., 1997). In addition to 
the DBD, amino acids in the N- and C-termini of the receptors are also required for 
efficient DNA binding (Chen et al., 1993a; Judelson and Privalsky, 1996; Lee et al., 
1993; Rastinejad et al., 1995; Wong and Privalsky, 1995).
4.2.2. The ligand binding dom ain (LBD)
The C-terminus of NRs, also referred to as E region, is essential and sufficient 
for hormone binding and hence is called the ligand binding domain (LBD). The LBD 
is also important for dimerisation, interaction with coactivators and corepressors, and 
integrates trans-activation  function (AF-2), trans-repression and nuclear translocation 
properties (Figure 3) (Baniahmad et al., 1992; Barettino et al., 1994; Dang and Lee, 
1989; Forman et al., 1989; Glass et al., 1989; Hamy et al., 1992; Marks et al., 1992) 
(reviewed in Thormeyer and Baniahmad, 1999).
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human apo-RXRa human RARf p lus 9 -c /s  RA
Figure 5 Crystal structure of nuclear receptor ligand binding domains. (A) The LBD of the 
human apo-RXRa (PDB Id: 1LBD; W.Bourguet & D.Moras; PDB Deposition: 22-May- 
1996). (B) Human RARy liganded with 9-cis retinoid acid (PDB Id: 3LBD; B.P.Klaholz, J.- 
P.Renaud, A.Mitschler & D.Moras; PDB Deposition: 4-Feb-1998). Note the different position 
of helix 12 in each situation.
Determination of the 3D structure of a number of NRs (RXRa, TRa, RAR, ER, 
PR and PPARy) revealed that they share a similar overall fold (Bourguet et al., 1995; 
Brzozowski et al., 1997; Egea et al., 2000; Nolte et al., 1998; Renaud et al., 1995; 
Shiau et al., 1998; Tanenbaum et al., 1998; Uppenberg et al., 1998; Wagner et al., 
1995; Williams and Sigler, 1998). The structure is termed the antiparallel a-helical 
sandwich and consists of 11 or 12 successive helices grouped into three layers (Figure 
5) (reviewed in Mangelsdorf and Evans, 1995). The central layer comprises helices 
H4, H5, H8 and H9 which are sandwiched by H6, H7, H10 and H11 on one side and 
by H1-H3 on the other (numbering of helices according to (Bourguet et al., 1995). The 
structure generates a pocket in which the ligand is buried and the last helix, comprising
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the AF-2 domain, acts as the lid of the pocket. In the unliganded apo-RXR, H12 
protrudes outwards from the core of the LBD (Figure 5A) (Bourguet et al., 1995), 
whereas in the agonist-bound LBD of RAR, TR, PR ER and PPAR H12 is folded back 
(Figure 5B). Modulation of the architecture of the LBD triggered by binding of the 
ligand have major implications in activation functions of NRs (Baniahmad et al., 
1995; Bocquel et al., 1989; Hollenberg and Evans, 1988; Tasset et al., 1990; reviewed 
in Evans, 1988; Tenbaum and Baniahmad, 1997).
4 .2 .2 .I .  Dimerisation of nuclear receptors
Class I NRs bind to their DNA responsive elements exclusively as homodimers. 
Although class II NRs are also known to bind as homodimers, they mainly form 
heterodimers with RXR on their cognate DNA elements (reviewed in Beato et a l ., 
1995; Mangelsdorf and Evans, 1995). Heterodimerisation of TR was first suggested 
from experiments showing that binding of TR to thyroid responsive elements (TREs) 
required the presence of a partner found in cell extracts (Forman et al., 1992; Lazar et 
al., 1991; Yen et al., 1992). Subsequently, RXR was shown to be the partner not only 
of TR but also of RAR and VDR. Heterodimerisation with RXR not only strongly 
enhances the DNA binding affinity of RAR, TR and VDR but it also modulates their 
trans-activation function (Bugge et al., 1992; Cheskis and Freedman, 1994; 
Hallenbeck et al., 1992; Jin and Pike, 1996; Kliewer et al., 1992; Yu et al., 1991; 
Zhang et al., 1992a). TR binds with highest affinity as heterodimer with RXR to direct 
repeats, while on everted and palindromic repeats TR preferentially binds as 
homodimer (Andersson et al., 1992; Harbers et al., 1996; Harbers et al., 1998; Katz 
and Koenig, 1993; Kurokawa et al., 1993; Wahlstrom et al., 1992).
4.2.3. The N-term inal p a rt of nuclear receptors
The N-terminal or A/B domain is evolutionary the least conserved part, mostly 
varying in length and sequence composition amongst the receptors. An ill-defined, but 
strong trans-activation function (AF-1) is localised in the N-terminus of most 
receptors; the AF-1 is hormone-independent (Figure 3). Frequently, AF-1 is cell type- 
and promoter-specific such as that of RXRy that was shown to be active in a muscle- 
specific manner (Bocquel et al., 1989; Dowhan and Muscat, 1996; Hollenberg and
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Evans, 1988; Tasset et al., 1990) (reviewed in Stunnenberg, 1993; Mangelsdorf and 
Evans, 1995; Rascle et al., 1997; Stunnenberg et al., 1999).
4.3. T ranscriptional regulation by NRs - M any actors on perform ance
NRs were thought to be the major players of transcriptional regulation because 
a number of HREs are found in promoters, enhancers and locus control regions 
(LCRs), i.e in regulatory regions of several genes. Originally, it was proposed that 
class II NRs only functioned as activators in the presence of their cognate hormone 
and that they were neutral in its absence. However, more recent data support a model 
that unliganded class II NRs repress transcription (reviewed in Mangelsdorf and 
Evans, 1995; Glass and Rosenfeld, 2000).
The transcriptional activity of NRs has been shown to be dependent on their 
association with TBP (TATA-box binding protein) and TFIIB (transcription factor 
IIB) (Blanco et al., 1995; Chen and Privalsky, 1997; Hadzic et al., 1995; Tong et al., 
1995). NRs also interact with a number of co-factors that serve as mediators or signal 
integrators to polymerase II (pol II) basal transcriptional machinery. The co-factors 
belong to two classes and are associated with NRs in a ligand-dependent manner. The 
first class comprises the coactivators, which interact mainly with the AF-2 domain of 
liganded NRs and are shown to enhance the ligand-mediated transcriptional activation 
(Masuyama et al., 1997) (Nolte et al., 1998) (Westin et al., 1998) (Blanco et al., 1998) 
(Feng et al., 1998) (Ren et al., 2000) (Rachez et al., 2000). The second class of 
cofactors comprises the so-called corepressors, which are associated with NRs only in 
the absence of ligand and they are postulated to enhance the ability of receptors to 
repress transcription. Thus, class II NRs act as ‘on-off5 switches of transcription. In the 
absence of ligand they bind to DNA and repress transcription while upon ligand 
binding they change conformation and activate transcription (reviewed in Glass and 
Rosenfeld, 2000).
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Figure 6 Structural features of nuclear receptor coactivators and corepressors. Conserved 
motifs or regions important for enzymatic activity are in bold text. Factors known to interact 
with these proteins are shown in plain text. Homology is represented as identity. (A) The 
structure of p300 versus CBP; AB, acidic basic; HAT, histone acetyltransferase activity; 
QQQ, glutamine rich; C/H, cysteine rich; Bromo, bromodomain. (B) SMRT versus SMRTe 
(SMRT extended) and NCoR. RD, repression domain; NR, nuclear receptor interacting 
domain; SG, serine/glycine rich; H, a-helical (adapted from Collingwood et al., 1999).
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4.3.1. Coactivators
The first coactivator identified to interact with NRs in a ligand-dependent 
manner was SRC-1 (Cavailles et al., 1994; DiRenzo et al., 1997; Halachmi et al., 
1994; Onate et al., 1995). Subsequent studies led to the identification of three genes 
that encode SRC-1-related factors, TIF2/GRIP-2/NCoA-1 and p/CIP/AIB- 
1/ACTR/RAC/TRAM-1 (Anzick et al., 1997; Chen et al., 1997; Hong et al., 1997; 
Kamei et al., 1996; Li et al., 1997a; Takeshita et al., 1997; Torchia et al., 1997). The 
SRC family of coactivators contain a highly conserved N-terminal basic helix-loop- 
helix (bHLH) domain that mediates protein-protein interactions. The C-termini of 
SRC-1 and ACTR possess histone acetyltransferase (HAT) activity (Spencer et al.,
1997). Ligand-mediated transactivation of RAR, PPAR, TR and VDR has been 
proposed to be critically dependent on their interaction with SRC-1 (Kurokawa et al., 
1998; Llopis et al., 2000; reviewed in Glass and Rosenfeld, 2000).
p300/CBP (CREB-binding protein) belong to the NR coactivators with HAT 
activity (Korzus et al., 1998). p300/CBP directly bind to the LBD of NRs in the 
presence of ligand and serve essential coactivator roles not only for NRs but also for 
many other classes of sequence specific transcription factors (Figure 6A) (Kamei et 
al., 1996; Torchia et al., 1997; reviewed in Glass and Rosenfeld, 2000). Substrates for 
acetylation by p300/CBP are not only free histones or histones assembled into 
nucleosomal complexes but also non-histone proteins such as p53, GATA-1 and 
EKLF (Boyes et al., 1998; Ogryzko et al., 1996; Zhang and Bieker, 1998). 
Hyperacetylation of histones facilitates transcription factor access and hence boosts 
transcription (reviewed in Collingwood et al., 1999).
Another coactivator displaying HAT activity is p/CAF (p300/CBP-associating 
factor) (Yang et al., 1996). It has been shown that p/CAF directly associates with 
RXR-RAR heterodimer and potentiates ligand-dependent transcriptional activation 
(Blanco et al., 1998). p/CAF is an essential component of the multisubunit coactivator 
complex, referred to as PCAF in mammals (Ogryzko et al., 1998).
A complex of at least nine proteins has been found to be associated with 
liganded TR termed TRAP (TR-associating proteins) (Fondell et al., 1996b). A very 
similar complex of vitamin D3 receptor (VDR)-interacting proteins (DRIP) has also 
been purified (Rachez et al., 1998). Surprisingly, several constituents of the
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TRAP/DRIP and the highly related ARC (activator recruited cofactor) complex are 
very similar to protein components of the recently identified CRSP, NAT and SMCC 
mediator complexes (Ito et al., 1999; reviewed in Hampsey and Reinberg, 1999; Malik 
and Roeder, 2000). These complexes, which were isolated independently, are 
reportedly required for in vitro  transcriptional activation from chromatin templates by 
a number of other transcription factors including SREBP, NF-kB and VP16 (Gu et al., 
1999; Ito et al., 1999; Naar et al., 1999; Ryu et al., 1999; Sun et al., 1998). Purified 
DRIP enhances ligand-dependent transcriptional activation of VDR in a chromatinised 
template (Rachez et al., 1999). Purified TRAP enhances in vitro  transcriptional 
activation of TR in a chromatin-free system while the effects on chromatinised 
templates are not yet reported (Fondell et al., 1999). Interestingly, TRAP/DRIP/ARC 
complex do not contain intrinsic HAT activity (Rachez et al., 1999; Yuan et al., 1998), 
which raises the question whether the various NR coactivators function at different 
stages of the gene-activation process.
4.3.2. Corepressors
v-ErbA was the first NR shown to repress transcription (Damm et al., 1989), 
and subsequently repressive function was confirmed for most unliganded class II 
receptors. A search for proteins interacting with unliganded receptors led to the 
identification of the corepressor molecules NCoR (NR corepressor) (Horlein et al., 
1995; Kurokawa et al., 1995) and the highly related SMRT (silencing mediator for 
retinoic acid and thyroid hormone receptors) (Chen and Evans, 1995) or TRAC-2 (TR 
associated cofactor) (Sande and Privalsky, 1996). While NCoR is a 270 kDa protein 
(Horlein et al., 1995) SMRT was initially reported to be a 170 kDa protein with high 
homology to the C-terminus of the NCoR sequence (Figure 6B) (Chen and Evans,
1995). Recently, SMRT variants of 270 kDa originating from alternative splicing have 
been cloned (SMRTe) with high overall homology to NCoR (Ordentlich et al., 1999; 
Park et al., 1999). Both NCoR and SMRT show a conserved bipartite structure: their 
N-termini contain at least three autonomous repressor domains (Chen and Evans, 
1995; Horlein et al., 1995). Their C-termini contain two distinct receptor interaction 
domains (RID) (Li et al., 1997b; Seol et al., 1996; Zamir et al., 1996) (Figure 6B). 
Corepressors are shown to potentiate the repressive function of receptors and to posses
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intrinsic function to repress transcription that is transferable to heterologous DNA- 
binding domains. It should be emphasised that corepressors interact only with 
unliganded NRs and they dissociate upon ligand binding (reviewed in Hu and Lazar, 
2000).
Besides binding to NRs, NCoR also interacts with the general transcription 
factor TFIIB and the TBP associated factors TAFn32 and TAFn70. Association of 
NCoR with TFIIB has been postulated to result in repression of transcription by 
preventing the productive interaction between TFIIB and TAFn32 (Muscat et al.,
1998). NCoR/SMRT also interact with and serve as corepressors for a number of 
transcription factors unrelated to NRs such as MyoD, a myogenic factor, Mad, a helix- 
loop-helix (HLH) repressor molecule and CBF-1/RBP-JK, a mammalian homologue 
of the drosophila protein suppressor o f  hairless. Thus, NCoR/SMRT may play a more 
general role in gene regulation than only facilitating the repressive function of NRs 
(Bailey et al., 1999; Heinzel et al., 1997; Kao et al., 1998; reviewed in Glass and 
Rosenfeld, 2000).
Further insight into the mechanisms of repression by NRs was obtained by the 
discovery that SIN3A and SIN3B, the mammalian homologues of yeast Sin3, interact 
with NCoR and SMRT (Alland et al., 1997; Ayer et al., 1995; Heinzel et al., 1997; 
Nagy et al., 1997; Schreiber-Agus et al., 1995). SIN3A/3B proteins are components of 
corepressor complexes that contain histone deacetylases (RPD3 in yeast and 
HDAC1/HDAC2 in higher eukaryotes) as well as a number of other proteins (Alland 
et al., 1997; Hassig et al., 1997; Heinzel et al., 1997; Kadosh and Struhl, 1997; 
Laherty et al., 1998; Laherty et al., 1997; Nagy et al., 1997; Taunton et al., 1996; 
Vidal et al., 1991; Zhang et al., 1997b). Deacetylation of histones renders chromatin 
structure in a repressive state, thereby limiting transcription factor accessibility. 
Recruitment of HDACs by NRs via corepressors appear to play a critical role in NR 
repressive functions (reviewed in Collingwood et al., 1999). More recently, distinct 
silencing domains of NCoR have been demonstrated to directly interact with HDAC3 
or members of the novel class II family of HDACs (HDAC4, HDAC5, HDAC7 and 
HDAC8) implying a redundant or combinatorial deacetylase-dependent repression 
(Grozinger et al., 1999; Hu et al., 2000; Huang et al., 2000; Kao et al., 2000; Wen et 
al., 2000). TBL (transducin beta-like protein 1) has very recently been shown to be a
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component of a SMRT/HDAC3 complex, and its expression potentiated repression by 
TRß. Mutations in TBL or TRß have been found in patients suffering from deafness, 
thus linking defective repressive function of TRß to deafness (Guenther et al., 2000).
Two other nuclear receptor corepressors are Alien and Sun-CoR. Alien is a 41 
kDa protein and although not related to NCoR/SMRT it might utilise a repression 
mechanism similar to that of NCoR/SMRT (Dressel et al., 1999). Sun-CoR is 16 kDa 
in size and might be specific for RevErb. Notably, Sun-CoR interacts with 
NCoR/SMRT (Zamir et al., 1997; Zamir et al., 1996).
4.3.3. Determ inants of coactivator and corepressor binding
In the last few years it has become clear that ligand binding is the driving force 
for changes in conformation of class II NRs and subsequently for cofactor association 
(reviewed in Glass and Rosenfeld, 2000). Crystal structure studies showed that upon 
ligand binding a conformational change of the AF-2 domain results in the formation of 
a surface suitable for interaction with coactivators. A short a-helical motif LXXLL 
present in many coactivators docks to a hydrophobic cleft on the surface of the LBD 
that is bounded on one side by the AF-2 in helix H12 and on the other by the end of 
helix H3 (Brzozowski et al., 1997; Darimont et al., 1998; Nolte et al., 1998; Renaud et 
al., 1995; Shiau et al., 1998; Wagner et al., 1995).
The interaction interface of NRs for corepressors NCoR/SMRT has been 
controversial. Originally, helix H1 of the LBD was thought to provide the interface for 
interaction with corepressors (Figure 8). Mutations in a small region within H1, 
termed the CoR-box, affected the interaction with NCoR/SMRT (Chen and Evans, 
1995; Horlein et al., 1995; reviewed in Hu and Lazar, 2000). However, CoR-box 
mutations also prevent interactions with RXR suggesting that the CoR-box might not 
directly interact with corepressors but rather serve a more global structural role 
(Collingwood et al., 1997; Zhang et al., 1997a; reviewed in Hu and Lazar, 2000). 
There is evidence that H12, plays a major role in corepressor recruitment; yet, ongoing 
studies also implicate helices H3, H4 and H5 in the corepressor interaction interface 
(Figure 8) (Baniahmad et al., 1995; Hu and Lazar, 1999; Li et al., 1997b; Lin et al., 
1997; Tagami et al., 1998; Zhang et al., 1999; Zhang et al., 1997a).
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Recently, a conserved LXXI/HIXXXI/L sequence has been discovered within the 
receptor interaction domain (RIDs) of the corepressors (Hu and Lazar, 1999; Nagy et 
al., 1999; Perissi et al., 1999). This LXXVhIXXXVl  motif forms an extended helix and 
is referred to as the CoRNR box. The CoRNR box has been reported to bind to a 
hydrophobic pocket formed by the LBD of NRs. In the liganded state H12 changes 
position and the same hydrophobic pocket, is now occupied by the coactivator helical 
motif LXXLL (Hu and Lazar, 1999; Nagy et al., 1999; Perissi et al., 1999). Since the 
ligand-activated pocket has exactly the length of the coactivator helix, closure upon 
ligand binding would inhibit the binding of the extended corepressor helix. It is 
suggested that the opening/closure of H12 might represent the molecular mechanism 
for ligand-dependent displacement of the corepressor complex (reviewed in Glass and 
Rosenfeld, 2000).
4.3.4. Transcription and chrom atin structure
The repeating unit of eukaryotic chromosomes is the nucleosome consisting of 
DNA wrapped around an octamer of histone proteins. Nucleosomes were initially 
thought to be merely compact and featureless inducers of DNA bending. Recent 
observations suggest that nucleosomal structure is dynamically/enzymatically 
regulated, thus playing an important role in transcriptional activation or repression. 
Indeed, eukaryotic transcription is an interlaced network of transcription factors, 
chromatin and chromatin-modifying complexes (Figure 7) (reviewed in Felsenfeld, 
1992; Kadonaga, 1998; Kingston et al., 1996).
The nucleosomal structure is important for the transcriptional regulation by 
NRs because a number of NR cofactors exhibit chromatin-modifying activity. The 
current view is that class II NRs regulate transcription by exerting either repressive or 
activation function to the polymerase II basal transcriptional machinery. Repression by 
NRs is attained in two ways. First, corepressors bound to NRs actively inhibit the 
formation and activity of the Pol II transcription preinitiation complex (PIC). This 
notion is consistent with findings showing that NCoR inhibits the productive 
interaction between general transcription factors and TFIIB (Fondell et al., 1996a; 
Fondell et al., 1993; Tong et al., 1995). Second, via association with HDACs,
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corepressors can render chromatin structure in a closed, repressive state and hence 
(positive) transcription factors accessibility is diminished.
Figure 7 Normal gene regulation controlled by class II nuclear receptors involves 
corepressors, coactivators, histone deacetylases and chromatin assembly. The receptors can 
recognise and bind specific DNA elements (HREs) in their unliganded form. Association of 
corepressors (NCoR/SMRT) inhibit transcription presumably via a non-productive interaction 
with the constituents (TFIIB) of the preinitiation complex (PIC), while histone deacetylases 
locally trigger a 'closed' chromatin state. Specifically binding of liganded RXR-TR or RXR- 
RAR to HREs will recruit coactivator complexes containing HAT activity (CBP, SRC-1) to 
promote formation of PIC and transcription.
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Ligand binding induces a conformation change in the receptors that permit 
dissociation of the corepressors. It is postulated that for activation of transcription by 
NRs in vivo, chromatin remodelling complexes are recruited to the promoter initially. 
The yeast SWI/SNF complex or its mammalian homologue BRG-1 posses an ATP- 
dependent ability to cause local changes in chromatin structure, thus, facilitating the 
binding of sequence specific transcription factors to nucleosomal DNA (Owen-Hughes 
et al., 1996). Interactions of receptors on chromatinised templates with BRG-1, 
SWI/SNF or ISWI (imitation SWI) are implicated in the transcriptional activation 
function of GR, ER and RAR (Chiba et al., 1994; Di Croce et al., 1999; Ichinose et 
al., 1997; Muchardt and Yaniv, 1993; Ostlund Farrants et al., 1997; Yoshinaga et al.,
1992). SWI/SNF-related complexes may relieve the repressive actions of chromatin 
and set the stage for a second chromatin-dependent step of gene activation requiring 
factors with HAT activity. It is postulated that recruitment of the PCAF complex 
might stimulate transcription by remodelling nucleosomal structure. Finally, the action 
of additional complexes such as TRAP/DRIP might be required to activate 
transcription (reviewed in Glass and Rosenfeld, 2000). The fact that TRAP/DRIP do 
not posses intrinsic HAT activity might reflect that they act late at the actual activation 
step. Such a sequential model is supported by the observation that thyroid hormone 
(T3)-mediated transcription was stimulated in the presence of p300 at a step 
subsequent to chromatin disruption (Li et al., 1999) and that the coactivators CBP and 
p160s are released late in RAR-dependent promoter activation (Chen et al., 1999).
Considering the above, it is remarkable that the transition of a NR between 
repressed and activated states is controlled by biochemical and enzymatic symmetry 
exerted by HDACs or HATs (reviewed in Glass and Rosenfeld, 2000). Should this 
symmetry exist for all the stages during repression, as it has been proposed for 
activation, more corepressor complexes with various enzymatic activities are still to be 
discovered.
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5. Why v-ErbA ?
The goal of the studies in this thesis was to investigate the role of nuclear 
receptors in transcriptional repression. We have chosen v-ErbA as a model system 
because its repressive activity has significant physiological implications and has been 
directly correlated with oncogenicity. Avian erythroblastosis virus (AEV), which 
encodes apart from v-erbA, a second oncogene, v-erbB, is a paradigm of many 
retroviruses that induce malignancies by the co-operation of two oncogenes. Other 
examples include the E26 virus encoding v-myb and v-ets (Graf et al., 1992) and the 
avian Mill-Hill-2 myelocytomatosis (MH-2) virus encoding v-mil and v-myc (Bechade 
et al., 1985; Jansen et al., 1983). The v-ErbA oncoprotein has a number of structural 
and functional similarities to the RAR translocation products PML-RARa and PLZF- 
RARa such as DNA binding, repression of gene transcription and ligand 
unresponsiveness. Since PML-RARa and PLZF-RARa fusion proteins cause human 
acute promyelocytic leukemias (APL), interrelated studies will be significant for 
understanding the molecular bases of gene regulation in malignancies (reviewed in 
Stunnenberg et al., 1999). At the outset of this work substantial progress had already 
been made in understanding the transformation function of v-erbA, as compared to 
other oncogenenic systems. Neveretheless, knowledge on molecular mechanisms 
responsible for transcriptional repression and consequently oncogenicity was 
rudimentary.
In terms of availability of materials, the chicken system has a number of 
conveniences. Primary erythroid progenitor cells suitable for the intended study 
(chapter 2) were at that time only available from chicken. Mouse primary cells could 
not be driven into differentiation in a synchronised manner and human primary cells 
could not be obtained in large amounts. Finally, v-ErbA-expressing erythroid 
progenitors are amenable to manipulations required to establish novel derivative cell 
lines.
In the following sections the current knowledge about v-ErbA is presented. 
Structural similarities and differences between v-ErbA and its cellular homologue, 
TRa, with implications in v-ErbA function will be discussed.
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6. Avian Erythroblastosis Virus (AEV)
AEV is an acutely leukemogenic retrovirus that induces fatal erythroleukemia 
in young chicks. The target cell for AEV transformation is a committed erythroid 
progenitor (Samarut and Gazzolo, 1982). The in vitro transformed erythroblast-like 
cells are rapidly proliferating and are tightly arrested in an immature state of 
differentiation (Graf and Beug, 1983). The AEV virus encodes two oncogenes: v- 
ErbB, a mutated trans-membrane receptor for epidermal growth factor (EGFR) and v­
ErbA, a mutated nuclear thyroid hormone receptor (TRa) (Downward et al., 1984; 
Sap et al., 1986).
v-erbB alone is sufficient for transformation of fibroblasts and erythroblasts in 
vivo  and in vitro. Both v-ErbB and overexpressed c-ErbB/EGFR, activated by TGFa, 
induce abnormal self renewal of erythroid progenitors (Beug et al., 1985; Lax et al., 
1988; Pain et al., 1991). In contrast to c-ErbB, v-ErbB renders erythroid progenitors 
independent of the erythroid growth factor Epo (Beug et al., 1982). However, a 
significant proportion of these v-ErbB-expressing cells escapes the differentiation 
arrest to spontaneously mature into erythrocytes (Beug et al., 1992). Cells expressing 
only v-ErbB could neither extensively self-renew nor could they be tightly arrested in 
differentiation unless certain batches of serums were used (Beug et al., 1995). 
Subsequently, it was found that these serum batches contained factors such as 
estrogens and glucocorticoids. Finally, v-ErbB appeared to co-operate with ligand 
activated receptors (GR and ER) to transform cells (Bauer et al., 1997; Hayman et al., 
1993; Schroeder et al., 1993; Wessely et al., 1997).
v-erbA affects the differentiation phenotype of erythroid cells in a fashion quite 
different from that of v-erbB. In vitro, v-ErbA expression drastically broadens the 
narrow limits of pH and ionic concentrations required for v-erbB-transformed 
erythroblasts to survive in culture. v-ErbA has no distinct transforming capacity of its 
own in vivo  (Frykberg et al., 1983; Gandrillon et al., 1989; Sealy et al., 1983) unless 
its expression is forced to extremely high levels (Casini and Graf, 1995). However, v­
ErbA blocks the spontaneous differentiation occurring in a subpopulation of v-erbB- 
transformed erythroblasts and increases the growth rate of these cells. Thus, v-erbA 
leads to a much more severe leukemic phenotype as compared to a v-erbB only- 
induced leukemia (Kahn et al., 1986; Forrest et al., 1990a; Graf et al., 1977; Hihara et
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al., 1983; Kahn et al., 1984; Miles and Robinson, 1985). Evidence for the co-operation 
between v-ErbA and v-ErbB came from experiments performed with cells expressing 
only v-ErbA. In vitro  transformation of these v-ErbA cells was dependent on the 
presence of additional factors or components present in chicken serum. One of these 
serum components is most likely an avian ligand for c-ErbB. This conclusion was 
based on the prime observation that certain normal chicken sera stimulate tyrosine 
autophosphorylation of chicken c-ErbB/EGFR (Pain et al., 1991; Schroeder et al.,
1992) (reviewed in Beug et al., 1996). The current view is that v-ErbA co-operates 
with ligand-activated tyrosine kinases such as TGFa-loaded c-ErbB or stem cell factor 
(SCF)-activated c-kit to arrest differentiation. Constitutively active, transforming 
oncoproteins such as v-ErbB, v-sea, v-src, v-H-ras and v-ets were also shown to co­
operate with v-ErbA to lead to a severe leukemic phenotype (Kahn et al., 1984; Kahn 
et al., 1986; Metz and Graf, 1992; Pain et al., 1991; Schroeder et al., 1990).
The precise mechanism by which v-erbA contributes to erythroblast 
transformation has been elusive for quite long. However, repression of the 
transcription of certain genes is thought to contribute to its oncogenicity. Three target 
genes have been suggested to be directly repressed by v-ErbA: the Carbonic 
Anhydrase II gene (CA II), the erythrocyte anion transport protein gene (Band 3) and 
the 8-aminolevulinate synthase gene (ALA-S) (Pain et al., 1990; Zenke et al., 1988). 
Re-expression of CA II partially abrogates the v-ErbA-induced arrest of differentiation 
(Fuerstenberg et al., 1992), suggesting that repression of CA II is an essential step in 
erythroleukemia.
CA II catalyses the reversible hydration of CO2 into bicarbonate anion: CO2 + 
H2O ^  HCO3-+ H+. The high cytosolic concentration of HCO3- drives its transport out 
of the erythrocyte in exchange of an entering Cl- anion by the membrane protein band 
3. Many of the protons (H+) generated are taken up by deoxyhemoglobin. One proton 
binds to hemoglobin for two molecules of O2 that are released. This uptake of protons 
helps to buffer the pH in metabolically active tissues (Stryer, 1995). Ion concentrations 
of blood plasma usually fluctuate, for example in an exercising skeletal muscle lactic 
acid contributes to the H+ pool. Thus, the exchange of HCO3- (equal to OH- + CO2) for 
Cl- dictates the direction of the CA II catalyzed reaction and finally regulates the 
cytosolic pH to remain near neutral (reviewed in Geers and Gros, 2000; Lindskog,
40 Chapter 1
1997; Tashian, 1989). In conclusion, CA II is important for the major task of the 
erythrocytes i.e. to provide O2 to the periphery.
7. The v-ErbA protein
7.1. S tructure of the protein
As stated previously, the v-erbA oncogene is a viral variant of the c-erbAa 
proto-oncogene, chicken TRa. It originates from the fusion of the c-erbA coding 
region with the viral gag gene during the genesis of AEV. The v-ErbA protein is a 75- 
kDa-fusion product of gag and c-ErbA/TRa sequences. In the v-ErbA protein the first 
12 amino acids of TRa have been replaced by 255 residues of gag (Figure 8, Figure 9) 
(Debuire et al., 1984; Henry et al., 1985; Sap et al., 1986; Vennstrom et al., 1980; 
Weinberger et al., 1986) (reviewed in Beug et al., 1994). Nine amino acids 
corresponding to the AF-2 region of TRa are also deleted. In addition, there are 13 
point mutations distributed along the receptor moiety. Two of these mutations are 
localised in the DNA binding domain; mutation at position 61 changes the class II 
EGCKG P-box into EGCKS, affecting the specificity and affinity for DNA binding 
(Bonde et al., 1991; Nelson et al., 1994; Nelson et al., 1995a; Nelson et al., 1995b; 
Smit-McBride and Privalsky, 1994). The other mutation at position 78 is located 
within the D-box. Two mutations are localised in the residual N-terminal domain and 
nine mutations are in the E domain. The mutations in the E domain together with the 
deletion of the AF-2 domain are responsible for the inability of the oncoprotein to bind 
hormone and impair its dimerisation properties (Barettino et al., 1993; Munoz et al., 
1988; Zenke et al., 1990).
In contrast to TRa, which is exclusively nuclear, v-ErbA is localised both in the 
nucleus and the cytoplasm (Bigler and Eisenman, 1988; Boucher et al., 1988; Boucher 
and Privalsky, 1990). The 12 N-terminal amino acids of TRa that are absent in v-ErbA 
have been demonstrated to be crucial for nuclear localisation (Andersson and 
Vennstrom, 1997). Mutations in the DBD and N-terminal part of LBD domains have
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also been implicated in the subcellular distribution of v-ErbA (Boucher and Privalsky, 
1990).
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Figure 8 Schematic representation of cTRa and v-ErbA. In TRa are shown regions that are 
either structurally or functionally defined. For clarity the c-ErbA molecule has been depicted 
twice. The upper part displays the zinc-finger regions and the P, D and T/A boxes. The lower 
part displays the regions that form an a-helical structure (Rastinejad et al., 1995). Between 
the two c-ErbA representations are shown (boxed) the v-ErbA amino acids that are different 
from cTRa. A boxed A represents deletion.
Figure 9 Multiple sequence alignment between the gag-v-ErbA protein, the chicken TRa 
and the human TRa protein using the programme CLUSTAL X (1.62b). Here we have 
numbered the v-ErbA protein by a negative numbering of the 252 amino acids belonging to 
the gag domain and then by a positive numbering the 387 ErbA specific amino acids (top 
numeration). The human c-ErbA/TRa protein is numbered below its sequence. In order to 
know the position of an amino acid in the chicken c-ErbA/TRa sequence one has to either 
add 12 from the v-ErbA numbering or to subtract 2 from the human c-ErbA numbering. * 
indicates identical amino acids. gag-v-ErbA protein is a composite sequence made from v­
ErbA (Genbank accession M32090, Damm et al., 1987) and p19 protein, accession S35743 
(NCBI accession 420624; direct submission) sequences, chicken TRa, Swiss-Prot accession 
P04625; (Sap et al., 1986) and human TRa protein, Swiss-Prot accession P21205; (Pfahl and 
Benbrook, 1987).
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7.2. Dimerisation of v-ErbA and DNA binding properties
Whether v-ErbA binds to HREs as a homodimer or as a heterodimer with RXR 
is still a controversial and debated issue. The apparent discrepancies may be due to the 
use of different experimental approaches (in vitro binding versus transfected cells) and 
different origins of the proteins (in vitro translated, baculovirus expressed, vaccinia 
virus expressed products or nuclear extracts from transfected cells). Due to a point 
mutation in the LBD at position 351, which changes the proline 363 in cTRa into a 
serine in v-ErbA, the v-ErbA oncoprotein has decreased affinity for RXR (Barettino et 
al., 1993; Chen and Privalsky, 1993). Reversion of this serine into a proline in a 
selected mutant of AEV, AEV-r12, restored the ability to heterodimerise with RXR 
and strongly enhanced the inhibitory effect of the v-ErbA mutant protein on RA- and 
T3-induced gene expression in erythroblasts (Barettino et al., 1993; Bauer et al., 
1997). Furthermore, the v-ErbA-r12 mutant functioned as a superactive oncogenic 
protein in erythroblasts (Damm et al., 1987).
Given that v-ErbA and TR have both similarities and differences in their DBDs, 
it could not be taken for granted that they share the same DNA responsive elements. In 
addition, the mutation at position 32 in v-ErbA is located in the upstream of the DBD 
zinc-fingers region, which comprises a very potent determinant of the DNA sequence 
specificity of class II NRs (Chen et al., 1993a; Judelson and Privalsky, 1996; Zechel et 
al., 1994a). There is evidence that sequences that mediate activation by T3 are not 
necessarily v-ErbA responsive elements (Subauste and Koenig, 1995). v-ErbA can 
bind as heterodimer with RXR on most natural TREs but with lower affinity than 
RXR-TR heterodimers (Barettino et al., 1993; Bonde and Privalsky, 1990; Damm et 
al., 1989; Hermann et al., 1993; Judelson and Privalsky, 1996; Sap et al., 1989; 
Subauste and Koenig, 1998; Wahlstrom et al., 1996; Yen et al., 1994). The optimal 
element for RXR-v-ErbA heterodimer is reportedly a direct repeat (DR4), while for v­
ErbA homodimers it is an everted repeat (Subauste and Koenig, 1998). v-ErbA 
homodimers can also bind to a DR4 but with lower affinity than v-ErbA heterodimers. 
Similarly, the RXR-v-ErbA heterodimer can bind to an everted repeat element but 
with lower affinity than v-ErbA homodimers (Judelson and Privalsky, 1996; Subauste 
and Koenig, 1998). An element in a silencer region of chicken lysozyme gene has 
been shown to convey strong repression upon v-ErbA binding. Mutational analysis
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showed that this element, designated F2, was an everted repeat-type element with two 
half-sites spaced by 6 nucleotides (TGACCCcagctgAGGTCA) (Baniahmad et al.,
1990). Transcriptional repression by v-ErbA can be conveyed via both DR4 and 
everted repeat elements, yet, RXR potentiates repression only via the DR4 (Subauste 
and Koenig, 1998).
RXR-v-ErbA can also bind to DR3 and DR5 but not to DR1 and DR2 (Chen 
and Privalsky, 1993; Hermann et al., 1993). The binding to DR5 elements depends 
highly on the fine structure of the element. DR5 from the mouse RARß gene 
composed of PuGTTCA motifs, binds v-ErbA weakly either as a monomer or as a 
heterodimer with RXR, whereas strong binding is achieved on a AGGTCA-type DR5 
motif (Chen and Privalsky, 1993).
There are also studies showing that v-ErbA, like TR, can bind to DNA as a 
monomer to the decameric DNA sequence 5’-T(A/G)AGGTCACG-3’ (Subauste and 
Koenig, 1995). In addition, the oncoprotein has been shown to bind on some TREs as 
heterodimer with TRa (Yen et al., 1994).
In summary, the DNA binding specificity of v-ErbA is determined by a number 
of parameters such as protein-protein interactions and the relative position of the 
molecules on the responsive element (Subauste and Koenig, 1998). Consequently, the 
architecture of the v-ErbA responsive element (VRE) affects the DNA binding 
selectivity and affinity and appears to be crucial for the v-ErbA repressive function on 
transcription (Judelson and Privalsky, 1996; Wahlstrom et al., 1996).
7.3. Phosphorylation
The v-ErbA oncoprotein has two serine residues at positions 16/17 (equivalent 
to serines 28/29 in cTRa), which are substrate sites for phosphorylation by PKA 
(Goldberg et al., 1988). These phosphorylation sites do not exist in any mammalian 
thyroid hormone receptor (Lazar et al., 1988; Weinberger et al., 1986) nor in the avian 
c-ErbAß/cTRß receptor (Forrest et al., 1990b; Showers et al., 1991; reviewed in 
Rascle et al., 1997). In v-ErbA, phosphorylation of Ser 16/17 is a prerequisite for its 
function as an oncogene and for repression of transcription of erythroid genes such as 
CA II and band 3 (Glineur et al., 1990). It has been postulated that v-ErbB triggers the
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phosphorylation of v-ErbA which is important for the v-ErbB/v-ErbA-induced block 
of differentiation. However, an Ala 16/17 mutant of v-ErbA can efficiently repress 
reporter gene transcription from a prototypic thyroid responsive element in transient 
transfection experiments (Glineur et al., 1990). It is notable that Ser 16/17 are located 
in a region that has been implicated in receptor DNA sequence recognition (Chen et 
al., 1993a; Wong and Privalsky, 1995). Recently, it has been reported that 
phosphorylation of the serines 16/17 inhibits the binding to DNA of the v-ErbA 
monomer but not of the homodimer or the heterodimer with RXR, suggesting 
differential protein/DNA contacts between receptor monomers and dimers 
(Tzagarakis-Foster and Privalsky, 1998).
7.4. Binding of v-ErbA to cofactors
Due to mutations that v-ErbA contains in the LBD and the deletion of the AF-2 
(activation function-2), it cannot bind ligand and hence v-ErbA cannot exert any 
activation function. Thus, it appears unlikely that v-ErbA can interact with 
coactivators. In fact, a direct interaction of v-ErbA with p300 or any other coactivator 
protein has not been reported.
In contrast, a number of studies have shown interaction of v-ErbA with the 
corepressors NCoR/SMRT in vitro (Busch et al., 2000; Hong et al., 1998; Lin et al., 
1997). v-ErbA was the first nuclear receptor suggested to convey repression of 
transcription. A transformation deficient variant of v-ErbA, termed td359-v-ErbA, 
which carries a mutation in helix H1 of the LBD (Pro 144^Arg), failed to repress 
transcription in transient transfection assays (Damm et al., 1987; Damm and Evans,
1993). Subsequent experiments showed that H1 was important for interaction with 
corepressors (Chen and Evans, 1995; Horlein et al., 1995; Li et al., 1997b). Recent 
findings have demonstrated that v-ErbA exhibits a novel tripartite structural 
requirement, i.e. helices 1, 5/6 and 8 of the LBD are simultaneously required for 
corepressor association and repressive function (Busch et al., 2000; Busch et al.,
1997). Very recently, a corepressor complex from Xenopus  oocytes extracts containing 
NCoR/HDAC3 but not SIN3 has been shown to associate with v-ErbA (Urnov et al., 
2000). Although there are no structural data yet available for the interaction between
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v-ErbA and corepressors, the fact that the v-ErbA-LBD bears mutations, as compared 
to TR, points to distinct structural requirements for v-ErbA and TRa with possible 
implications for their transcriptional repression properties.
7.5. Models for v-ErbA-mediated transcriptional regulation
v-ErbA was initially demonstrated to constitutively inhibit the transcriptional 
activation of genes mediated by T3 (Baniahmad et al., 1992; Damm et al., 1989; Pain 
et al., 1990; Sap et al., 1989; Zenke et al., 1990). Subsequent studies showed that v­
ErbA also represses genes activated by liganded RAR (Chen and Privalsky, 1993; 
Sande et al., 1993; Sharif and Privalsky, 1991). The mechanisms underlying the 
antagonistic function of v-ErbA on TR/RAR remain largely unclear due to a lot of 
conflicting data. A number of models have been proposed, yet none of them alone can 
explain all the findings in the literature. In the following I present an overview of 
models that have been proposed during the last two decades (Figure 10).
7.5.1. Binding site occlusion model
According to the binding site occlusion model, v-ErbA exerts its repressive and 
oncogenic function by occluding liganded TR from binding to its cognate sites (Figure 
10A) (Damm et al., 1989; Pain et al., 1990; Sap et al., 1989; Sharif and Privalsky,
1991). Since v-ErbA cannot bind ligand, occlusion of TR results in inhibition of T3- 
dependent transcriptional activation. This model emerged from studies swapping 
DBDs between v-ErbA and TRa, which showed that v-ErbA is unable to bind ligand 
and to exert any activation function (Barettino et al., 1994; Munoz et al., 1988). 
Moreover, substitution of the LBD of v-ErbA with that of c-ErbA resulted in proteins 
able to drive full differentiation program of transformed erythroblasts after 
administration of T3 (Disela et al., 1991; Schroeder et al., 1992; Zenke et al., 1990). 
This notion was further supported by the observation that overexpression of TR and 
addition of ligand could overcome the block of differentiation of erythroid progenitors 
caused by v-ErbA (Disela et al., 1991). However, the finding that v-ErbA binds to 
conventional TREs with lower affinity than TR, due to mutations in the P- and D- 
boxes of the DBD, puts the occlusion model under dispute (Barettino et al., 1993;
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Nagl et al., 1995; Nelson et al., 1995b). Restoring the P-box mutation in v-ErbA 
restored wild type TRa DNA binding affinity but, unexpectedly, abolished the ability 
of v-ErbA to inhibit RAR-dependent transcriptional activation as well as to transform 
erythroid progenitors (Bauer et al., 1997; Sharif and Privalsky, 1991). Therefore, it 
seemed likely that in vivo  v-ErbA might function through distinct responsive elements 
that are not necessarily the known TREs and that other mechanistic models had to be 
postulated.
7.5.2. Sequestration of auxiliary factors required for TR/RAR activation 
function
It has been reported that v-ErbA binds to most TREs as a heterodimer with 
RXR (Judelson and Privalsky, 1996; Subauste and Koenig, 1998; Wahlstrom et al.,
1996). Given that heterodimerisation of TR or RAR with RXR is required for their 
efficient DNA binding and function (Bugge et al., 1992; Hallenbeck et al., 1992; Jin 
and Pike, 1996; Kliewer et al., 1992; Yu et al., 1991; Zhang et al., 1992a), it is 
conceivable that sequestration of RXR by v-ErbA could impair the function of TR and 
RAR (Figure 10B). However, a number of observations strongly oppose a 
sequestration model. Firstly, v-ErbA contains a mutation (Pro 351 to Ser) that impairs 
its ability to heterodimerise with RXR (Barettino et al., 1993; Chen and Privalsky,
1993). Secondly, in vitro  v-ErbA binds as heterodimer with RXR to most TREs but 
with lower affinity than RXR-TR (Hermann et al., 1993; Subauste and Koenig, 1998; 
Wahlstrom et al., 1996). Finally, restoring the heterodimerisation ability of v-ErbA 
(r12-v-ErbA) yields a superactive oncogene (Barettino et al., 1994; Damm et al., 
1987), suggesting that wild type v-ErbA is not able to efficiently sequester RXR.
7.5.3. Squelching of co-factors
Squelching of class II NR coactivators appears unlikely to contribute to 
repressive/oncogenic function of v-ErbA, because interactions between activator and 
receptor require the receptor AF-2 domain (Figure 10C) (reviewed in Glass and 
Rosenfeld, 2000). The nine amino acids deletion comprising the AF-2 together with 
point mutations of the LBD render v-ErbA unable to interact with coactivators 
(Barettino et al., 1994; Munoz et al., 1988). Swapping experiments of v-ErbA LBD
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with that of TRa yielded proteins able to drive full differentiation of transformed 
erythroblasts after T3 administration, linking the repression function of v-ErbA with 
its inability to be ligand-activated (Barettino et al., 1994; Disela et al., 1991; Forrest et 
al., 1990a; Lin et al., 1997; Munoz et al., 1988; Sap et al., 1989; Zenke et al., 1990).
A B
Squelching Silencing
Fig 10 At least four models exist to explain the ability of v-ErbA to repress TR mediated 
activation via a DNA responsive element. (A) Occlusion: v-ErbA, as a dimer, occludes 
liganded TR from its cognate binding sites. (B) Sequestration of RXR: Since v-ErbA is 
overexpressed, it binds RXR in solution, thus, forbidding TR to heterodimerise with RXR. 
Subsequently, no functional RXR-TR heterodimers are formed that could bind to TREs to 
activate transcription. (C) Squelching: v-ErbA squelches positive co-factors required for the 
enhanced transcriptional activation by liganded RXR-TR. (D) Silencing: v-ErbA directly and 
constitutively interacts with corepressors resulting in silencing of transcription.
7.5.4. HRE-independent model: The AP-1 case
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So far I have described models interpreting the repression function of v-ErbA 
mediated in cis i.e. via binding of v-ErbA to a DNA responsive element. Nevertheless, 
there are also data showing that DNA binding-independent interactions between NRs 
and other proteins can also account for their repressive function. For example, 
interference of NRs with the AP-1 transcriptional pathways has been initially reported 
for the glucocorticoid receptor and subsequently verified for TR and RAR (reviewed 
in Pfahl, 1993). Liganded TR inhibits AP-1 activation function presumably by 
preventing its binding to the TPA responsive elements. In the absence of hormone, TR 
cannot interfere with the AP-1 activation pathway (Desbois et al., 1991; Nicholson et 
al., 1990; Saatcioglu et al., 1997; Salbert et al., 1993; Schmidt et al., 1993; Schule et 
al., 1991; Zhang et al., 1991). Since AP-1 responds to mitogenic signals responsible 
for sustaining cell proliferation, and given that hormones are differentiation signals, it 
is conceivable that a cross-talk between the two pathways at AP-1 sites functions as a 
sensitive balance between proliferation and differentiation. v-ErbA is not able to 
interfere with the AP-1 pathway, most probably because of deletion of the AF-2 
domain responsible for ligand and AP-1 interaction (Schmidt et al., 1993). It is likely 
that v-ErbA supports the proliferation program driven by AP-1, reinforcing the notion 
that arrest of differentiation is regulated by various pathways (Desbois et al., 1991).
7.5.5. Constitutive corepressors binding
The discovery of the corepressors NCoR/SMRT shed new light on the 
mechanism by which NRs repress transcription, and these findings were extrapolated 
to the action of v-ErbA in erythroleukemia. The current model is that v-ErbA, when 
stably bound to DNA, is constitutively associated with NCoR/SMRT (reviewed in 
Stunnenberg et al., 1999). NCoR/SMRT are thought to facilitate the repressive activity 
of v-ErbA in two ways. First, NCoR/SMRT prevent the formation and activity of the 
preinitiation complex (PIC) and second, via recruitment of HDACs, they facilitate a 
condensed, deacetylated and hence repressive chromatin structure in the 
neighbourhood of the v-ErbA responsive element (Stunnenberg et al., 1999). Recently, 
a NCoR/HDAC3 containing complex from Xenopus  oocytes extracts has been shown 
to enhance transcriptional repression by v-ErbA only on chromatinised templates 
(Urnov et al., 2000). The constitutive corepressors binding model is further supported
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by findings showing that overexpression of TR and ligand administration overcomes 
the v-ErbA induced block of differentiation (Disela et al., 1991). Nevertheless, ‘proof- 
of-principle’ that NCoR/SMRT associate with v-ErbA in vivo  and instigate repressive 
activity from a chromatin embedded v-ErbA responsive element (VRE), remains to be 
demonstrated.
In conclusion, it appears that v-ErbA inhibits transcription through a number of 
mechanisms that are dependent on the nature of the element, cell type-specific factors 
and possibly other parameters. More studies are required to unequivocally establish 
the connection between v-ErbA repression function and oncogenicity.
8. Outline of this thesis
At the outset of this work several studies had demonstrated the role of v-ErbA 
in the capacity of AEV to transform cells. Several features and mutations of v-ErbA 
had been characterised with respect to its oncogenicity, which were correlated with the 
ability of v-ErbA to repress transcription. However, little was known about the 
molecular mechanism of transcriptional silencing by v-ErbA. From transfection 
assays, using artificial v-ErbA responsive elements or thyroid responsive elements it 
was inferred that v-ErbA represses transcription in cis in vivo. Hence, there was a clear 
need for a model target gene with a chromatin embedded v-ErbA responsive element 
that would enable molecular studies on the mechanisms and factors involved in 
silencing by v-ErbA.
In chapter 2, the identification of two prime candidate regions (HS1 and HS2) 
for transcriptional regulation in the locus of carbonic anhydrase II (CA II) gene is 
described. The discovery of a v-ErbA responsive element (VRE) located within HS2 
established that CA II is a true and direct target gene. We showed that v-ErbA binds to 
this VRE both in vitro and in vivo  and that it is able to repress transcription of the CA 
II gene. In differentiating cells, v-ErbA binding was alleviated in vivo  concomitant 
with a relief of repression of CA II transcription.
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To further investigate the function of v-ErbA and the possibility for an interplay 
between v-ErbA and other factors bound to HS2, we next performed a detailed 
functional characterisation of HS2 (chapter 3). HS2 was demonstrated to behave as a 
potent enhancer in the absence of v-ErbA, and GATA-factor binding sites were shown 
to govern the erythroid-specific enhancer activity of HS2. v-ErbA appeared to 
neutralise the positive action of factors bound to GATA-sites, a function shared by 
unliganded TRa. Because v-ErbA is postulated to be the paradigm of an unliganded 
receptor that represses transcription, we compared its repressive function via the HS2- 
VRE with that of TRa and found that they are not equivalent in this aspect of gene 
regulation.
In chapter 4 we set out to investigate whether and which corepressors are 
involved in repression by v-ErbA in vivo. A dominant negative corepressor-approach 
was taken using a truncated NCoR protein (C-NCoR) that contains the receptor 
interaction domains but lacks transcriptional silencing function. AEV transformed 
cells stably expressing C-NCoR were established. Although a physical interaction 
between v-ErbA and NCoR and/or C-NCoR was demonstrated using 
immunoprecipitation assays, relief of transcriptional repression of the endogenous CA 
II gene in the presence of C-NCoR was not observed in v ivo . The data presented 
question the role of NCoR in the repressive function of v-ErbA.
In chapter 5, the main conclusions derived from these studies as well as 
perspectives for future research are discussed.
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Abstract
v-ErbA, a mutated thyroid hormone receptor alpha (TR), is thought to 
contribute to avian erythroblastosis virus (AEV)-induced leukemic transformation by 
constitutively repressing transcription of target genes. However, the binding of v-ErbA 
or any unliganded nuclear receptor to a chromatin-embedded response element as well 
as the role of the N-CoR-SMRT-HDAC co-repressor complex in mediating repression 
remain hypothetical. Here we identify a v-ErbA-response element, VRE, in an intronic 
DNase I hypersensitive site (HS2) of the chicken erythroid carbonic anhydrase II (CA 
II) gene. In vivo footprinting shows that v-ErbA is constitutively bound to this HS2- 
VRE in transformed, undifferentiated erythroblasts along with other transcription 
factors like GATA-1. Transfection assays show that the repressed HS2 region can be 
turned into a potent enhancer in v-ErbA-expressing cells by mutation of the VRE. 
Differentiation of transformed cells alleviates v-ErbA binding concomitant with 
activation of CA II transcription. Co-expression of a gag-TRa fusion protein in AEV- 
transformed cells and addition of ligand derepresses CA II transcription. Treatment of 
transformed cells with the histone deacetylase inhibitor, trichostatin A, derepresses the 
endogenous, chromatin-embedded CA II gene, while a transfected HS2-enhancer 
construct remains repressed. Taken together, our data suggest that v-ErbA prevents 
CA II activation by ‘neutralizing’ in cis the activity of erythroid transcription factors.
Introduction
Leukemic transformation of hematopoietic cells is manifested as an imbalance 
between proliferation and differentiation caused by the combined action of two or 
more co-operating oncogenes. Gradually, the concept has emerged that the decision of 
a hematopoietic cell to either self-renew (i.e. proliferate but not differentiate) or to 
undergo terminal differentiation is determined by the cooperative action of receptor 
tyrosine kinases and nuclear hormone receptors. In humans, 80% of acute 
promyelocytic leukemia (APL) patients bear translocations juxtaposing the RAR gene 
locus to either the PLZF or PML genes. The resultant fusion proteins (Borrow et al., 
1990; De Thé et al., 1990; Alcalay et al., 1991; Chen et al., 1993) block differentiation
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of hematopoietic progenitors (Grignani et al., 1993; Rousselot et al., 1994). Murine 
bon marrow cells expressing a dominant negative RAR lacking its ligand-dependent 
activation function, AF-2, are blocked at the stage of lymphohematopoietic 
progenitors (Tsai et al., 1994). In chickens, the avian erythroblastosis virus (AEV) 
induces fatal erythroleukemia (for reviews see Beug et al., 1994; Gandrillon et al., 
1995). AEV expresses two co-operating oncogenes, v-erbA and v-erbB, that together 
tip the balance between proliferation and differentiation towards self renewal. v-ErbB 
is a mutated and truncated viral variant of the epidermal growth factor receptor 
(EGFR) that promotes cell growth. v-ErbA is a highly mutated variant of chicken 
thyroid hormone receptor alpha, cTRa (Sap et al., 1986; Weinberger et al., 1986) that 
arrests the differentiation of erythroblast progenitors by preventing the expression of 
differentiation stage-specific erythroid genes (Zenke et al., 1990; Disela et al., 1991). 
Because v-ErbA requires cooperation with kinases to arrest differentiation, AEV- 
transformed cells can be induced to differentiate in the presence of specific kinase 
inhibitors (Choi et al., 1986; Zenke et al., 1988). Although it has been postulated that 
phosphorylation of v-ErbA is crucial for its oncogenic capacity, little is known about 
the consequences of kinase activity on v-ErbA function.
The discovery that v-ErbA is a mutated TRa initiated an extensive comparative 
analysis of presumed TR functions that are absent in the v-ErbA oncoprotein. The 
oncogenic requirements do not include transcriptional activation functions, since v­
ErbA is severely crippled with respect to T3 binding (Munoz et al., 1988; Zenke et al., 
1990), dimerization with RXR (Selmi and Samuels, 1991; Barettino et al., 1993) and 
transactivation (Saatcioglu et al., 1993; Barettino et al., 1994). The first clue as to the 
activity of v-ErbA required for oncogenicity stems from the observations that v-ErbA 
antagonizes ligand-dependent activation by TR (Damm et al., 1989; Sap et al., 1989; 
Zenke et al., 1990). The finding that overexpression of TR and addition of ligand can 
overcome the block of differentiation by v-ErbA lent support to this notion (Disela et 
al., 1991). A v-ErbA variant, td359, which failed to block differentiation also failed to 
repress transcription in transient transfection assays (Damm et al., 1987; Damm and 
Evans, 1993). Recently, the mutation in td359 causing the transformation defect has 
been shown to diminish the affinity of v-ErbA for the co-repressor SMRT in vitro 
(Chen and Evans, 1995). These and other observations have led to the formulation of
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an occlusion-repression model for the action of v-ErbA at the molecular level: v-ErbA 
occludes TR and/or RAR from binding to their cognate sites (Damm et al., 1989; Sap 
et al., 1989) and represses transcription of target genes in cis (Damm and Evans,
1993). Repression is assumed to involve a co-repressor complex (Chen and Evans, 
1995; Hörlein et al., 1995; Heinzel et al., 1997).
Transient transfection experiments revealed that the ability of v-ErbA to repress 
transcription is an active mechanism shared by other unliganded class II nuclear 
receptors (Baniahmad et al., 1990, 1992; Damm and Evans, 1993). Recently, ample 
biochemical data suggest that in the absence of a cognate ligand, TR and RAR can 
associate with co-factors, termed N-CoR and SMRT, that have intrinsic transcriptional 
repression activities (Chen and Evans, 1995; Hörlein et al., 1995). N-CoR and SMRT 
in turn appear to be part of a large complex(es) consisting of factors that display 
transcriptional repression activities, such as SIN3A, or that are thought to stabilize 
repressive nucleosomal structures such as the histone deacetylase, HDAC (Alland et 
al., 1997; Heinzel et al., 1997; Nagy et al., 1997). Following treatment with the 
cognate ligand, the receptors undergo conformational changes leading to dissociation 
of the repressor complexes thus enabling their interaction with a different set of 
proteins that include SRC-1/TIF2 type proteins (Onate et al., 1995; Voegel et al., 
1996; Hong et al., 1997; Torchia et al., 1997) and CBP/p300 (Chakravarti et al., 1996; 
Kamei et al., 1996). These factors have intrinsic transcriptional activation activity as 
well as histone acetylase activity (Yang et al., 1996). A picture emerges in which 
nuclear receptors act as ligand-operated, molecular on-off switches.
This model is questioned by several observations. A mutation in the DNA- 
recognition helix (P-box) of v-ErbA both diminishes its overall affinity for DNA and 
alters its sequence specificity (Bonde and Privalsky, 1990; Wahlstrom et al., 1992; 
Barettino et al., 1993; Judelson and Privalsky, 1996). Reverting that DBD mutation 
increases the affinity of that receptor for the canonical half-site AGGTCA (Nelson et 
al., 1994). Unexpectedly, a v-ErbA variant with restored wild-type DNA-binding 
properties does not function as a ‘super-oncoprotein’; on the contrary, it is now fully 
impaired in its ability to transform erythroid cells (Sharif and Privalsky, 1991; Bauer 
et al., 1997). Furthermore, a mutation in the dimerization interface has caused a loss of 
affinity for the presumed partner, RXR (Selmi and Samuels, 1991; Barettino et al.,
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1994). Collectively, these results suggest that v-ErbA binds to a repertoire of cis- 
acting elements that is distinct from, or only partially overlapping with, natural thyroid 
hormone response elements (TREs) and retinoic acid response elements (RAREs). 
Alternatively, v-ErbA may be targeted to chromosomal loci via protein-protein 
interactions such as described for AP1-GR (Konig et al., 1992; Reichardt et al., 1998).
An ensuing search for erythroid target genes repressed by v-ErbA identified the 
erythrocyte anion transporter (band 3) and carbonic anhydrase II (CA II) (Zenke et al.,
1990). Repression of these genes by v-ErbA is important for the v-ErbA-induced 
leukemic phenotype, and accounts for the tolerance of AEV-transformed erythroblasts 
to wide variations in the pH or HCO3- ion concentration required for survival of the 
leukemic cells in peripheral blood. Re-expression of these genes in transformed 
erythroblasts revealed that the v-ErbA-induced tolerance to pH variation was 
abrogated; however, the v-ErbA-induced block of differentiation remained largely 
unaffected (Fuerstenberg et al., 1990, 1992). Transient transfection experiments 
involving v-ErbA expression vectors and either the promoter region of the CA II 
and/or synthetic reporters have yielded ambiguous and sometimes conflicting results 
(Disela et al., 1991; Hermann et al., 1993; Rascle et al., 1994; G.G.Braliou, 
D.Barettino and H.G.Stunnenberg, unpublished observations).
Another wrinkle to the model is that binding of an unliganded receptor to its 
cognate response element in vivo in a chromosomal context has not yet been 
demonstrated. Although in vivo footprinting clearly revealed binding site occupancy 
by a ligand-activated retinoid receptor, it failed to reveal receptor binding in the 
absence of ligand (Minucci et al., 1994; Chen et al., 1996). Injection into Xenopus 
oocytes of a TRß A gene minilocus which reconstitutes chromatin, permitted analysis 
of the TR binding site and its effect on the chromatin structure (Wong et al., 1995, 
1997). These data corroborate and extend the model of an unliganded receptor that 
acts in cis to repress transcription and to induce changes in the chromatin topology. 
More experiments on natural target genes within their chromosomal loci in vivo are 
required to elucidate whether and how a class II unliganded receptor represses 
transcription as well as to ascertain the physiological role of repression.
To unravel the mechanism of transcriptional repression by v-ErbA in vivo, we 
set out to identify the regions required for transcriptional regulation of the CA II gene
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during erythroid differentiation. We assessed whether v-ErbA acts directly or 
indirectly through (one of) these regulatory regions. We identified a novel VRE in an 
intronic enhancer and found that this VRE is occupied in vivo in undifferentiated cells, 
but not in differentiating, CA II-transcribing erythroid cells. We discovered that v­
ErbA represses the activity of the intronic enhancer by ‘neutralizing’ the positive 
action of transcription factors such as GATA-1. We show that a liganded thyroid 
receptor variant, gag-cTRa, overcomes v-ErbA action and unleashes enhancer 
activity. Finally, we show that addition of the histone deacetylase inhibitor, 
trichostatin A, results in derepression of the endogenous CA II gene, whereas a 
transfected, repressed HS2-enhancer construct remains unaffected by this treatment.
Results 
DNase I hypersensitivity site induction in the CA II locus during erythroid 
differentiation
To identify regulatory regions in the CA II locus we explored the chromatin 
status using DNase I hypersensitivity assays in primary chicken erythroid progenitors. 
In both immature primary erythroblasts and in terminally differentiating primary 
erythrocytes, prominent DNase I hypersensitive sites were detected ~5 kb upstream 
and ~8 kb downstream of the transcription start site, designated HS1 and HS2, 
respectively (Figure 1A and B). Although the putative enhancers, HS1 and HS2, 
appear to be fully accessible in immature primary cells, CA II mRNA could not be 
detected on Northern blots (Figure 1C). Increased DNase I sensitivity was observed in 
the promoter region of CA II, designated prHS, only in differentiating, primary cells 
that actively transcribe the gene but not in non-CA II transcribing, proliferating 
erythroid progenitors (Figure 1B and C). We conclude that in proliferating, primary 
erythroid progenitors, the CA II locus is primed for expression.
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In the AEV-transformed HD3 cell line, HS1 and HS2 were detectable only at 
relatively high DNase I concentrations as compared with primary erythroid 
progenitors (Figure 1D). Upon induction of differentiation, HS1 and HS2 became 
hypersensitive, concomitant with the appearance of CA II mRNA and of -globin 
mRNA, an established differentiation marker (Figure 1D and E). The opening of 
chromatin at HS1 and HS2 in the course of differentiation in HD3 cells was confirmed 
and corroborated by restriction enzyme accessibility assays (Figure 1F). The extent of 
restriction enzyme cutting increased 2-fold in HS1 from 20% in proliferating 
erythroblasts to ~40% in terminally differentiating cells, and ~5-fold in HS2, from 11 
to 54%. Taken together, these results identify HS1 and HS2 as the prime candidate 
regulatory regions involved in activation of CA II transcription and in conveying 
regulation by v-ErbA.
Figure 1 Analysis of the chicken CA II locus during differentiation of primary erythroblasts 
and v-ErbA transformed HD3 cells. (A) Schematic diagram of the CA II genomic locus. 
Exons 1-4 (black boxes) and the relative positions of the XbaI (X), SacI (S) and StuI (St) 
sites, and riboprobes used for end-labeling are indicated. The DNase I hypersensitive regions 
designated HS1 and HS2 are indicated by open boxes, with the sizes of arrows indicative of 
the relative DNase I sensitivity. prHS indicates the expression-linked DNase I sensitive sites 
in the promoter region. (B and C) DNase I hypersensitive site mapping and corresponding 
Northern blot analysis using primary chicken erythroblasts before (day 0) and after induction 
of differentiation (day 3). (D and E) DNase I hypersensitive site mapping and corresponding 
Northern blot analysis using chicken erythroid HD3 cells before (day 0) and 1, 2 and 4 days 
after induction of differentiation. (F) Restriction enzyme accessibility assay of HS1 and HS2 
using nuclei prepared from HD3 cells before (day 0) and 4 days after induction of 
differentiation. Arrows indicate fragments that were uncleaved in vivo, with SpeI and StyI, 
respectively, marking the cleaved fragments.
84 Chapter 2
Localization of a v-ErbA response element
We used an unbiased immunoprecipitation approach to identify putative v­
ErbA binding sites. A contiguous genomic fragment (17 kb) that includes the HS1, 
HS2 and CA II promoter regions (Figure 1A) was digested with frequently cutting 
restriction endonucleases, labeled and incubated with HD3 extracts. Protein-DNA 
complexes were precipitated with an anti-v-ErbA monoclonal antibody (1G10) 
coupled to paramagnetic beads. The predominant immunoprecipitated restriction 
fragments spanned the HS2 region (Figure 2A). In vitro DNase I footprinting using a 
fragment extending over HS2 and the v-ErbA-containing HD3 extracts yielded a 
distinct protection (bar) and enhanced DNase I cutting (arrow heads) (Figure 2B). 
Immuno-enrichment of HD3 extracts for v-ErbA prior to DNase I treatment 
diminished the enhanced DNase I cutting but did not affect the footprint (lanes 5 and 
6). The complementary result was obtained using HD3 extracts immunodepleted of v­
ErbA; the footprint was abolished but the enhanced DNase I cutting was unaffected 
(lanes 7 and 8).
Inspection of the sequence encompassing the footprinted region revealed a 
direct repeat consisting of one perfect and one imperfect half-site spaced by four 
nucleotides, designated VRE (Figure 2C). The arrangement of the half-sites is 
reminiscent of a conventional thyroid response element (DR4). Despite the mutation in 
the dimerization interface of v-ErbA that reduces the affinity of v-ErbA for RXR 
(Selmi and Samuels, 1991; Barettino et al., 1993), a v-ErbA-RXR heterodimer 
complex with an oligonucleotide containing the VRE was revealed in vitro by 
bandshift and antibody-supershift assays (Figure 2D). Two sequences known to bind 
v-ErbA, a canonical DR4 sequence and the F2 sequence of the chicken lysozyme gene 
(Baniahmad et al., 1990), competed for binding of v-ErbA-RXR, albeit less efficiently 
than the VRE probe itself. In contrast, the M1 oligonucleotide containing a mutation in 
the first half-site did not compete (Figure 2D). Thus, we have identified a novel v­
ErbA binding site located in the second intron of the CA II gene and within the DNase
I hypersensitive region HS2.
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v-ErbA binds to the CA II-VRE in vivo
To determine whether v-ErbA binds to this putative HS2-VRE in vivo, dimethyl 
sulfate (DMS) and DNase I genomic footprinting experiments were performed in 
undifferentiated and differentiating HD3 cells, chicken embryo fibroblasts (CEF) and 
on naked genomic DNA. Comparison of the cleavage patterns revealed that two G- 
residues in the first, and one G-residue in the second half-site of the VRE were 
protected from DMS methylation in undifferentiated HD3 cells (Figure 3A, lane 2), 
but not in naked genomic DNA or CEF cells (Figure 3 A, lanes 1 and 4). On the 
opposite strand, a single G-residue in the 3' half-site was protected from DMS 
methylation and a DNase I protection was obtained within the VRE in undifferentiated 
HD3 cells (Figure 3B, lanes 2 and 6). In contrast, in differentiating HD3 cells that 
transcribe the CA II locus, DMS or DNase I protections of the VRE could not be 
detected (Figure 3, lanes 3 and 7). Western blot analysis (Figure 5E, lanes 3 and 4) 
shows that the absence of a footprint is not due to a reduction in the concentration of 
v-ErbA protein in differentiating as compared with fully transformed HD3 cells.
Figure 2 Identification and characterization of a v-ErbA binding site in CA II. (A)
32Immunoprecipitation of v-ErbA-DNA complexes. P-labeled DNA fragments generated by 
HinfI (H), DdeI (D) and RsaI (R) digestion of clone pCA IIX/N were incubated with HD3 
extracts, with increasing concentrations of F2 competitor oligonucleotide. gag-v-ErbA-DNA 
complexes were immunoprecipitated with anti-gag 1G10 mAb bound to Dynal beads. Arrows 
indicate the position of the selected fragments. (In) input; (M) DNA marker and fragment size 
(bp). Also shown is a schematic presentation of the selected fragments with respect to the 
HS2 region. (B) In vitro DNase I footprinting on the RsaI fragment (coding strand). Naked 
DNA (lanes 1-2), incubated with HD3 extract (lanes 3-4), with anti-gag 1G10 mAb- 
immunoenriched (lanes 5-6) or -immunodepleted HD3 extracts (lanes 7-8). The protected 
region is marked VRE; arrows point to subtle changes in the DNase I pattern that overlap a 
putative GATA-factor binding site; lanes labeled G, A, T and C are dideoxynucleotide 
sequencing reactions. (C) Nucleotide sequence of the RsaI-AluI DNA fragment spanning the 
HS2. The VRE is marked by arrows and three putative GATA-factor binding sites are
32underlined and numbered. (D) Gel-retardation assay of a P-labeled synthetic oligonucleotide 
containing the VRE sequence using HD3 nuclear extract. The complex was super-shifted with 
mAb against v-ErbA (1G10) and RXR (4RX-1D12) or competed by cold VRE, TRE-DR4, F2 
and M1-VRE oligonucleotides.
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Intriguingly, additional G residues outside of the VRE were found to be 
protected from DMS methylation in erythroid cells regardless of their differentiation 
state. This protection indicates that the putative regulatory complex on HS2 may at 
least be partially assembled in undifferentiated cells prior to activation of CA II 
expression. Two of these DMS protections are within potential binding sites of 
members of the GATA family of transcription factors (Ko and Engel, 1993), located at 
nucleotides 31-35 (G1) and 58-61 (G2) (underlined in Figure 2C). Taken together, the 
occupancy of the HS2-VRE in vivo in undifferentiated erythroid progenitors correlates 
with the lack of transcription at the CA II promoter and lends support to the notion that 
v-ErbA represses CA II transcription through the putative HS2 enhancer.
B Non-coding strand
V
R
E
DMS DNase I
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8
Figure 3 DMS and DNase I in vivo footprinting. DMS (lanes 1-4) and DNase I (lanes 5-8) 
in vivo footprinting of (A) the coding strand, and (B), the non-coding strand, in HD3 cells 
before (lanes 2 and 6) and after (lanes 3 and 7) induction of differentiation, in chicken embryo 
fibroblasts (lanes 4 and 8) and on naked genomic DNA (lanes 1 and 5). The VRE and putative 
GATA-sites are boxed; protected G-residues are indicated by asterisks (*).
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HS2 is an enhancer
To test whether the HS2 indeed functions as an enhancer, the 137 bp RsaI-AluI 
fragment spanning the HS2 region was cloned in front of a tk promoter-CAT reporter 
and tested in HD3 cells (Figure 4A). Transcription originating from the tk promoter 
was minimally activated ~2-fold by HS2 (Figures 4B). However, a HS2 fragment 
carrying a mutation in the VRE that abolishes v-ErbA binding (Figure 2D and data not 
shown) and placed in front of the tk promoter (M1-HS2) boosted the level of 
transcription ~20- to 30-fold as compared with the level of transcription obtained with 
the wild-type HS2 enhancer (Figure 4B). The very potent activation of transcription 
from the HS2 enhancer obtained upon mutating the v-ErbA binding site can best be 
explained by the loss of v-ErbA repression. Placing an oligonucleotide comprising the 
VRE in front of tk repressed the level of transcription only ~2-fold whereas the F2- 
element from the chicken lysozyme gene (F2-tk) (Baniahmad et al., 1990) conveyed 
5- to 7-fold repression. A multimerized VRE placed in front of tk did not result in a 
significant potentiation of the repressive activity (data not shown); neither did an 
oligonucleotide M1 give significant enhanced activity. Furthermore, HS2 and M1-HS2 
did not function as enhancers in the non-erythroid cell lines tested suggesting that the 
enhancer may be erythroid-specific (G.G.Braliou and H.G.Stunnenberg, unpublished 
observations). We conclude that HS2 comprises a genuine enhancer whose activity is 
repressed by the action of v-ErbA.
We next assessed the identity and biological significance of the putative GATA 
factor binding site as identified by in vivo DMS footprinting in immature as well as 
differentiating HD3 cells (Figure 3B). Bandshift assays revealed the presence of a 
protein in HD3 extracts that binds to an oligonucleotide spanning nt 24-44 (comprising 
the first putative GATA-factor binding site). This protein-DNA complex could be 
supershifted with a monoclonal antibody directed against GATA-1, but not by 
antibodies against GATA-2 and -3 (Figure 4C). To assess the biological significance 
of this GATA site in vivo, a mutation that abolished GATA binding in bandshift assays 
(data not shown) was introduced within the context of the HS2- and M1-HS2 
fragments, yielding G1-HS2 and G1-M1-HS2 (Figure 4B). Mutation of the GATA-1 
site reduced the transcriptional activity of the HS2-enhancer from an ~2-fold 
activation obtained with HS2-tk to a 2-fold repression with G1-HS2-tk. Moreover,
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mutation of this GATA-1 site in the context of the M1-fragment (mutated v-ErbA 
binding site) caused a 15-fold reduction of the enhancer activity of HS2 as compared 
with M1-HS2-tk. This shows that the GATA-site is critical for the activity of the HS2 
enhancer.
A
B
HS2-tk 
Mt-HS2-tk 
G1 -HS2-tk 
G1-Ml-HS2-Ik
I 1 I I
VB6-tk 
M1-VRE-tk 
F2-tk
Figure 4 Transcriptional repression in v-ErbA expressing HD3 cells is mediated by the 
VRE. (A) Schematic diagram of the tk reporter constructs containing either fragments of HSV 
or synthetic oligonucleotides. The nucleotide sequence of the VRE, M1-VRE and F2 
oligonucleotides are shown, with arrows indicating the half-sites and the crosses indicating 
the mutated bases. In addition to the RsaI-AluI fragment spanning HS2, that fragment 
carrying mutations in the VRE (M1-HS2) or in a GATA site (G1-HS2) or in both sites (G1- 
M1-HS2) was tested. (B) Transient transfection assays of HD3 cells with the above tk 
reporter constructs. Transcription is expressed relative to that of the tk promoter alone. (C) 
Gel-retardation assay of a 32P-labeled synthetic oligonucleotide containing the GATA factors 
binding site using HD3 nuclear extract. mAbs specific for GATA-1, GATA-2 and GATA-3 
transcription factors were added.
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Taken together, mutation of the v-ErbA binding site in the context of the HS2 
enhancer resulted in a marked increase in the activity of the enhancer, as would be 
expected to occur upon inactivation of a repressor binding site. Moreover, 
transcription from the G1-HS2-tk reporter was lower than that obtained by the HS2-tk 
alone (Figure 4B), i.e. the balance between activation by GATA-1 and other 
(erythroid) factors and repression by v-ErbA is shifted towards repression. 
Intriguingly, the v-ErbA binding site does not appear to convey strong repression on 
its own outside of the HS2 context because the level of transcription from the 
heterologous tk- or any other tested promoter can only be reduced 2- to 3-fold (Figure 
4B; data not shown). However v-ErbA very efficiently represses in cis the activity of 
the HS2-enhancer thus ‘neutralizing’ the transcriptional activity of GATA-1 and 
presumably other transcription factors (G.G.Braliou and H.G.Stunnenberg, 
unpublished observations).
Liganded TRa activates transcription through the HS2 enhancer
We reported previously that HD3-V3 cells expressing a gag-cTRa fusion 
protein (V3) to levels similar to that of v-ErbA (Disela et al., 1991; Figure 5E, lanes 1 
and 2) can be induced to express erythroid-specific marker genes such as CA II upon 
addition of T3 (Disela et al., 1991; Schroeder et al., 1992) without inducing 
differentiation. These and other experiments suggested that TR can overcome v-ErbA 
repression by binding to cis-acting sequences that might include the CA II-VRE. We 
therefore pursued the possibility that addition of T3, which should convert the gag- 
cTRa repressor to an activator, would revert the v-ErbA block of CA II expression 
and might induce chromatin changes. In undifferentiated HD3-V3 cells, the HS2 site 
was detectable at relatively high DNase I concentrations and became more pronounced 
within 24 h  of T3 addition comparable with the results obtained in HD3 cells (Figure 
5 A; data not shown). HS1 and prHS also became more apparent upon T3 induction 
concomitant with the appearance of CA II mRNA (Figure 5B and C). The overall 
effects of T3-activated gag-cTRa are modest with respect to chromatin alterations, 
probably due to the presence of the constitutive repressor v-ErbA. These data 
nevertheless suggest that gag-cTRa instigates chromatin changes upon ligand 
activation in line with the studies of Wong and colleagues of the autoregulated
Chapter 2 91
Xenopus TRß gene using an in vivo chromatin reconstitution system based on 
injection of single stranded plasmid DNA into Xenopus oocytes (Wong et al., 1997).
Figure 5 Transcriptional activation and chromatin remodeling instigated by ligand-activated 
gag-cTR. (A and B) DNase I hypersensitive site mapping in HD3 cells expressing gag-cTRa 
(named HD3-V3) before or after 24 h of T3 treatment. (C) Northern blot analysis of CA II 
and c-myb in the course of T3 induction in HD3-V3 and the parental HD3 cells. (D) Transient 
transfection analysis of MoMLV-TRE-, HS2-VRE- and M1-HS2-tk containing reporter 
constructs in HD3-V3 cells; before harvesting transfected cells were incubated 22 h in the 
absence (-) or presence (+) of T3. (E) Western blot analysis of gag-v-ErbA and gag-cTRa 
using anti-gag antibody 1G10. Lanes 1 and 2 are HD3-V3 cells 0 and 22 h after T3 treatment; 
lanes 3 and 4 are HD3 cells on day 0, and 4 days after induction of differentiation.
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Next, we tested the ability of the HS2-, M1-HS2-tk and of natural TREs from 
the Moloney murine leukemia virus (MoMLV) (Sap et al., 1990) and from the 
lysozyme gene (F2) (Baniahmad et al., 1990) placed in front of tk to mediate a T3 
response in transient transfection assays in HD3-V3 cells. In the absence of ligand, the 
F2-tk as well as the MoMLV-tk appeared to be repressed (5- and 3-fold, respectively); 
addition of T3 boosted their level of transcription ~5- and 8-fold, respectively. For the 
HS2-tk reporter, addition of T3 resulted in a 4-fold activation, which is significantly 
lower than the maximal level of transcription obtained with the M1-HS2 construct that 
carries the VRE mutation. This reduced T3 responsiveness of the HS2-tk reporter is 
the sum of activation by liganded gag-cTRa and constitutive repression by v-ErbA, 
i.e. positive and negative factors competing for binding to the VRE.
Trichostatin A fails to induce HS2 activity on transfected plasmids, but induces 
transcription from the endogenous CA II gene
So far, we have demonstrated that the VRE bound by v-ErbA conveys strong 
repression of a transfected HS2-enhancer. Furthermore, ligand-activated gag-cTRa 
can partially relieve the repression of the CA II gene if expressed to equivalent levels 
as the constitutive repressor, v-ErbA (Disela et al., 1991; Figure 5E). Taken together 
with our observations that the VRE is occupied in vivo in erythroid cells that do not 
transcribe the CA II gene and that v-ErbA binds to the VRE in vitro, we tentatively 
conclude that v-ErbA acts to repress the CA II gene. A plethora of biochemical, yeast 
two-hybrid and transient transfection assays suggest that an unliganded receptor 
represses transcription via the N-CoR-SIN3A-HDAC complex that possesses intrinsic 
histone deacetylase activity (Chen and Evans, 1995; Hörlein et al., 1995; Alland et al., 
1997; Heinzel et al., 1997; Nagy et al., 1997). Several recent observations have 
reinforced the notion that histone deacetylation plays an important role in repression. 
For example, trichostatin A (TSA) enhances the effects of RA on induction of 
differentiation of myeloid precursors (HL60, NB4 and U937 cells expressing PML- 
RAR and PLZF-RAR), and on activation of transiently transfected RARE reporters in 
these cells (Nagy et al., 1997; Grignani et al., 1998; Lin et al., 1998). Inhibition of 
histone deacetylases can also relieve repression by unliganded TR-RXR bound on a 
TRE-containing template assembled into nucleosomes (Wong et al., 1995, 1997).
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We therefore examined whether histone deacetylases play a role in the 
repression of CA II transcription in HD3-V3 and HD3 cells (Figure 6A; data not 
shown). In HD3-V3 cells, addition of T3 resulted in a 3-fold activation of the HS2-tk 
reporter, while addition of TSA did not affect the level of transcription from this 
promoter. Unexpectedly, addition of both T3 and TSA reproducibly resulted in a 
reduction of transcription rather than an additional increase, as compared with that 
obtained with T3 alone. T3 or TSA treatment activated transcription from the F2-tk 
reporter and the combination of T3 plus TSA resulted in an additional 2-fold 
enhancement. Whether the additive effect of T3 plus TSA is relevant remains to be 
determined, since T3 plus TSA also caused a 2- to 3-fold activation of the parental tk- 
reporter. Transfection of a 3x(RARE2)-tk reporter and addition of RA plus TSA 
resulted in a very strong synergistic activation of transcription (G.G.Braliou and 
H.G.Stunnenberg, unpublished observations). These data imply that although the 
HD3-V3 cells can respond to TSA and T3 or RA treatment as described for other cell 
lines, transcription from the HS2-tk reporter was not similarly affected.
Finally, we performed in parallel Northern blot analysis of the transfected and 
TSA and/or T3 treated cells to test whether the endogenous CA II gene was activated 
upon these treatments (Figure 6B). Surprisingly, the TSA treatment alone resulted in 
significant activation of transcription from the endogenous CA II locus; in addition, 
TSA further boosted the strong activation given by T3 alone. In contrast, the level of 
transcription from the endogenous MYB gene, a marker of undifferentiated erythroid 
cells, was weakly reduced upon T3 treatment (see also Figure 5C) and markedly 
down-regulated by TSA treatment. A combined TSA plus T3 treatment enhanced this 
down-regulation as obtained with TSA alone. The mRNA levels from a constitutive 
gene, band 4.1, were not markedly affected by T3 and/or TSA. Thus, the endogenous 
CA II gene was sensitive to TSA as well as to T3 treatment whereas the transfected 
HS2 enhancer only responded to ligand, but not to TSA treatment. Similar results were 
obtained with the HD3 cells (data not shown).
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Figure 6 Effect of TSA and T3 treatment of HD3-V3 cells. (A) Transient transfection assays 
with the indicated constructs, with CAT activities expressed relative to the tk reporter alone. 
(B) Northern blot analysis of endogenous genes in the treated cells. Cells were treated with 
the indicated reagents for 22 h before harvesting.
Discussion 
v-ErbA acts in cis to repress CA II transcription
To date, the best-documented biological phenomenon which correlates with 
repression by a nuclear receptor is the block of differentiation of chicken erythroid 
progenitors mediated by the v-ErbA and v-ErbB oncogenes (Zenke et al., 1988, 1990; 
reviewed in Beug et al., 1996). v-ErbA is postulated to contribute to erythroleukemia
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by repression of erythroid-specific target genes such as CA II (Zenke et al., 1990; 
Disela et al., 1991; Bauer et al., 1997). It has remained unclear whether this 
presumptive negative function of v-ErbA is mediated in cis through a v-ErbA response 
element or via protein-protein interactions with other transcription factors. We and 
others initially identified and characterized a TRE in the promoter region of CA II 
(Disela et al., 1991; Rascle et al., 1994). Notwithstanding extensive analysis, we could 
not demonstrate unambiguously that this element functioned as a genuine v-ErbA cis- 
acting element.
In this study, we have assessed the chromatin state and the regulation of CA II 
expression in primary erythroid progenitors and in AEV-transformed erythroid cell 
lines during the course of differentiation. Using in vivo DNase I mapping, we have 
identified two hypersensitive regions, one positioned ~5 kb upstream of the 
transcription start site and one ~8 kb downstream, in the second intron, termed HS1 
and HS2, respectively. Transient transfection experiments revealed that the HS2 
hypersensitive region functions as a genuine enhancer that governs CA II expression. 
Several lines of evidence suggest that v-ErbA binding to the HS2-VRE causes 
repression of transcription. First, immunoprecipitation assays identified a high affinity 
v-ErbA binding site, VRE, that is located in the HS2. Secondly, bandshift assays as 
well as in vitro footprinting showed that v-ErbA specifically binds to this VRE. 
Thirdly, a mutation causing loss of v-ErbA binding to the VRE in vitro resulted in a 
marked derepression of the HS2 enhancer activity in vivo. Fourthly, in transient 
transfection experiments, ligand activation of a gag-cTRa fusion protein partially 
reverted the repression of transcription from the HS2 enhancer which was dependent 
on the presence of the VRE. Finally, DMS and DNase I in vivo footprinting revealed 
that the VRE was protected in undifferentiated cells, whereas protection was lost in 
differentiating cells in which the v-ErbA oncoprotein is inactive.
Besides v-ErbA, other (erythroid) factors are bound to the HS2 enhancer in 
undifferentiated cells, indicating that an enhancer complex is at least partially 
assembled on the HS2 before the onset of CA II transcription. One of the bound 
factors was identified as the erythroid-specific GATA-1 factor. In undifferentiated 
cells, that is in the presence of an active v-ErbA oncoprotein, the pre-assembled 
enhancer complex does not instigate productive transcription. In differentiating cells,
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v-ErbA binding to the VRE cannot be detected and CA II is transcribed, suggesting 
that v-ErbA prevents the activity of the enhancer complex by ‘neutralizing’ the 
activity of transcription factors such as GATA-1. In line with this hypothesis, transient 
transfection assays in undifferentiated HD3 cells revealed that mutation of the VRE 
unleashed potent enhancer activity. Therefore, transcription factors capable of driving 
the HS2 enhancer are present in an active state in undifferentiated cells.
The question arises how v-ErbA prevents the activity of a pre-assembled 
enhancer complex. The widely accepted molecular switch model for nuclear receptor 
action suggests that the unliganded receptor tethers the co-repressor complex 
containing N-CoR-SMRT, SIN3A/B and the histone deacetylase, HDAC (Chen and 
Evans, 1995; Hörlein et al., 1995 ; Alland et al., 1997; Heinzel et al., 1997; Nagy et 
al., 1997). An extension of this model predicts that the v-ErbA-co-repressor complex 
either participates in or instigates the local organization of the chromatin into a 
repressive state. Actually, initial studies suggested that thyroid hormone action was 
mediated by a receptor that stably associates with chromatin independent of the 
presence or absence of ligand (Perlman et al., 1982). This concept was corroborated 
and extended by the recent data from Wolffe and co-workers showing that unliganded 
TR may indeed assist or even be instrumental in setting up a repressive chromatin state 
in Xenopus oocytes (Wong et al., 1995). Our observation that the DNase I 
hypersensitivity of the HS2 as well as of the HS1 region is markedly reduced in fully- 
transformed, v-ErbA-expressing HD3 progenitors as compared with primary erythroid 
progenitors is consistent with a role of v-ErbA in setting up or stabilizing repressive 
chromatin. Our TSA experiments strongly suggest that histone deacetylases play a role 
in repression of the chromatin-embedded CA II gene. Similarly, Wong and co-workers 
showed that histone acetylation/deacetylation plays a role in repression and activation 
by wild-type TR in Xenopus oocytes (Wong et al., 1997). It seems likely that the 
histone deacetylase-containing N-CoR-SMRT-SIN3A-HDAC complex is targeted to 
the CA II locus by v-ErbA; however, formal proof is lacking at this stage. Recruitment 
of the HDAC activity to the locus is, however, unlikely to be the only step leading to 
repression. In fact, our transient transfection assays performed in the presence of TSA 
and/or T3 suggest that v-ErbA can repress the HS2-enhancer activity independent of 
histone deacetylase activity. Hence, v-ErbA binding to its site in the HS2 enhancer
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may also act directly or via the N-CoR-SMRT or SIN3A components of the co­
repressor complex on (erythroid) transcription factors bound to the CA II enhancer to 
‘neutralize’ their transcriptional activity. The observed non-responsiveness from the 
HS2 enhancer to TSA or TSA plus T3 treatments is particularly striking in light of the 
results with the F2-tk reporter. Furthermore, a strong synergism between RA and TSA 
has been observed in NB4 cells (Lin et al., 1998), in U937 cells stably transfected with 
PML-RAR and PLZF-RAR (Grignani et al., 1998), in P19 EC cells (Minucci et al., 
1997) or HD3 cells (G.G.Braliou and H.G.Stunnenberg, unpublished observation). In 
all these cases, however, artificial reporter configurations were tested. One 
interpretation of our results is that HDACs do not contribute to repression of the HS2 
enhancer by v-ErbA. Alternatively, acetylation/deacetylation of histones or other 
(basal) transcription factors may be effective only if the HS2 enhancer contains a 
positioned nucleosome. We favor the latter explanation which is in agreement with the 
frequent observations that nucleosomal assembly of transfected plasmids is 
anomalous, for example with the MMTV promoter (Archer et al., 1992). Our findings 
and those of Wong and colleagues underscore the importance of the topology of the 
chromatin-embedded TRE to support TR binding and transcriptional regulation (Wong 
et al., 1997 and this study).
Intriguingly, induction of HD3 differentiation lead to a loss of v-ErbA binding 
to the HS2-VRE, which did not result from a markedly decreased concentration of v­
ErbA in differentiating versus undifferentiated HD3 cells (Figure 5E). One possible 
explanation could be that loss of v-ErbA binding to the VRE was due to changes in 
concentrations of auxiliary factors or in the phosphorylation status of v-ErbA. 
Phosphorylation of v-ErbA at serine residues 16 and 17 was previously shown to be 
critical for its oncogenic activity (Glineur et al., 1990). Also, nuclear hormone 
receptors need to cooperate with receptor tyrosine kinases to block differentiation of 
multipotent hematopoietic cells (Bauer et al., 1997). For example, v-ErbA-expressing 
primary erythroblasts can only be triggered into differentiation upon omission of stem 
cell factor (SCF), whereas AEV-transformed HD3 cells can be triggered into 
differentiation only upon inactivation of the tyrosine kinase oncogene with specific 
inhibitors and upon addition of erythropoietin and insulin (Choi et al., 1986; Zenke et
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al., 1988). It therefore seems plausible that this interruption of tyrosine kinase 
signaling may have affected phosphorylation of v-ErbA or associated (co)factors.
CA II-HS2 enhancer is activated in response to T3
Our previous studies have shown that TRa is likely to take part in erythrocyte 
differentiation as well as in CA II activation (Disela et al., 1991; Schroeder et al., 
1992; Gandrillon et al., 1994). We now show that the HS2 becomes fully open only 
upon T3 treatment and that increased DNase I sensitivity can be observed in the 
promoter region. This ability of liganded TR to remodel the chromatin structure is 
consistent with biochemical experiments, describing the physical interaction among 
nuclear receptors and protein complexes that possess an intrinsic histone 
acetyltransferase activity (Yang et al., 1996). Thus, liganded TR indeed appears to 
counteract the repressive action of v-ErbA by destabilizing the repressive chromatin 
configuration and setting up active chromatin, thereby explaining the observation that 
the HS1 and HS2 hypersensitive sites of CA II, which are only poorly developed in v­
ErbA expressing cells, are very prominent in HD3-V3 cells.
Our transient transfection data with HD3-V3 cells, show that the CA II-HS2 
enhancer can mediate T3-dependent transactivation. The data corroborate and extend 
the notion that v-ErbA occludes TRa from binding to the HS2-VRE, because in the 
presence of T3 the enhancement of transcription by the HS2 is significantly lower 
compared with the M1-HS2, i.e. in the absence of a v-ErbA binding site. In vitro DNA 
binding studies indicate that the v-ErbA-RXR heterodimer has a relatively high 
affinity for the HS2-VRE as compared with a canonical DR4 or F2 element (Figure 
2C). The VRE deviates from the consensus DR4 in the sequence of the 3' half-site (- 
AGGGCT-). Intriguingly, v-ErbA presumably contacts the 3' half-site and the G- 
residue at that fourth position was shown to be preferred by a DNA-binding domain 
containing the GlySer mutation present in the P-box of v-ErbA (Nelson et al., 1994).
Is repression in cis by unliganded receptors a general phenomenon?
Our data clearly show that v-ErbA binds to a response element embedded in 
chromatin and represses transcription of CA II in cis. It is tempting to speculate that, in 
the absence of their respective ligands, other wild-type class II receptors function in a
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manner similar to that observed for v-ErbA. Up to now, only a few biological 
phenomena have been described that may be attributed to repression. The Xenopus 
TRß A gene is repressed by unliganded TRß through a TRE-DR4 (Wong et al., 1995). 
Unliganded TR and v-ErbA repress transcription of the chicken lysozyme gene in vivo 
through the TRE-F2 element (Baniahmad et al., 1990). The 3' hoxb-1 gene is 
reportedly regulated by an enhancer which contains two activating RAREs and one 
repressing RARE (Studer et al., 1994; reviewed in Marshall et al., 1996). In the latter 
two cases, however, it has not yet been demonstrated that the unliganded receptor 
indeed binds to its target site in vivo.
In contrast to the occupancy of the HS2-VRE we observed in erythroid 
progenitors, in vivo footprint assays did not reveal occupancy of the RARE present in 
the RAR2 promoter in the absence of ligand, although a clear protection was seen 
upon RA treatment (Minucci et al., 1994; Chen et al., 1996; Bhattacharyya et al.,
1997). This result is surprising because the RAR2 promoter displays DNase I 
hypersensitivity in undifferentiated P19 embryonal carcinoma cells (Bhattacharyya et 
al., 1997; our unpublished observations) before the onset of transcription. It is not 
inconceivable that the binding of an endogenous RAR receptor may not as readily be 
demonstrable by in vivo footprinting as with the highly expressed oncogenic v-ErbA 
receptor.
The role of unliganded receptors in hematopoietic disorders
Although v-ErbA may not be the prototypic unliganded receptor, the 
phenomenon of repression linked to hematopoietic disorders is a recurring theme. The 
hybrid proteins PML-RAR and PLZF-RAR, the causative agents of APL (Hofmann, 
1992), have recently been shown to block differentiation at a promyelocytic stage by 
acting as transcriptional repressors. Intriguingly, APL cells carrying the PLZF-RAR 
fusion have lost their response to RA treatment and do not differentiate; this correlates 
with the ability of PLZF to interact, independently from the RAR hinge region, with 
co-repressors such as N-CoR or SMRT (Grignani et al., 1998; Lin et al., 1998). 
Overexpression of a dominant negative variant of RAR lacking activation functions in 
lymphohematopoietic progenitors reveals the ability of this truncated protein to block 
differentiation of these cells; the repressor activity of RAR seems to contribute at least
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in part to this phenotype (Tsai et al., 1994). Thus, class II nuclear receptors in the 
repressive ‘off5 mode may play an important role, both in hematopoiesis and in other 
biological processes. Unraveling the mechanisms of gene silencing is likely to provide 
novel insight into the multifaceted activities of class II nuclear receptors either as 
transcriptional repressors or as activators, in normal and in disregulated differentiation.
Materials and methods 
Cell culture
Two derivatives of the AEV-transformed cell line HD, namely HD3-EpoR and 
HD3-V3, expressing, respectively, the murine erythropoietin receptor or a gag-chicken 
TRa fusion, were used. Primary erythroblasts and these cell lines were grown in CFU- 
E medium (Dolznig et al., 1995); the medium for primary erythroblasts was 
supplemented with SCF to promote proliferation (Mellitzer et al., 1996). 
Differentiation was induced in differentiation medium (Dolznig et al., 1995). In HD3- 
EpoR cells, 5 ^M of the tyrosine kinase inhibitor PD 153035 (Fry et al., 1994) was 
added to inhibit signaling from the v-ErbB oncoprotein. Before T3 treatment, HD3-V3 
cells were grown for 48 h in medium containing stripped serum; 150 nM T3 was 
added to the medium where indicated. CEF were grown as described (Fuerstenberg et 
al., 1992).
DNase I hypersensitivity assay
In vivo DNase I hypersensitivity assays were performed essentially as described 
(Stewart et al., 1991). Briefly, cells were washed twice with phosphate-buffered saline 
(PBS) and incubated for 4 min at room temperature in a buffer containing 0.2% NP-40 
and increasing concentrations of freshly prepared DNase I; HD3-EpoR cells with 1, 2, 
4, 8, 16 and 32 and primary erythroblasts with 1, 2, 4 U per 106 cells, respectively. The 
reactions were stopped by the addition of 20 mM EDTA and 20 ^g/ml RNaseA (final 
concentrations). Cells were lysed by addition of 1% SDS, 50 mM Tris-HCl pH 8 and 
200 ^g/ml Proteinase K and incubation overnight at 37oC; DNA was then purified by
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phenol extraction and ethanol precipitation. Genomic DNA (20 ^g) was digested with
32XbaI and hybridized with the P-labeled riboprobes, SacI-XbaI and StuI-XbaI, as 
indicated schematically in Figure 1A.
Enzyme accessibility assay
Nuclei were prepared from differentiating and undifferentiated HD3-EpoR 
cells, resuspended in the appropriate restriction enzyme buffer and incubated for 1 h  
with 200 U of SpeI or StyI for HS1 and HS2 analyses, respectively. DNA was 
extracted and analyzed as described in the above paragraph.
Northern blot
Total RNA was extracted using the guanidium-CsCl method; CA II, c-myb, 
band4.1 and a-globin mRNA level were detected by Northern blot analysis as 
previously described (Zenke et al., 1990).
Co-immunoprecipitation of v-ErbA-DNA complexes
The clone pCA IIX/N containing a 17 kb fragment of the CA II gene (cloning 
will be described elsewhere) was digested with HinfI, RsaI and DdeI, respectively, and 
labeled. DNA (5 pmol) was incubated with HD3 extracts in 20 mM HEPES pH 7.9, 
100 mM NaCl, 5 mM MgCl2, 15% (v/v) glycerol, 0.1% Triton-X 100, 0.3 mg/ml 
poly(dI-dC) and 2 mM dithiothreitol in the presence of increasing amounts (0.1, 1, 10 
and 100 ng) of a unlabeled competitor oligonucleotide TRE-F2 containing the v-ErbA 
binding site from the chicken lysozyme gene (Baniahmad et al., 1990). v-ErbA-DNA 
complexes were immunoprecipitated using anti-gag 1G10 mAb and goat-anti mouse 
IgG-coated paramagnetic beads (Dynal). Precipitated fragments were analyzed in a 6% 
sequencing gel.
Oligonucleotides used for gel-retardation assays and for cloning in pBLCAT2 vector 
Coding strand:
VRE: 5'-TCGACCCAGCAAGGTCACAGCAGGGCTTTTTTTC-3';
M1-VRE: 5'-TCGACCCAGCAATTTCACAGCAGGGCTTTTTTTC-3',
F2: 5'-TCGACTTATTGACCCCAGCTGAGGTCAAGTTACC-3'
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GATA: 5'-TCGACTCTGACCTATCTCTCTGGAAC-3'
Non-coding strand:
VRE: 5'-TCGAGAAAAAAAGCCCTGCTGTGACCTTGCTGGG-3';
M1-VRE: 5'-TCGAGAAAAAAAGCCCTGCTGTGAAATTGCTGGG-3',
F2: 5'-TCGAGGTAACTTGACCTCAGCTGGGGTCAATAAG-3'
GATA: 5'-TCGAGTTCCAGAGAGATAGGTCAGAG-3'
Oligonucleotide used for mutagenesis: 
mutagenesis-VRE: 5'-CCCTGCTGTGAAATTGCTG-3'; 
mutagenesis-GATA: 5'-CTGACCTAAATCTCTGGAAC-3'.
Gel-retardation assay
Labeled VRE oligonucleotide (20 pmol) was incubated with HD3 protein 
extract for 15 min on ice in the same binding buffer as used for the co- 
immunoprecipitation assays; in antibody-supershifting experiments, anti-gag 1G10 
mAb, anti-RXR mAb or anti-GATA-1, -GATA-2, -GATA-3 were added and 
incubated on ice for an additional 15 min; competition was performed by adding a 
100-fold molar excess of unlabeled VRE, TRE, M1-VRE or F2 oligonucleotides. 
Reactions were loaded on pre-cooled 0.5xTBE, 5% acrylamide gels.
Transient transfection assays
HD3, HD3-EpoR and HD3-V3 cells were transfected using the DEAE-dextran 
transfection procedure as previously described (Choi and Engel, 1988). In a typical 
experiment 10 cells were transfected with 5 ^g of reporter construct together with 1 
^g of EF1-Luc as an internal control, and harvested after 48 h. CAT and luciferase 
activity were measured as described previously (Barettino et al., 1993). Additions of 
150 nM T3 and/or 100 nM TSA were made to HD3-V3 transfected cells grown in 
culture medium containing stripped serum for the last 22 h.
Cloning
An RsaI-AluI fragment of 137 bp spanning HS2 was inserted into the HindII- 
BamHI site of pBLCAT2 vector, yielding pHS2-tk. The HS2 mutants M1-HS2-tk, G1- 
HS2-tk and G1-M1-HS2-tk were generated by oligonucleotide-directed site-specific
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mutagenesis using the oligonucleotides, M1-VRE and G1-GATA, respectively. pVRE- 
tk, pM1-VRE-tk and F2-tk, were constructed by cloning the corresponding 
oligonucleotides containing cohesive SalI and XhoI termini into the XhoI site of 
pBLCAT2.
In vitro DNase I solid-phase footprinting
In vitro DNase I solid-phase footprinting was performed as described 
(Sandaltzopoulos and Becker, 1994). A 291 bp RsaI fragment spanning the HS2 was 
labeled and incubated with HD3 extracts or with HD3 extracts either immunoenriched 
or immunodepleted for v-ErbA using mAb 1G10.
In vivo DMS and DNase I footprinting
Cells resuspended in 1 ml media were treated with 2 |ji DMS for 2 min at room 
temperature, washed twice with cold PBS and resuspended in nuclei buffer (NB: 0.3 
M sucrose, 60 mM KCl, 15 mM NaCl, 60 mM Tris-HCl pH 8.2, 0.15 mM spermine, 
0.5 mM spermidine, 0.5 mM EGTA, 2 mM EDTA, 0.5% NP-40). After incubation at 
4oC for 5 min, nuclei were pelleted, washed twice with NB without sucrose and NP- 
40; DNAs were then extracted as described above for the DNase I hypersensitivity 
assays. DMS-treated DNA samples were treated with piperidine (1 M) for 45 min at 
96oC, chloroform-extracted and precipitated. DNA samples prepared for DNase I 
hypersensitive site mapping were also used for ligand-mediated PCR (LM-PCR) 
mediated DNase I in vivo footprinting using a biotinylated oligonucleotide approach as 
described (Quivy and Becker, 1993) and 1.2 ^g of genomic DNA. The following 
gene-specific primers sets were used: coding strand: 5'-
AGATGTGAACCTGAATGA-3', 5'-CCAGTCTGTGCCAAGTAGTTC-3', 5'- 
GCTGAGTTGAAATCACTG-3'; non-coding strand: 5'-
TGACAAGCAGGAGAGTAA-3', 5'-GAGTAAGAACAGGACGCAA-3', 5'- 
AGCGGATGATGTAGAGAT-3'; the PCR cycling was: 1 min denaturation at 96oC, 2 
min annealing at 50oC and 3 min elongation at 72oC using Expand Long Template 
PCR system (Boehringer Mannheim). Labeled fragments were separated on 6% 
sequencing gels.
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Abstract
v-ErbA is a mutated variant of thyroid hormone receptor (TRa/NR1A1) borne 
by the Avian Erythroblastosis virus causing erythroleukemia. TRa is known to 
actively repress specific genes in the absence of its cognate ligand, T3 hormone. v­
ErbA is unable to bind ligand, and hence cannot act as a positive transcription factor. 
v-ErbA is thought to contribute to leukemogenesis by actively repressing erythroid- 
specific genes such as the carbonic anhydrase II gene (CA II). In the prevailing model, 
v-ErbA occludes liganded TR from binding to its cognate elements and constitutively 
interacts with the corepressors NCoR/SMRT. We previously identified a v-ErbA 
responsive element (VRE) within a DNase I hypersensitive region (HS2) located in the 
second intron of the CA II gene. We now show that HS2 fulfils all the requirements 
for a genuine erythroid-specific enhancer that functions independent of its orientation 
and position. We find that the HS2 enhancer activity is governed by two adjacent 
GATA-factor binding sites. v-ErbA prevents HS2 activity by quenching the positive 
function of factors bound to GATA-sites. However, v-ErbA does not convey active 
repression to silence the transcriptional activity intrinsic to the heterologous tk 
promoter. In contrast, unliganded TR can efficiently quench HS2 enhancer activity as 
well as actively repress a downstream promoter. We propose that depending on the 
sequence and context of the binding site, v-ErbA contributes to leukomogenesis by 
occluding liganded TR as well as unliganded TR thereby preventing activation or 
repression, respectively.
Introduction
Malignant transformation of hematopoietic cells is caused by the disturbance of 
a delicate balance between proliferation and differentiation. The correct functioning of 
members of the nuclear hormone receptor superfamily is required to maintain 
homeostasis, and to promote differentiation of hematopoietic cells. Not surprisingly, 
therefore, mutated, aberrant nuclear receptors are found in many types of cancer and
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diseases (Goldhirsch and Gelber, 1996). Paradigms are fusion proteins involving 
retinoic acid receptor (RARa), PML-RARa, PLZF-RARa and NPM-RARa that 
cause human acute promyelocytic leukemia (APL) (Warrell et al., 1993) and v-ErbA, 
an oncogenic version of chicken thyroid hormone receptor (TRa), involved in avian 
erythroleukemia (AEL) (Beug et al., 1996). Fatal avian erythroleukemia is caused by 
infection with the Avian erythroblastosis virus (AEV) which expresses two co­
operating oncogenes (v-ErbB and v-ErbA). v-ErbB is a mutated epidermal growth 
factor receptor (EGFR) with constitutive tyrosine kinase activity whereas v-ErbA does 
not bind ligand and hence is proposed to display a constitutive silencing activity. 
While v-ErbB alone causes a partial differentiation arrest and a delayed, weak 
erythroleukemia, v-ErbA itself induces disease only when vastly overexpressed (Beug 
et al., 1996). The transformation promoting activity of v-ErbA lies in its ability to 
arrest differentiation of v-ErbB expressing erythroblasts by effectively silencing stage- 
specific erythroid genes such as the carbonic anhydrase II gene (CA II) (Disela et al.,
1991).
Due to mutations in the presumed ligand binding domain, v-ErbA can neither 
bind T3 nor activate transcription. Consequently, v-ErbA is thought to act as a 
dominant negative oncogenic receptor variant that antagonises T3-mediated 
transcriptional activation (Sap et al., 1989). TRa (NR1A1) (Nomenclature committee, 
1999), acts as a ligand-operated molecular switch; firstly, in the absence of ligand, TR 
is proposed to repress transcription via association with corepressors such as 
NCoR/SMRT (Horlein et al., 1995). The corepressors, in turn, recruit histone 
deacetylase (HDAC)-containing complex(es) that stabilise(s) repressive, ‘closed’ 
chromatin structure to assure efficient silencing of downstream genes (Bauer et al., 
1998; Heinzel et al., 1997). Second, upon ligand binding, the receptor undergoes a 
conformational change that causes dissociation of the corepressor complex(es) and 
permits subsequent association of coactivator complexes such as p300/CBP, SRC and 
TRAP/SMCC to activate transcription (reviewed in Glass and Rosenfeld, 2000). 
Hence, the ability of v-ErbA to transform erythroid progenitors can be attributed to its 
repressive unliganded ‘mode’ (Horlein et al., 1995). The fact that many of the 
mutations in v-ErbA abolish activation functions present in genuine TRa (NR1A1), 
(Barettino et al., 1994) is consistent with the occlusion/corepressor model. Although
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attractive, this model awaits in vivo verification; thus far, supporting data have been 
obtained almost exclusively from transient transfection assays, two-hybrid assays and 
in vitro GST-pull down experiments. One observation in particular is difficult to 
reconcile with this model. v-ErbA, as compared to TR, shows lower affinity and 
altered DNA specificity for classical thyroid responsive elements (TREs) mainly due 
to a mutation in the DNA-recognition helix (P-box) (Judelson and Privalsky, 1996). 
Reversion of this mutation restores wild type (TR) DNA binding affinity. However, 
rather than acting as a superoncogene (due to increased DNA binding properties), the 
P-box-reverted v-ErbA variant has lost the ability to transform erythroid cells (Nelson 
et al., 1994). These observations imply that v-ErbA does not merely function as a 
constitutive unliganded TR; moreover, the set for v-ErbA binding sites appears to be 
distinct from or only partially overlapping with that of TR.
In a previous study, we identified a DNase I hypersensitive site (HS2) in the 
second intron of the chicken carbonic anhydrase II (CA II) gene (Ciana et al., 1998). 
CA II is a direct target gene of v-ErbA and deregulation of CA II transcription 
partially accounts for the v-ErbA induced transformation (Fuerstenberg et al., 1992). 
Our data suggested that HS2 might act as an enhancer. We showed that the v-ErbA 
oncoprotein bound to a v-ErbA responsive element (VRE), located within the HS2, 
prevented the activity of the enhancer. Here, we report on a detailed analysis of the CA 
II-HS2 enhancer that provides insight into the mechanism by which v-ErbA affects 
transcription of erythroid-specific genes, therefore blocking differentiation during 
lineage commitment. Using transient transfection assays in AEV-transformed 
erythroid progenitor (HD3) cells we have assessed cis-acting sequences governing the 
CA II-HS2 function and have defined HS2 as a true tissue-specific enhancer that acts 
independent of its position and orientation with respect to the promoter. Furthermore, 
the activation of the HS2 enhancer is dependent on factors bound to GATA-protein 
binding sites and v-ErbA acts by quenching their activity. Our study reinforces that v­
ErbA acts as a dominant negative TR by occluding the VRE and ablating the T3- 
mediated activation of CA II. However, when the HS2-VRE is linked to the tk 
promoter, v-ErbA, but not unliganded TR, is inefficient in repressing the 
transcriptional activity intrinsic to the tk promoter. These data suggest that v-ErbA 
exerts only part of the full complement of negative, repressive activity intrinsic to TR.
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Results 
Carbonic anhydrase II HS2 region acts as a true enhancer
Using DNase I hypersensitivity mapping, we have previously identified a novel 
v-ErbA responsive element (VRE), comprised of two half-sites in a direct repeat 
configuration spaced by 4 nucleotides (DR4), located in a hypersite in the second 
intron of carbonic anhydrase II (CA II) gene, termed HS2 (Ciana et al., 1998). 
Transient transfection assays in AEV-transformed HD3 cells using a HS2-containing 
reporter (HS2-tk) showed that HS2 does not confer any transcriptional activity to the 
promoter. However, mutation of the first half-site of the VRE (M1-HS2-tk), that 
abolished v-ErbA binding resulted in a 30-fold enhancement of transcription (Ciana et 
al., 1998). These and other observations suggested that the HS2 region likely functions 
as an enhancer which is repressed by v-ErbA.
Operationally, enhancers are defined as cis-acting sequences that activate 
transcription of promoters in a position- and orientation-independent manner. To test 
orientation (in)dependency we first placed the M1-HS2 element in both orientations (+ 
and -) upstream of its cognate CA II promoter (-180 to +51) yielding M1-HS2(+)- 
CAII and M1-HS2(-)-CAII constructs, respectively. Transient transfection assays in 
HD3 cells showed that M1-HS2 boosted the level of transcription via the CA II 
promoter to the same extent as observed for the tk promoter reporter (Figure 1B). 
Moreover, the HS2 enhancer acted in both orientations. As expected, the HS2 
fragment with the wild type VRE did not activate transcription from the CA II 
promoter (data not shown). Similar results were obtained with M1-HS2 as an enhancer 
in combination with a longer CA II promoter fragment (1.4 kb, position -1362 to +51) 
(data not shown).
Since the natural position of the HS2 enhancer in CA II gene is in the second 
intron (Figure 1A), we tested whether HS2 could enhance transcription from a position 
downstream of the CA II promoter. Transcription of the resulting constructs (CAII- 
M1-HS2) was boosted 11- to 16-fold (Figure 1C). Analogously, the M1-HS2 fragment 
placed in either orientation downstream of the tk promoter also enhanced transcription 
but to a lesser extent (data not shown).
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Taken together, these results unambiguously show that HS2 acts both upstream 
and downstream of its natural CA II promoter as well as the heterologous tk promoter 
in an orientation independent fashion and is therefore a bona fide  enhancer. 
Furthermore, v-ErbA appears to impair the activity of the potent HS2 enhancer.
HS2 is an erythroid-specific enhancer
To assess whether HS2 acts as a ubiquitous cell-type specific enhancer we 
performed transfection experiments using the HS2-tk and M1-HS2-tk reporters in a 
number of different cell lines including mouse erythroleukemia cells (MEL), chicken 
embryonic fibroblasts (CEF) or mouse fibroblasts (L). The experiments revealed HS2- 
mediated activation of transcription in MEL cells but not in the non-erythroid CEF or 
L cells (Figure 2). The HS2 enhancer activity, therefore, appears to be confined to 
erythroid lineages. In MEL cells, the transcriptional activity obtained with the HS2-tk 
reporter was 6-fold compared to tk reporter alone. This rather moderate level of 
enhancement by HS2-tk as compared to M1-HS2-tk is surprising since MEL cells do 
not express v-ErbA and thus full enhancer activity was anticipated. The lower level of 
enhancer activity in MEL cells is most probably due to differences inherent to these 
two erythroid cell lines used (see also discussion).
Figure 1 The HS2 fragment functions as a true enhancer (A) Schematic representation of the 
CA II locus with exons 1-4 (black boxes) and DNase I hypersensitive sites HS1 and HS2 
(open boxes). The insert details the 288bp (RsaI-RsaI) fragment with Alu I site defining the 3’ 
boundary of the 135 bp fragment used in most of the following experiments. GI, GII and GIII 
indicate position of GATA-sites that were mutated and M1, M2 and M3 show the mutated 
receptor-half-sites. The VRE sequence is boxed. Letters below the sequence indicate the 
substitution mutations in the various HS2 constructs. (B) Transient transfection assays in HD3 
cells with CA II promoter reporter constructs carrying the 135 bp M1-HS2 enhancer fragment 
in both orientations. The values represent the mean value of the relative chloramphenicol 
acetyltransferase (CAT) activity, as normalised by luciferase values of the internal control, of 
at least three experiments, with error bars shown. Transcriptional activity of tk-CAT construct 
is arbitrarily set to 1. (C) Transfection assays in HD3 cells with reporters containing the M1- 
HS2 fragment downstream of the CA II promoter as indicated. Transcriptional activity of CA 
II reporter is set to 1.
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CEF cells L cells
Figure 2 The HS2 enhancer activity is erythroid-specific. Transient transfection assays with 
the indicated tk reporter constructs in various cell lines as shown. The values represent the 
mean value of the relative CAT activity of at least three experiments. Transcriptional activity 
of tk-CAT construct is arbitrarily set to 1.
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Delineation of the HS2 enhancer
To dissect the molecular mechanism of repression by the v-ErbA oncoprotein, 
we set out to identify cis-acting sequences that are important for the observed HS2 
enhancer activity. Given the presence of high levels of v-ErbA in HD3 cells, fragments 
spanning the HS2 and carrying the wild type VRE sequence do not display enhancer 
activity (Ciana et al., 1998). Therefore, we constructed a series of 5’ and 3’ deletion 
mutants within the context of M1(883-1175)-tk, a 288bp fragment encompassing the 
entire HS2, to screen for cis-acting sequences (Figure 3). This construct showed 
enhancer activity comparable to that of the previously analysed, 135 bp containing 
M1-HS2-tk reporter. Two deletions from the 5’ end of the M1(883-1175)-tk fragment 
significantly reduced the HS2 activity (Figure 3), while further deletion including the 
VRE (plasmid (979-1175)-tk) resulted in abolishment of the enhancer activity.
Figure 3 Delineation of the intronic enhancer region HS2 of the CA II gene. Assays of CAT 
expression of HD3 cells transfected with the indicated fragments of HS2 enhancer cloned in 
front of tk promoter. The values represent the mean value of the relative CAT activity of at 
least three experiments. Transcription is expressed relative to tk promoter alone.
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Analysis of a 3’ deletion mutant of M1-HS2-tk (up to position -983) revealed a 
transcriptional activity similar to M1-HS2-tk, while further 3’ deletion including the 
VRE (up to position -958) resulted in slightly lower levels of transcription. Taken 
together, our data show that sequences critical for the enhancer activity are located 
mostly upstream of the VRE. For reasons of consistency, the 135-bp HS2 region used 
in our previous study (Ciana et al., 1998), which exhibits the full enhancer activity in 
HD3 cells, was used in the remainder of the experiments.
GATA-factors binding sites contribute to the HS2 enhancer activity
The obtained overall activity of the HS2 enhancer probably is the net result of 
repression instigated from the VRE and enhancement from positive (erythroid- 
specific) factors binding to the enhancer. We have previously shown (Ciana et al.,
1998) that two of the three potential GATA-factor binding sites present in the HS2 
enhancer fragment (positions 913 and 940 referred to as I and II, respectively) (Figure 
1A) were protected in DMS footprint assays in vivo and showed DNase I 
hypersensitive cutting in vitro. A third potential GATA-site (III, position 990) was 
protected only in in vitro footprint assays. Using electrophoretic mobility shift assays 
(EMSA), we also showed that the GATA-1 protein present in HD3 cells binds to 
GATA-site I. Transient transfection assays confirmed that this GATA-element was 
required for the HS2 enhancer activity.
To elucidate the function of the two other GATA-sites, we introduced 
mutations in these sites in the M1-HS2-tk context i.e. in a configuration in which the 
contribution of the GATA-sites can be monitored. In transient transfection assays in 
HD3 cells, mutation of either of the GATA-sites I or II (GI-M1-HS2 and GII-M1-HS2, 
respectively) abolished enhancer activity (Figure 4). In contrast, mutation of the 
GATA-site III (GIII-M1-HS2) resulted only in a moderate reduction of the enhancer 
activity. These results are in accordance with the deletion analysis (Figure 1B) 
showing that DNA sequences downstream of the VRE do not significantly contribute 
to the overall activity of the enhancer. In conclusion, the HS2 enhancer activity is 
strongly dependent on the two adjacent GATA-factor binding sites (I and II) located 
upstream of the VRE. These observations corroborate and extend the notion that v-
122 Chapter 3
ErbA quenches the positive transcriptional activity of factors (possibly GATA- 
proteins) bound to these GATA-sites.
Figure 4 GATA-factor binding sites are required for the HS2 enhancer activity. Transient 
transfection assays in HD3 cells with tk reporters carrying the M1-HS2 fragment with 
mutations of the individual GATA-sites. The values represent the mean value of the relative 
CAT activity of at least three experiments. Transcriptional activity of tk-CAT construct is 
arbitrarily set to 1.
HS2 contains multiple half-sites
We have previously shown that v-ErbA binds to the VRE as a heterodimer with 
RXR (Ciana et al., 1998). The HS2-VRE deviates from a canonical TRE element in 
the second half-site, an AGGgCt sequence rather than AGGTCA (Figure 1A). Closer 
inspection of the HS2 sequence revealed additional potential nuclear receptor half­
sites. Of particular interest is the non-consensus half-site (position 949-954) located 
six base-pairs upstream of the VRE, which together with the first half-site of the VRE 
form an everted repeat (ER) spaced by 6 nucleotides (Figure 1A). Given that ER6-type 
elements, such as the F2 from the chicken lysozyme promoter, have been shown to be
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targets for v-ErbA regulation of transcription (Baniahmad et al., 1990), we 
investigated the relative contribution of each of these half-sites in the v-ErbA mediated 
transcriptional repression via HS2 by mutagenesis analysis (Figure 5). Transient 
transfection assays of the resulting M2-HS2-tk and M3-HS2-tk constructs in HD3 cells 
revealed enhancement of HS2 transcription suggesting that both the DR4 and the ER6 
elements equally contribute to repression of the enhancer activity. Furthermore, we 
observed that the central consensus half-site alone was sufficient to confer repression 
(2-fold) (Figure 5), consistent with data from Baniahmad and co-workers (Baniahmad 
et al., 1990). Thus, all three half-sites contribute to the v-ErbA-mediated repression, 
but only the central consensus half-site is critical.
tk
^ — 6 I — ► HS2-tk
^ - 6 ■ — M1-HS2-tk
^ - 6 M2-HS2-tk
i — M3-HS2-tk
M1M3-HS2-tk
— ►4 M2M3-HS2-tk
i-------- 1---------1-------- 1-------- 1-------- 1-------- r
0 10 20 30 40 50 60
Relative CAT activity
Figure 5 The HS2 enhancer contains multiple half-sites that can mediate repression by v­
ErbA. Transient transfection assays in HD3 cells with tk reporters containing mutations of the 
indicated potential half-sites (see Figure 1A for sequence). The values represent the mean 
value of the relative CAT activity of at least three experiments. Transcription is expressed 
relative to tk promoter alone.
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VRE can act as a TRE
Given the altered DNA binding specificity of v-ErbA due to the P-box mutation 
(Judelson and Privalsky, 1996), it was not a priori granted that TR could bind to the 
CA II-VRE and mediate T3-dependent activation. We, therefore, performed EMSA 
experiments using the VRE oligonucleotide and extracts from HD3 cells or nuclear 
receptors expressed from vaccinia virus. As shown in Figure 6A, RXR-TR efficiently 
bound to the VRE (lane 8) suggesting that this element may serve as a TRE. Neither v­
ErbA nor RXR alone bound efficiently to the VRE under these conditions (lanes 3-5). 
Addition of the same amounts of v-ErbA plus RXR (lanes 6 and 7) led to formation of 
a protein-DNA complex with a mobility similar if not identical to that obtained with 
HD3 cell extracts (lane 2). The faster migrating complex (lanes 3, 4, 6 and 7) most 
likely represents a v-ErbA monomer bound to the VRE.
To measure the relative affinities of RXR-v-ErbA and RXR-TR for the VRE, 
off-rate experiments were performed. As a competitor, unlabelled VRE probe was 
added in 100- or 1000-fold molar excess to pre-formed complexes and aliquots were 
loaded on a running gel at the indicated time-points. As shown in Figure 6B (and data 
not shown), the complex formed by RXR-v-ErbA disappeared immediately upon 
addition of competitor, whereas under the same conditions the RXR-TR was 
detectable up to 4 minutes after addition of the competitor. The t1/2 for the RXR-v- 
ErbA complex on the VRE is in the range of seconds while that for RXR-TR is in a 
range of minutes. These results show that the affinity of RXR-v-ErbA for the HS2- 
VRE is significantly lower than that of RXR-TR. A gag-TRa receptor fusion (termed 
V3) expressed in the HD3V3 cells (Disela et al., 1991) appeared to bind to the HS2- 
VRE in conjunction with endogenous RXR with kinetics similar to that of 
recombinant RXR-TR (data not shown). These observations suggest that the 
differential binding behaviour of RXR-v-ErbA and RXR-TR was not due to an 
intrinsic difference in DNA binding characteristics between recombinant, vaccinia 
expressed and ‘natural’ receptors. It should be noted that the RXR-TR complex 
formed on the MoMLV-TRE (DR4-type) or on a consensus DR4 is more stable than 
on the VRE (Bugge et al., 1992), emphasising that the VRE is not an optimal binding 
site for RXR-TR.
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To investigate whether the HS2-VRE can mediate T3-induced activation, we 
performed transient transfection assays in HD3V3 cells in which the level of 
expression of V3 (gag-TRa) is comparable to that of v-ErbA (Disela et al., 1991). 
Transfection of the HS2-tk reporter construct in these cells yielded transcription levels 
comparable to those obtained in HD3 cells, thereby suggesting that HS2 enhancer 
activity can be quenched by gag-TRa . Addition of T3 boosted the level of 
transcription 4.5-fold, which is only 25% of the activity obtained with M1-HS2-tk in 
these cells (Ciana et al., 1998). The impaired ability of the wild type HS2 enhancer to 
display full activity in response to T3 is most likely due to the high levels of v-ErbA in 
HD3V3 cells opposing the activation by ligand-bound RXR-V3.
To directly compare the function of the VRE with that of a canonical TRE in 
the context of HS2 enhancer, we replaced the VRE with a consensus DR4 element by 
changing the 3’ most half-site of the VRE (position 971-976) into AGGTCA yielding 
DR4-HS2. In HD3V3 cells and in the absence of hormone, transcription of the DR4- 
HS2-tk construct is repressed to levels similar to that obtained with HS2-tk suggesting 
that unliganded v-ErbA and/or V3 quenched the enhancer activity via a DR4. 
Administration of T3 resulted in elevated levels of activation as compared to HS2-tk 
(7- and 4.5-fold, respectively) (Figure 6C).
Figure 6 Liganded TR binds to and activates transcription from the HS2-VRE. (A) A gel
32mobility shift assay of P-labelled synthetic oligonucleotide containing the VRE sequence 
using HD3 cell-extract or vaccinia-expressed receptor proteins, as indicated. RXR-v-ErbA 
and RXR-TR dimers are indicated with arrows and v-ErbA monomer with an aterisk. (B) Off­
rate assay performed with the same probe as in Figure 6A and either HD3 cell-extract or 
vaccinia-expressed RXR-TR. Lane 1: free probe; lane 2: VRE probe plus HD3 cell-extract; 
lanes 3-7: as in lane 2 plus 1000-fold of unlabeled VRE probe added as competitor, with 
aliquots loaded on the gel at the indicated time points; lane 8: VRE probe plus vaccinia- 
expressed RXR-TR; lane 9-13: as in lane 8 plus unlabeled VRE probe as competitor with 
aliquots loaded on the gel at the indicated time points. (C) Transient transfection assays in 
HD3V3 cells, expressing gag-TRa and v-ErbA, with the indicated tk reporter constructs. 
Black bars denote relative CAT activities in the absence of hormone while hatched bars 
represent CAT values in the presence of T3. Transcription is arbitrarily set to 1 for the to tk 
promoter alone in the absence of hormone.
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To further investigate the ability of the VRE to mediate a T3-response, 
transfection assays were performed in HD3V3 cells using a reporter plasmid 
containing the minimal VRE sequence placed in front of the tk promoter (VRE-tk). 
T3-dependent transcriptional activation of the VRE-tk was merely 1.7-fold, while of 
the F2 element and of the well-characterised MoMLV-TRE was 6- and 8-fold, 
respectively ( Sap et al., 1989; Ciana et al., 1998; and data not shown).
In summary, these data show that thyroid hormone responsiveness can be 
mediated by the VRE in the HS2 context. DR4, however, is more potent since it nearly 
restores enhancer activity as defined by the M1-HS2. Secondly, the VRE by itself 
possess very little activation potential in cells that co-express v-ErbA and gag-TRa.
v-ErbA and gag-TRa act differently to instigate repression via the HS2 enhancer
Unliganded TR and v-ErbA are thought to repress transcription of T3-regulated 
genes. Support for this model is provided by experiments using the F2 element from 
the chicken lysozyme gene promoter; transcription of the F2 element is repressed 6- to 
7-fold as compared to tk alone in HD3 cells (Baniahmad et al., 1992). We have so far 
shown that the wild type HS2 enhancer is ‘neutral’, i.e. it neither enhances nor 
represses transcription from the homologous or from a heterologous promoter in HD3 
cells. This suggests that positive and negative factors regulating its activity are in 
balance. To investigate whether v-ErbA could actively repress the transcriptional 
activity of the heterologous tk promoter we mutated GATA-sites I and II within the 
wild type HS2 enhancer so that the negative transcriptional activity of v-ErbA would 
prevail (Figure 7A). Surprisingly, transfection experiments in HD3 cells showed that 
mutation of these GATA-sites (GI-HS2-tk and GII-HS2-tk reporters) did not reduce 
transcription significantly below that of the enhancerless tk promoter (less than 2-fold) 
(Figure 7A). These data suggest that in HD3 cells v-ErbA does not efficiently, if at all, 
repress the transcriptional activity intrinsic to the heterologous tk promoter.
To test whether the incapacity of v-ErbA to convey transcriptional repression to 
the linked tk promoter was an intrinsic property of v-ErbA and/or dictated by the VRE 
element, similar experiments were performed in HD3V3 cells that express equivalent 
levels of gag-TRa (V3) and v-ErbA. In HD3V3 cells, the levels of transcription of 
GI-HS2-tk and GII-HS2-tk were strongly repressed as compared to HS2-tk and more
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importantly to tk alone (6-fold and 3.5-fold, respectively) (Figure 7A). An even more 
pronounced effect was obtained when a DR4-HS2 enhancer derivative carrying a 
mutation in the GATA-site I was tested. The GI-DR4-HS2-tk reporter yielded a 10­
fold repression of transcription as compared to tk alone in HD3V3 cells whereas the 
repression was less than 2-fold in HD3 cells. Finally, in HD3 cells the minimal HS2- 
VRE element (VRE-tk) yielded 1.3-fold repression of transcription as compared to tk 
whereas in HD3V3 cells the repression was up to 5-fold. Taken together these results 
show that v-ErbA in contrast to gag-TRa is unable to convey repression to the tk 
promoter when bound to the HS2-VRE. This differential activity is dictated by both 
the HS2 context and the VRE since transcription of the F2-tk is equally repressed in 
both cell lines (Figure 7A). Taken together, our data indicate that the ability of the v­
ErbA oncoprotein to repress is not equivalent to that of unliganded gag-TRa.
Discussion
In this study we have continued to probe the function of the leukemia inducing 
oncoprotein, v-ErbA, in the control of transcriptional repression. Our detailed analysis 
of the previously identified regulatory region in the erythroid stage-specific CA II 
gene (Ciana et al., 1998) now provides a more precise model for the v-ErbA-mediated 
repression. Firstly, we have shown that the regulatory region of the CA II gene located 
in the second intron, termed HS2, is a true enhancer that can activate transcription 
independently of its position and orientation relative to the promoter. The apparent 
erythroid-specific activity of the enhancer is dictated primarily by two adjacent 
GATA-factor binding sites. The v-ErbA oncoprotein as well as the unliganded TR can 
efficiently quench the activity of the HS2 enhancer thereby suggesting that v-ErbA 
and unliganded TR interfere with the positive function of the erythroid GATA-factors. 
Secondly, we have shown that the HS2 enhancer can convey T3-mediated activation to 
a heterologous or CA II promoter (Figure 6C and data not shown), providing 
additional evidence for the role of T3 in the activation of CA II transcription (Disela et 
al., 1991). Thirdly, we have provided evidence that v-ErbA bound to VRE, in contrast 
to unliganded TR, is impaired in repressing the tk promoter.
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Figure 7 v-ErbA, unlike unliganded gag-TRa, cannot repress the transcriptional activity 
intrinsic to the tk promoter, when bound to the HS2-VRE. (A) Transient transfection assays in 
HD3 cells (left) and in HD3V3 cells (right) with the indicated tk reporters. The values 
represent the mean value of the relative CAT activity of at least three experiments. 
Transcription is expressed relative to tk promoter alone for both cell lines. (B) Proposed 
model whereby unliganded gag-TRa can both quench the HS2 enhancer and the transcription 
from tk promoter whereas the v-ErbA oncoprotein can only quench the activity of the 
enhancer.
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Mutation and deletion analyses (Figure 3, 4) showed that the HS2 enhancer 
activity is greatly dependent on two GATA-factor binding sites and that v-ErbA when 
bound to the VRE can quench their positive transcriptional activity. Interference of 
nuclear receptor superfamily members with the function of GATA-factors appears to 
be a recurring theme. For example, the promoter of the slow myosin heavy chain 
(MyHC) 3 gene contains one GATA-site and one Vitamin D3 responsive element 
(VDRE). While GATA-factors enhance the transcriptional activity of the MyHC 3 
promoter in both ventricular and atrial cardiomyocytes, VDR inhibits transcriptional 
activity only in ventricular cardiomyocytes (Wang et al., 1998). Moreover, liganded 
glucocorticoid receptor has been shown to inhibit the function of GATA-1 protein on 
the promoters of the ß-major and ß-minor globin genes, which both contain a GATA- 
site adjacent to a GRE. The functional inhibition of GATA-1 was explained as the 
result of a direct interaction between GATA-1 and GR (Chang et al., 1993). In pilot 
immunoprecipitation experiments, we did not observe a direct interaction between 
GATA-factors and v-ErbA; under the same conditions the interaction between v-ErbA 
and NCoR could readily be detected (G. B. and H. S. unpublished observations).
The presence of enhancers in introns, regulating transcription of tissue-specific 
genes, such as the HS2 from the CA II gene is not uncommon. Examples in the 
hematopoietic system are the 3’ enhancer of the chicken adult ß-globin and the 
intronic immunoglobin enhancer (E^) (Emerson et al., 1987). The 3’ intronic enhancer 
of the chicken adult ß-globin gene binds GATA-factors that could co-operate with 
GATA-factors bound to a site proximal to the TATA box to instigate transcription of 
ß-globin gene (Emerson et al., 1987). We speculate that a similar mechanism may be 
in place for the CA II locus since the CA II promoter contains a GATA-motif. Our 
findings that HS2 can enhance transcription from its own CA II promoter more 
efficiently compared to the heterologous tk promoter, is in line with this model. 
Further investigations are required to address the nature of the interference of v-ErbA 
with GATA-factors activity on the CA II-HS2 enhancer.
In the erythroid MEL cells, the activity of the HS2 enhancer is moderate 
relative to that obtained in HD3 cells (Figure 2). This apparent discrepancy probably 
reflects intrinsic differences in the constellation of transcription factors in the cell lines 
used. In MEL cells, endogenous TR could not be detected and T3-treatment of MEL
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cells transfected with HS2-tk did not result in significant activation of transcription 
(data not shown) implying that the endogenous TR levels in MEL cells are low and not 
responsible for the diminished HS2 enhancer activity. Moreover, transfection of a F2- 
tk reporter containing the strong VRE/TRE from the chicken lysozyme gene 
(Baniahmad et al., 1992) did not yield transcriptional repression in this cell line in the 
absence of TR co-expression (Figure 2). Given that the HS2 enhancer activity is 
dependent mainly (if not solely) on erythroid factors bound to GATA-sites (Figure 4), 
the moderate six-fold enhancer activity of HS2 in MEL cells as compared to HD3 cells 
may be explained by lower levels of transcriptionally ‘competent’ GATA-factors. In 
fact, MEL cells are kept in an undifferentiated state due to overexpression of the 
transcription factor PU.1, which directly interacts with GATA-1 to inhibit its ability to 
activate transcription and to drive erythroid cells to terminal differentiation (Rekhtman 
et al., 1999).
In previous studies we and others showed that TRa is likely to be involved in 
erythroid differentiation (Disela et al., 1991). We showed that liganded TRa plays a 
role in CA II activation presumably by increasing the accessibility of the HS2 (Ciana 
et al., 1998). The notion that v-ErbA occludes liganded TR from its binding site is 
supported by the fact that substitution of the VRE with a canonical DR4, a better 
binding site for TR, potentiates the T3 response (Figure 6C). Therefore, the sequence 
composition of the VRE is critical for the efficiency of the occlusion since v-ErbA 
occludes liganded gag-TRa more efficiently on the VRE than on the DR4.
As mentioned before, v-ErbA prevents the HS2 enhancer by quenching the 
GATA-factors activity, a function that is exerted locally within the HS2 region. Gag- 
TRa can also quench HS2 activity (Figure 7A, compare HS2-tk in HD3 and HD3V3 
cells) consistent with the observation that in erythroid cells overexpressing gag-TRa 
CA II is repressed in the absence of T3 (Disela et al., 1991; Bauer et al., 1998). 
However v-ErbA, unlike unliganded gag-TRa, was unable to actively repress 
transcription from the heterologous tk promoter when bound to the HS2-VRE (Figure 
7A). Unliganded TRa and TRß have been reported to interfere with the preinitiation 
complex (PIC) assembly to actively repress transcription. It has been shown that TR 
directly interacts with TFIIB (Baniahmad et al., 1993; Fondell et al., 1996; Fondell et 
al., 1993) while v-ErbA is impaired in such an interaction (Urnov et al., 2000). We
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speculate that v-ErbA is unable to interact with TFIIB in the context of the HS2-VRE, 
and thus cannot interfere with factors governing the basal transcription of the tk 
promoter. More and direct experiments will be needed to unravel whether and how v­
ErbA communicates with TFIIB and are expected to shed more light in understanding 
the correlation between repression of gene networks by v-ErbA and its oncogenicity.
Recent data have implicated helix 12 (H12) of the receptors LBD in corepressor 
binding (Renaud et al., 2000; Zhang et al., 1999). Given that v-ErbA lacks an intact 
H12, it is possible that distinct binding affinities for corepressors might account at 
least partially for the differential v-ErbA and TR repression capacity. Our finding that 
v-ErbA and TR show distinct repression activities on the VRE but not on the F2 
element are consistent with observations suggesting repression and corepressor release 
to be dependent on the architecture of TREs (Olson et al., 1998; Wahlstrom and 
Vennstrom, 1998).
In conclusion, v-ErbA appears to regulate transcription in at least three ways: 
firstly, by quenching the activity of GATA-factors bound to the HS2, secondly, by 
occluding liganded TRa and thirdly by interfering with the repression function of 
unliganded TRa (Figure 7B). Similar mechanisms might be in place for other 
erythroid v-ErbA target genes. We propose that v-ErbA, apart from the already known 
ability to occlude liganded TR, can antagonise the function of unliganded TRa as well 
when bound to the HS2-VRE, thus preventing the full silencing function of TRa. It is 
possible that this functional difference in the repressive, unliganded modes of v-ErbA 
and gag-TRa may contribute to v-ErbA oncogenic activity.
Studies on v-ErbA function are moving our knowledge forward to unravelling 
the connections between transcriptional repression and oncogenicity. Applying this 
knowledge will certainly provide novel insights into the molecular mechanisms 
controlling normal and abnormal erythroid differentiation.
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Cell culture
The derivatives of the AEV-transformed cell line HD, HD3-EpoR and HD3- 
V3, expressing the murine erythropoietin receptor or a gag-chicken TRa fusion, 
respectively, were grown in CFU-E medium (Dolznig et al., 1995). Before T3 
treatment, HD3-V3 cells were grown for 48 hours in medium containing stripped 
serum using the anion-exchange resin AG 1-X8 (BIORAD). Chicken embryo 
fibroblasts (CEF) were grown in Iscoves’ medium (Gibco-BRL) supplemented with 
8% fetal calf serum, 2% chicken serum, 100 U/ml penicillin and 100^g/ml 
streptomycin. MEL cells were a kind gift from Philipsen and were grown in DMEM 
(Gibco-BRL) supplemented with 10% fetal calf serum, penicillin-streptomycin and 
non-essential amino-acids (Philipsen et al., 1990). L cells were a kind gift from 
Baniahmad and were grown in DMEM (Gibco-BRL) supplemented with 10% fetal 
calf serum and penicillin-streptomycin as described (Baniahmad et al., 1992).
Transient transfection assays
HD3-EpoR and HD3-V3 cells were transfected using the DEAE-dextran 
transfection procedure as previously described (Choi and Engel, 1988). In a typical
7
experiment, 10 cells were transfected with 5 ^g of reporter construct together with 1 
^g of EF1a-Luc as internal control, and harvested after 48 hours. In HD3-V3 
transfected cells grown in stripped serum-containing culture medium 150 nM T3 was 
added for the last 24 hours where indicated. CAT and luciferase activities were 
measured as described previously (Barettino et al., 1993).
MEL cells were transfected by electroporation as described (Philipsen et al., 
1990). Briefly 2x10 cells were incubated on ice for 10’ with 20 ^g of reporter 
construct together with 5 ^g of EF1a-Luc as internal control and 15 ^g of empty pSG7 
vector to keep the same amount of transfected DNA in all samples. Subsequently, the 
cells were electroporated in a BIORAD gene pulser at 960 ^F and 280 V and after 10’ 
incubation on ice were plated in 10 ml of complete medium. After 48 hours, the cells 
were harvested for measurement of CAT and lusiferase activities.
Materials and Methods
134 Chapter 3
CEF cells and L cells were transfected with the calcium phosphate method as 
described (Barettino et al., 1993). Briefly, 3x105 cells were transfected with 5 ^g of 
reporter construct along with 1 ^g of EF1a-Luc as internal control and 5 ^g of empty 
pSG7 vector to keep the same amount of transfected DNA in all samples. After 16 
hours the cells were washed with phosphate buffer saline (PBS) and harvested after 24 
hours for measurement of CAT and lusiferase activities.
O ligonucleotides u sed  f o r  g e l  retardation  assays a n d  f o r  c lon ing in p B L C A T 2  vector  
Oligonucleotides used for gel retardation 
Coding strand:
VRE: 5'-TCGACCCAGCAAGGTCACAGCAGGGCTTTTTTTC-3';
Non coding strand:
VRE: 5'-TCGAGAAAAAAAGCCCTGCTGTGACCTTGCTGGG-3';
Oligonucleotides used for mutagenesis: 
pBL5’: 5’-TCCCAGTCACGACGTTGTAAA-3’ in pBLCAT2; 
pBL3’: 5’- GTTCGAATTCGCCAATGACAA-3’ in pBLCAT2; 
mutagenesis-VRE-M1: 5'-CCCTGCTGTGAAATTGCTG-3'; 
mutagenesis-VRE-M2: 5’-AAAGCAATGCTGTGACCTTG-3’ 
mutagenesis-VRE-M3: 5’-TTGCTGGTTTACTAGCCTGATAAGG-3’; 
mutagenesis-GI-GATA: 5'-GTTCCAGAGATTTAGGTCAG-3’; 
mutagenesis-GII-GATA: 5’-GGACTAGCCTTGTAAGGTA-3’; 
mutagenesis-GIII -GATA: 5’-CTACGTAATTGGTAAATCATA-3’; 
mutagenesis-VRE-DR4: 5’-CTCATAAGAAAAAATGACCTGCTGT-3’ 
Oligonucleotides used for cloning:
Upper strand
M 1-927-945: 5 ’ -CCC AAGCTTATCCTTGCTACCTTATCAG-3 ’ (HindIII site 
underlined)
M 1-951-971: 5’-CCCAAGCTTTCCCCCAGCAATTTCACAGCA-3 ’ (HindIII site 
underlined)
979-998: 5’-GCTCTAGAGCTTTCTTATGAGATACCAA-3’ (XbaI site underlined); 
underlined)
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CAII upper: 5’-CTTTGATCTGCGCCTCCA-3’
Lower strand
1021-1004: 5’-GCTCTAGAGCTTCACCAAAAGAACCTA-3’ (XbaI site underlined) 
M1-983-966: 5 ’-GCTCTAGAGCGAGAAAAAAAGCCCTGCTGT-3 ’(XbaI site 
underlined)
958-938: 5’-GCTCTAGATGGGGGACTAGCCTGATAAG-3’ (XbaI site underlined) 
CAII lower: 5’-CGGGATCCCGCCAGTGATGGGACCTGGTG-3’ (BamHI site 
underlined)
G el retardation assay
20 pmoles of labeled VRE -oligonucleotide were incubated with HD3 protein 
extract (40^g) or vaccinia-virus expressed v-ErbA, TR and RXR proteins for 20’ on 
ice (de Magistris and Stunnenberg, 1988). Binding was performed in 80mM MgCl2 ,
0.1% Triton-X 100, 0.1mg/ml poly(dI-dC), 1 mg/ml BSA, 0.2 mM EDTA, 34%(v/v) 
glycerol and 4 mM DTT. Off-rate competition was performed by adding a 100- or 
1000-fold molar excess of unlabeled VRE-oligonucleotide and aliquots were applied 
on pre-cooled and pre-run 0.5xTBE, 5% polyacrylamide gels at the indicated time 
points.
Plasm ids
A RsaI/RsaI fragment of 288 bp spanning the HS2 was inserted into EcoRV site 
of pBlueScript and subsequently subcloned into SalI/BamHI sites of pBLCAT2 
(Luckow and Schutz, 1987), yielded plasmid HS2(883-1175)-tk. M1(883-1175)-tk 
was generated from HS2(883-1175)-tk by oligonucleotide-directed site-specific 
mutagenesis (Seraphin and Kandels-Lewis, 1996) using the oligonucleotides pBL5’ 
and pBL3’ and the mutagenesis oligonucleotide M1-VRE. The HS2-tk construct was 
generated from HS2(883-1175)-tk by PCR amplification using primers pBL5’and 
1021-1004, digested with SalI/XbaI and inserted into SalI/XbaI sites of pBLCAT2. 
M1-HS2-tk was generated from HS2-tk by oligonucleotide-directed site-specific 
mutagenesis using the oligonucleotide M1-VRE.
M1(927-1175)-tk and M1(951-1175)-tk constructs were generated by PCR 
amplification of M1(883-1175)-tk using primers 927-945 and M1-951-971,
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respectively, along with pBL3’, digested with HindIII/XbaI and inserted into 
HindIII/XbaI site of pBLCAT2. (979-1175)-tk construct was generated by PCR 
amplification of HS2(883-1175)-tk using primers 979-998 and pBL3’, digested with 
XbaI and inserted into XbaI site of pBLCAT2. The proper orientation of the insert was 
assessed by sequencing analysis. PCR amplification of M1-HS2-tk with primers 
pBL5’ and M1-983-966 or 958-938, digesting with HindIII/XbaI and subsequent 
cloning into HindIII/XbaI site of pBLCAT2, yielded plasmids M1(883-983)-tk and 
(883-958)-tk respectively. F2-tk plasmid was a kind gift from Baniahmad (Baniahmad 
et al., 1992). Annealing of primers VRE-upper and VRE lower and ligation with 
pBLCAT2 digested with SalI yielded plasmid VRE-tk.
A CA II promoter fragment was PCR amplified using primers CAII-upper and 
CAII-lower (has a mutation in the ATG of CA II), digested with ApaI, filled in with 
Klenow and digested with BamHI. The resulting 263 bp promoter fragment, inserted 
into XbaI, filled in with Klenow and BamHI sites of pBLCAT3, yielded construct 
CAII. Digesting the CAII with SalI, filling in with Klenow and ligating with an 
excised insert from M1-HS2 with SalI/XbaI and filled in with Klenow, yielded 
plasmids M1-HS2-CAII(+) and M1-HS2-CAII(-). For the generation of CAII-M1- 
HS2(+)/(-) the M1-HS2 insert was excised from M1-HS2-tk construct with SalI/XbaI 
filled in with Klenow, and ligated with CAII plasmid digested with SmaI.
M2-HS2-tk and M3-HS2-tk were generated from HS2-tk by oligonucleotide- 
directed site-specific mutagenesis using the mutagenesis oligonucleotides M2-VRE 
and M3-VRE respectively. M1M3-HS2-tk and M2M3-HS2-tk were generated from 
M1-HS2-tk and M2-HS2-tk using the M3-VRE oligonucleotide.
M1-HS2 constructs carrying mutations of the GATA-sites were generated from 
M1-HS2-tk and mutagenesis oligonucleotides GI-GATA, GII-GATA and GIII-GATA. 
Likewise, the GI- and GII-HS2-tk constructs were created from the HS2-tk. DR4-HS2- 
tk was constructed with the mutagenesis oligonucleotide VRE-DR4 from HS2-tk 
construct and from this, using the mutagenesis oligonucleotide GI-GATA, the GI- 
DR4-HS2-tk plasmid was generated. All constructs were checked using sequencing 
analysis.
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Abstract
Unliganded type II nuclear hormone receptors such as thyroid hormone and 
retinoic acid receptors (TR and RAR, respectively) when bound to their cognate cis- 
acting elements are thought to repress transcription via binding to a corepressor 
complex consisting of NCoR/SMRT, HDACs and other polypeptides. v-ErbA, a 
mutated thyroid hormone receptor alpha, shows oncogenic activity which correlates 
with its ability to repress transcription of differentiation-specific genes. In this study, 
we have assessed the role of NCoR (and SMRT) in silencing transcription by v-ErbA. 
We show that endogenous NCoR can interact with v-ErbA in immunoprecipitation 
assays. Using a dominant negative approach, we transiently or stably transfected v­
ErbA expressing HD3 cells with the C-terminus of NCoR (C-NCoR) that do not 
display silencing activity but have retained the ability to interact with nuclear 
receptors. Data presented here show that expression of C-NCoR did not result in 
derepression of transcription of the v-ErbA target gene carbonic anhydrase II (CA II) 
neither did it affect the repression ability of v-ErbA on DR4-containing reporter 
constructs, notwithstanding that v-ErbA could interact with C-NCoR. Therefore, we 
conclude that C-NCoR does not functionally act as a dominant negative corepressor in 
vivo  under the tested conditions.
Introduction
Nuclear hormone receptors are sequence-specific transcriptional regulators that 
are involved in the control of cell proliferation, differentiation, physiology as well as 
in cancer (reviewed in Mangelsdorf and Evans, 1995; Mangelsdorf et al., 1995). Their 
modular structure is well conserved among the members of the family, particularly the 
DNA binding domain (DBD) and the ligand-binding domain (LBD). Nuclear receptors 
such as RAR and TR can act both as activators as well as repressors of transcription 
depending on ligand binding. Extensive studies on the mechanism of transcriptional 
regulation revealed that the function of nuclear receptors is largely mediated by
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coactivators and corepressors that associate with the LBD. Upon ligand binding, the 
conformation of the receptor becomes permissive to interaction with coactivators such 
as CBP/p300, PCAF (Blanco et al., 1998) and the p160 family proteins such as SRC- 
1, GRIP/TIF2, ACTR/RAC3/P/CIP and TRAM1 (reviewed in Horwitz et al., 1996; 
McKenna et al., 1999; Glass and Rosenfeld, 2000). Recently the coactivator proteins 
were shown to either posses intrinsic histone acetyltransferase (HAT) activity or to 
recruit/interact with HATs (reviewed in Glass and Rosenfeld, 2000). Hyperacetylation 
of histones is correlated with transcriptionally active genes and thus, it is postulated 
that coactivator recruitment by nuclear receptors contributes to the stabilisation of an 
‘open’, active chromatin structure (reviewed in Pazin and Kadonaga, 1997).
In the absence of ligand, nuclear receptors repress transcription. Originally, it 
was postulated that the repressive function of receptors was due to their ability to 
squelch limiting coactivators (Kamei et al., 1996) or auxiliary heterodimerisation 
partners such as RXR (Barettino et al., 1993; reviewed in Glass and Rosenfeld, 2000). 
More recently, a search for cofactors involved in the repressive function of nuclear 
receptors led to the identification of Nuclear receptor Co-Repressor (NCoR) (Horlein 
et al., 1995; Kurokawa et al., 1995; Zamir et al., 1996), Silencing Mediator for 
Retinoid and Thyroid hormone receptors (SMRT) (Chen and Evans, 1995), TR- 
associated cofactor (TRAC2) (Sande and Privalsky, 1996), SunCoR (Zamir et al.,
1997) and Alien (Dressel et al., 1999). NCoR is 270 kDa protein and shows a bipartite 
structure consisting of a repression region at the N-terminus and a receptor interaction 
region at the C-terminus. The repression region comprises at least three autonomous 
repression domains that can transfer active repression to a heterologous DNA binding 
domain (Chen and Evans, 1995; Horlein et al., 1995; Li et al., 1997; Nagy et al.,
1997). SMRT was initially reported to be a 170 kDa protein, however, more recently, 
alternative splice variants encoding a 270 kDa protein have been reported with an 
analogous bipartite structure like NCoR (Ordentlich et al., 1999; Park et al., 1999). 
NCoR/SMRT interact with unliganded RAR and TR via two receptor interaction 
domains (RID) located at the very C-terminus of the corepressors (Horlein et al., 1995; 
Sande and Privalsky, 1996; Seol et al., 1996; Li et al., 1997; Cohen et al., 1998; Hu 
and Lazar, 1999; Perissi et al., 1999; Wong and Privalsky, 1998).
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NCoR and SMRT are thought to be essential for the transcriptional repression 
activity of nuclear receptors (Chen and Evans, 1995; Horlein et al., 1995; Kurokawa et 
al., 1995; Li et al., 1997; Hu and Lazar, 1999). NCoR antibody microinjection into 
cells blocked active repression mediated by TR (Heinzel et al., 1997). Thyroid 
hormone resistance syndrome correlates with mutations in the LBD of TRß that 
enhance ligand independent interactions of TRß and NCoR/SMRT (Yoh et al., 1997). 
The model of corepressors association with class II nuclear receptors to repress 
transcription has become more complicated since the discovery of mammalian 
homologues of the yeast Sin3 repressor, which interact with NCoR and SMRT (Alland 
et al., 1997; Heinzel et al., 1997; Nagy et al., 1997). Purification of the murine SIN3 
complex showed interaction of SIN3 with the histone binding proteins RbAp 48/46, 
the histone deacetylases HDAC1/2 and two small proteins SAP30 and SAP18 (Zhang 
et al., 1997b; Laherty et al., 1998). The model was proposed that nuclear receptors via 
their association with corepressors interact with the SIN3 complex, which in turn 
recruits HDACs. Recruitment of HDACs leads to a more compact, repressive state of 
chromatin and thus repression by nuclear receptors is attained not only via 
corepressors but also via ‘repressive’ chromatin modifications (Alland et al., 1997; 
Heinzel et al., 1997; Nagy et al., 1997; Wong and Privalsky, 1998; reviewed in Pazin 
and Kadonaga, 1997; Wolffe, 1997). Recently, novel HDAC factors that belong to the 
class II family of HDACs as well as HDAC 3, have been shown to directly interact 
with distinct repression domains of NCoR/SMRT, implying redundant or 
combinatorial mechanisms for HDAC-dependent repressive activity of nuclear 
receptors (Grozinger et al., 1999; Huang et al., 2000; Kao et al., 2000; Wen et al., 
2000).
The v-ErbA protein is an oncogenic mutated variant of TRa and has been 
proposed to interact with corepressors (reviewed in Stunnenberg et al., 1999). v-ErbA 
is encoded by the avian erythroblastosis virus (AEV) which causes sarcoma 
development and fatal erythroleukemia in chickens. AEV expresses a second 
oncogene, v-ErbB, which is a mutated epidermal growth-factor receptor (EGFR) with 
constitutive tyrosine kinase activity. v-ErbB alone causes a delayed, weak form of 
erythroleukemia. v-ErbA potentiates the AEV leukemic phenotype and its 
transformation capacity lies in its ability to tightly arrest differentiation of v-ErbB-
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expressing erythroblasts by effectively silencing different stage-specific erythroid 
genes such as the carbonic anhydrase II gene ( Zenke et al., 1990; Disela et al., 1991). 
It is also postulated that v-ErbA competes with TR for binding to thyroid responsive 
elements (TREs) to represses transcription of T3-regulated genes (Horlein et al., 1995; 
Sap et al., 1989; reviewed in Stunnenberg et al., 1999; Thormeyer and Baniahmad, 
1999). Because of several mutations and a deletion in its C-terminus, v-ErbA cannot 
bind ligand and has lost known activation functions (Barettino et al., 1994). Ligand 
unresponsiveness is thought to lead to constitutive interaction of v-ErbA with the 
NCoR/SMRT corepressor complex.
The interaction interface for NCoR in nuclear receptors was initially reported to 
be the N-terminal part of the LBD (Helix 1) (Horlein et al., 1995; Chen and Evans, 
1995). This was particularly appealing because a transformation deficient molecule of 
v-ErbA designated td359-v-ErbA (Royer-Pokora et al., 1979), that caries a mutation in 
the helix 1, is unable to repress transcription of TRE regulated reporters (Damm et al., 
1987; Damm and Evans, 1993). Likewise, TRa with engineered mutations at helix 1 
fails not only to repress transcription but is unable to interact with SMRT (Chen and 
Evans, 1995; Horlein et al., 1995). However, more recent data demonstrated that the 
extreme C-terminus of LBD (helix 12) as well as helices 3, 4 and 5 comprise the 
critical requirements for the nuclear receptor/corepressor interaction (Baniahmad et 
al., 1995; Lin et al., 1997; Yoh et al., 1997; Hu and Lazar, 1999; Zhang et al., 1999). 
The notion that more than one helices of the LBD are involved in corepressor binding 
is further supported by data demonstrating that three subdomains of v-ErbA on helices
1, 5/6 and 8 co-operatively interact with NCoR and convey the repressive function of 
v-ErbA (Busch et al., 1997; Busch et al., 2000). However, notwithstanding the flood 
of reports, ‘proof of the principle’ for the repressive role of NCoR/SMRT in the 
repressive function of class II nuclear receptors in vivo  remains to be shown.
In the present study, we have assessed the involvement of NCoR in v-ErbA- 
mediated gene repression in v ivo . We have taken a dominant negative approach by 
using the C-terminal part of NCoR, which only comprises the receptor interaction 
domains without any silencing domains. We show that v-ErbA can interact with 
overexpressed C-NCoR as well as with endogenous NCoR from v-ErbA-expressing 
erythroid progenitor (HD3) cells. However, transient or stable expression of C-NCoR
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did not abrogate the v-ErbA mediated transcriptional repression. Similarly, the mRNA 
levels of the v-ErbA target gene, carbonic anhydarse II were not derepressed in HD3 
cells stably expressing C-NCoR. Our results suggest that NCoR/SMRT are not 
involved in the v-ErbA-mediated repression under the conditions used and that 
additional mechanisms apart from transcriptional repression might contribute to the v­
ErbA induced oncogenicity.
Results 
The N-terminus of the LBD plays a critical role in the v-ErbA repressive function
Using in vivo  footprinting experiments we have previously shown that v-ErbA 
binds to a v-ErbA responsive element (VRE) located in an intronic DNase I 
hypersensitive region of CA II gene, named HS2. Evidence for the function of HS2 as 
a genuine erythroid-specific enhancer was obtained by mutating the first half-site of 
the VRE. This mutation unleashed an enhancer activity of 30-fold as a consequence of 
abolishment of v-ErbA binding (Ciana et al., 1998 and chapter 3). These and other 
observations led us to conclude that v-ErbA is a strong repressor when bound to the 
HS2 enhancer thereby neutralising its enhancer activity.
In this study we set out to unravel the molecular mechanism that v-ErbA 
utilises to repress transcription and whether auxiliary factors such as SMRT or NCoR 
are required. To consolidate that the observed repression of the HS2 enhancer was 
instigated by v-ErbA, cotransfection experiments were carried out in mouse 
erythroleukemia (MEL) cells that do not express v-ErbA. In MEL cells, the level of 
transcription of HS2-tk reporter was 6-fold higher than that of tk alone, which is 
consistent with the erythroid specificity of the HS2 enhancer (Figure 1). Transfection 
of HS2-tk along with a v-ErbA expression vector, resulted in repression of 
transcription to the level of tk alone, reinforcing the notion that repression of the HS2 
enhancer activity was indeed instigated by the v-ErbA protein (Figure 1). A v-ErbA 
variant carrying a mutation in helix 1 of LBD, designated td359-v-ErbA, was shown to 
fail to repress transcription from reporters containing artificial TREs (Damm et al.,
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1987; Damm and Evans, 1993). Insertion of the corresponding mutation in TR 
abrogated the interaction of TR with NCoR (Chen and Evans, 1995; Horlein et al., 
1995). Cotransfection experiments in MEL cells showed that td359-v-ErbA did not 
convey transcriptional repression on HS2 (Figure 1), while cotransfection of 
unliganded TR repressed HS2 transcription to the same levels as v-ErbA. These 
observations are in line with data from others (Damm and Evans, 1993) and show that 
mutations in helix 1 of LBD of the v-ErbA affect the repressive function. Combined 
with the recent observation that td359-v-ErbA protein is unable to interact with 
NCoR/SMRT (E Caldenhoven, unpublished observations), our data suggest that 
NCoR/SMRT indeed plays a role in the v-ErbA repressive function.
MEL cells8 i
tk +
HS2-tk + + + +
v-ErbA +
td359-v-ErbA +
c-ErbA +
Figure 1 The HS2 enhancer of CA II is repressed by v-ErbA. Transient transfection assays in 
MEL cells with HS2-tk reporter along with expression vectors for v-ErbA, td359-v-ErbA, c- 
ErbA (chicken TRa) or empty pSG5 vector. The values represent the mean value of the 
relative chloramphenicol acetyltransferase (CAT) activity, as normalised by luciferase values 
of the internal control, of at least three experiments, with error bars shown. Transcriptional 
activity of tk-CAT construct is arbitrarily set to 1.
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v-ErbA interacts with overexpressed exogenous and endogenous NCoR
It has been shown for a number of cell lines that v-ErbA can interact with 
corepressors in mammalian two hybrid assays (Sande and Privalsky, 1996; Hong et 
al., 1998; Busch et al., 2000). Therefore we wished to assess whether such a physical 
interaction between v-ErbA and NCoR can also occur in HD3 cells. We performed 
two-hybrid assays (Figure 2A and data not shown) using Gal4-DBD fused to receptor 
LBDs and a VP16 fusion of a C-terminal part of NCoR (aa 1945-2453). In HD3 cells, 
Gal4-RARa(143-403), a RARa variant that lacks helix H12 (Baniahmad et al., 1992; 
Damm et al., 1993) and Gal4-v-ErbA caused 5-fold repression of transcription 
compared to Gal4-DBD alone whereas Gal4-TRa and Gal4-TRß, caused a 2- to 3-fold 
repression (Figure 2A black bars). Cotransfection of VP16-C-NCoR resulted in a 
moderate but significant derepression of transcription, 3-fold and 9-fold for Gal4-v- 
ErbA and Gal4-RARa(143-403), respectively. The transcription from Gal4-TR fusion 
proteins was not affected by the presence of VP16-C-NCoR. Gal4-v-ErbA and Gal4- 
RARa(143-403) in contrast to Gal4-TRa and Gal4-TRß, do not posses an intact helix 
H12 in their LBDs. It has been demonstrated that absence of H12 strengthens the 
interaction between receptors and corepressors (Chen and Evans, 1995; Chen et al., 
1996; Li et al., 1997; Wong and Privalsky, 1998; Hu and Lazar, 1999; Zhang et al., 
1999). Therefore, it is likely that differential activation by the Gal4-LBDs reflect the 
higher ability of Gal4-v-ErbA and Gal-RARa(143-403) to interact with corepressors 
as compared to Gal4-TRa and Gal4-TRß.
Of note is that neither repression by Gal4-LBDs nor activation with VP16-C- 
NCoR were robust in HD3 cells. A possible explanation is that v-ErbA, present in high 
levels in HD3 cells, squelches endogenous corepressors and consequently transfected 
Gal4-LBDs failed to efficiently interact with corepressors to repress transcription. 
Similarly, VP16-C-NCoR might not be expressed to sufficiently high levels to interact 
with Gal4-LBDs and displace endogenous NCoR. To assess the interaction between v­
ErbA and endogenous NCoR from HD3 cells imunnoprecipitation experiments were 
carried out. v-ErbA was efficiently immunoprecipitated using the monoclonal 
antibody 1G10 directed against the gag-moiety of the v-ErbA protein (Figure 2B). 
Probing the blot with a polyclonal antibody against NCoR revealed its presence in the
150 Chapter 4
1G10 immunoprecipitates. An unrelated monoclonal antibody against the myc epitope 
did neither precipitate v-ErbA nor NCoR (Figure 2B, compare lanes 1 and 3).
Figure 2 ^
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CEF cells
Gal4-1usion DBD v-ErbA TRa TRß RARa
(143-403)
Figure 2 v-ErbA interacts with C-NCoR as well as with endogenous NCoR. (A) Transient 
transfection assays in HD3 cells with a 3xUAS-tk-luc reporter construct along with Gal4- 
DBD, Gal4-v-ErbA Gal4-TRa Gal4-TRß Gal4-RARa (146-403). An expression vector for 
VP16-C-NCoR fusion protein was cotransfected where indicated. (B) Extracts from HD3 
cells were subjected to immunoprecipitation using the monoclonal antibodies against v-ErbA 
(1G10) and myc-epitope (control). Equal amounts of precipitates were analysed by SDS- 
PAGE (7% or 10% polyacrylamide gels) and immun obi otted using antibodies against TRa 
(polyclonal) (upper panel) or NCoR (monoclonal) (lower panel). The input lanes represent 
25% of the extract analysed with immunoprecipitation. (C) Transient transfection assays in 
CEF cells with plasmids as in (A).
Since immunoprecipitation experiments demonstrated the interaction of v-ErbA 
with NCoR but two hybrid assays showed low affinity for this interaction in HD3 
cells, we tested whether Gal4-v-ErbA and VP16-C-NCoR could interact in cells that 
lack endogenous v-ErbA. Therefore transient transfection experiments were performed 
in chicken embryonic fibroblasts (CEF cells). As shown in Figure 2C expression of the
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various Gal4-LBDs strongly repressed (30- to 40-fold) transcription from the 3xUAS- 
tk reporter as compared to Gal4-DBD alone. Upon co-transfection of VP16-C-NCoR, 
a robust 30-fold increase in the level of transcription could be obtained with Gal4- 
RARa(143-403) and Gal4-TRa. A lower but significant 6-fold activation was 
obtained with Gal4-v-ErbA and Gal4-TRß (Figure 2C). Note that the expression levels 
of the transfected Gal4-fusion proteins were similar (data not shown). Taken together, 
these results suggest that type II nuclear receptors including v-ErbA can interact in 
vivo  with NCoR.
Effect of transient transfection of the C-terminus of NCoR/SMRT on 
transcription
To further elucidate the role of the NCoR/SMRT corepressors in vivo, we set 
out to establish a dominant negative approach. The C-terminal parts of NCoR or 
SMRT (from aa 970 to aa 2453 for NCoR and from aa 981 to aa 1495 for SMRT) 
were found to have retained the ability to bind to class II nuclear receptors but do not 
display repression activity in transfection assays (Chen and Evans, 1995; Horlein et 
al., 1995). Thus, co-expression of the receptor interaction domains (RID) would be 
expected to displace the endogenous corepressors bound to v-ErbA, leading to 
abrogation of repression.
We therefore performed transient transfection assays in HD3 cells using 
reporters containing either a single F2 element (everted repeat 6-type TRE), a triplicate 
F2 element, the HS2 enhancer or the MoMLV-TRE (Sap et al., 1989) along with an 
expression vector for C-terminal SMRT (aa 981-1495) or C-terminal N-CoR (aa 1586­
2453) (Chen and Evans, 1995; Soderstrom et al., 1997). Although SMRT-(981-1495) 
and NCoR-(1586-2453) were readily detected in transfected cells by Western blot 
analysis (Figure 3B and 3D), derepression of transcription of the reporter constructs 
appeared to be minor (2- to 4-fold only for SMRT) (Figure 3A and 3C). Taken 
together our results show that C-terminal fragments of NCoR and SMRT do not 
display the anticipated dominant negative activity in terms of transcriptional 
derepression in transfected HD3 cells.
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Assuming a one to one stoichiometry of v-ErbA/NCoR or SMRT in a complex, 
the apparent impairment of NCoR-(1586-2453) and SMRT-(981-1495) to act as 
dominant negative corepressors in HD3 cells, may be due to relatively low levels of 
expression as compared to the high levels of v-ErbA. Moreover, it is possible that the 
function of a C-terminal part of NCoR could primarily be exerted in a chromosomal 
context and only have minor effects in transfection assays. To overcome these 
potential problems we established a HD3 cell line stably expressing the C-part of 
NCoR comprising aa 1945-2453 (C-NCoR). This 1945-2453 region does not contain 
any known Sin3 or HD AC interaction domains (Alland et al., 1997; Heinzel et al., 
1997; Kao et al., 2000; Nagy et al., 1997; Wen et al., 2000). Individual cell clones 
were analysed for continued expression of v-ErbA and de novo  expression of C-NCoR 
using immunoprecipitation assays with the 1G10 (anti-gag) antibody. Apart from 
minor clonal variation, C-NCoR was expressed to similar levels in all individual 
clones analysed. Two cell clones containing either empty vector or C-NCoR (named 
HD3-vec and HD3-dn5, respectively) were selected and used in subsequent 
experiments.
Figure 3 Transiently transfected C-terminal parts of NCoR and SMRT do not significantly 
derepress v-ErbA mediated repression of various reporters. (A) Transfection assays in HD3 
cells with tk, or HS2-, and F2- or MoMLV-TRE-containing reporters along with 1, 3 or 5 .^g 
of SMRT-(981-1495). Transcriptional activity of tk-CAT construct cotransfected with empty 
vector is arbitrarily set to 1. (B) Extracts from HD3 cells transfected with HS2-tk and SMRT- 
(981-1495) were analysed by SDS PAGE and immunoblotted with the anti-SMRT antibody. 
(C) Transfections in HD3 cells with reporters as in (A) along with 3 and 5 .^g of NCoR 
(1586-2453). Transcriptional activity of tk-CAT construct cotransfected with empty vector is 
arbitrarily set to 1. (D) Extracts from HD3 cells transfected with HS2-tk and NCoR-(1586- 
2453) were analysed by SDS PAGE and immunoblotted with the anti-NCoR antibody.
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As shown in Figure 4A, overexpression of C-NCoR did not affect the level of 
v-ErbA expression (lanes 1 and 5). Immunoprecipitation using the 1G10 antibody 
showed that equivalent amounts of v-ErbA were precipitated from HD3, HD3-vec, and 
HD3-dn5 cell extracts (Figure 4 A lanes 2 and 6 and data not shown). Probing the 
Western blot with a NCoR-specific antibody revealed that C-NCoR was efficiently co- 
immunoprecipitated from the HD3-dn5 cell extract (Figure 4B). The unrelated 
antibodies SL39 (against TBP) or M73 (against E1A) did neither precipitate v-ErbA 
nor C-NCoR. In addition, cell fractionation revealed that the vast majority of C-NCoR 
expressed in the HD3-dn5 cell line was localised in the nucleus (Figure 4C). Taken 
together these results showed that stably expressed C-NCoR had retained its ability to 
interact with v-ErbA in co-immunoprecipitation experiments.
Figure 4 Biochemical characterisation of the novel stably transfected HD3-dn5 cell line 
expressing C-NCoR (aa1945-2453). (A) and (B) Extracts from HD3-vec and HD3-dn5 cells 
were subjected to immunoprecipitation using the monoclonal antibodies against v-ErbA 
(1G10) and TBP (SL39) or E1A (M73) as control. Equal amounts of precipitates were 
analysed by SDS-PAGE (10% or 7% polyacrylamide gels) and immunoblotted using a 
polyclonal antibody against TRa (A) or a monoclonal against NCoR (B). The input lanes 
represent 10% of the extracts analysed with immunoprecipitation. (C) Cytosol and nuclear 
extract were prepared from HD3-vec and HD3-dn5 cells, analysed by SDS-PAGE (8% 
polyacrylamide gel) and immunoblotted using the NCoR antibody.
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Activity of C-NCoR
Next we attempted to evaluate the effect of stably expressed C-NCoR on the 
ability of the HD3-dn5 cells to proliferate and to differentiate. HD3-vec and HD3-dn5 
cells were kept in standard growth S13 medium for 9 days and as revealed by 
measurements of cumulative cell number as well as by optical observation of cell 
morphology they did not display any difference in their proliferation potential (Figure 
5A). When the two cell lines were kept under conditions that allow terminal 
differentiation into erythrocytes for 8 days, HD3-vec and HD3-dn5 cells also showed 
similar growth rates (Figure 5B). During all stages of maturation there was a similar 
progression in hemoglobin accumulation in HD3-vec and HD3-dn5 cells (Figure 5C). 
Morphological and histochemical analyses of cytospins confirmed the above results 
(data not shown). Taken together, our data suggest that stable overexpression of C- 
NCoR did neither affect culture requirements nor the overall physiology and growth 
behaviour of HD3 cells.
Since carbonic anhydrase II (CA II) is a v-ErbA target gene and given that C- 
NCoR interacts with v-ErbA, as revealed by immunoprecipitation and two hybrid 
assays, we next assessed whether C-NCoR overexpression affected the transcription of 
CA II. As shown in Figure 7B (lanes 1 and 2, and data not shown), the CA II mRNA 
levels were unaffected in HD3-dn5 cells as compared to those in HD3-vec, suggesting 
that under the tested conditions the function of C-NCoR and consequently of NCoR is 
not crucial for the v-ErbA mediated repression of CA II.
Next we tested whether C-NCoR interfered with v-ErbA-mediated silencing in 
transient transfection assays. In the HD3-vec cell line, transcription levels of the F2-tk 
reporter and the HS2 enhancer were repressed (as compared to tk alone and M1-HS2- 
tk, respectively) to the same extend as in the parental HD3 cell line (compare Figure 
3A and Figure 6, and data not shown). Transcription of the F2 reporters was, if at all, 
only very moderately derepressed in HD3-dn5 cells, (hatched bars) as compared to 
HD3-vec (black bars). Similarly, the levels of transcription from the HS2 enhancer- 
containing reporter (HS2-tk) and the MoMLV-TRE-tk were not significantly affected 
by stable overexpression of C-NCoR (Figure 6). In summary, these data suggest that 
under the employed conditions C-NCoR does not function as a dominant negative 
NCoR with respect to v-ErbA repression via the HS2-, F2- or MoMLV-TRE.
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Figure 5 Biological characterisation of the novel stable transfected HD3-dn5 cell line. (A) 
HD3-vec and HD3-dn5 cells were grown in normal S13 medium and cumulative cell number 
measurements were taken each day. (B) HD3-vec and HD3-dn5 cells were grown in medium 
containing differentiation agents (Epo, Ins and PD 153,035) and cumulative cell number 
measurements were taken each day. (C) Aliquots from HD3-vec and HD3-dn5 cells grown in 
conditions as in (B) were taken each day and subjected to hemoglobin assay as described in 
material and methods.
Does v-ErbB affect v-ErbA/NCoR interaction?
In an attempt to explain the inability of C-NCoR to function as a dominant 
negative NCoR, we tested whether the constitutive tyrosine kinase receptor v-ErbB, 
present in HD3 cells could affect the affinity of v-ErbA for NCoR. An inhibition by v-
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ErbB signalling has been reported for the v-ErbA/SMRT interaction (Hong et al.,
1998). HD3-vec and HD3-dn5 cells were grown in the absence or presence of the 
tyrosine kinase inhibitor PD153,035 to inactivate v-ErbB; SCF, the ligand of c-kit, was 
added to prevent differentiation of the cells (Fry et al., 1994; Bauer et al., 1997). 
Immunoprecipitation experiments using the anti-gag-v-ErbA antibody and HD3-vec or 
HD3-dn5 cell-extracts revealed no difference in the level of coimmunoprecipitated C- 
NCoR (Figure 7A), suggesting that v-ErbB does not affect the v-ErbA/C-NCoR 
interaction.
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Figure 6 Stably overexpressed C-NCoR does not derepress v-ErbA mediated repression of 
various reporters. Transfection assays in HD3-vec (black bars) and HD3-dn5 (hatched bars) 
cells with tk or HS2-, F2-1x-, F2-3x- or MoMLV-TRE-containing reporters. Transcription is 
expressed relative to tk promoter alone for each cell line.
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Figure 7 v-ErB does not interfere with the v-ErbA/C-NCoR physical and functional 
interaction. (A) Extracts from HD3-vec and HD3-dn5 cells grown in normal S13 medium 
plus SCF and in the presence or absence of the tyrosine kinase inhibitor PD 153,035 were 
subjected to immunoprecipitation using the monoclonal anti-v-ErbA antibody 1G10 (middle 
panel) or an unrelated antibody against c-kit (right panel). Equal amounts of precipitates were 
analysed by SDS-PAGE (7% polyacrylamide gels) and immun obi otted using the antibody 
against NCoR. The input lanes (left panel) represent 20% of the extracts analysed with 
immunoprecipitation. The asterisk denotes a non-specific protein that migrates faster than C- 
NCoR. (B) Total RNA was isolated from HD3-vec and HD3-dn5 cells grown as in (A) and 
subjected to Northern blot analysis using probes for CA II and GAPDH.
We, finally, tested whether C-NCoR could affect the regulation of CA II by v­
ErbA in the absence of v-ErbB signalling. As shown in Figure 7B addition of 
PD153,035 did not differentially alter CA II mRNA levels in the HD3-vec and in 
HD3-dn5 cells. It should be noted that in the presence of functional v-ErbB, the 
metabolic activity of the cells is strongly increased which is evident from increased
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levels of GAPDH mRNA. Thus, it appears that v-ErbB signalling does not 
differentiate the CA II mRNA levels in cells expressing C-NCoR.
Discussion
The molecular mechanism that nuclear receptors utilise to regulate gene 
expression has recently received a lot of attention because repression appears to 
correlate with diseases such as thyroid hormone resistance (THR) syndrome (Tagami 
and Jameson, 1998), acute promyelocytic leukemia (Lin et al., 1998) or AEV induced 
erythroleukemia (Graf and Beug, 1983). In this study we have investigated the 
putative role of the corepressors NCoR/SMRT in the v-ErbA-mediated transcriptional 
repression and transformation ability. We employed a dominant negative approach by 
expressing a putative dominant negative corepressor protein, C-NCoR, with the goal to 
relieve the ability of v-ErbA to repress transcription. We showed that although v-ErbA 
was able to interact with overexpressed C-NCoR in immunoprecipitation experiments, 
C-NCoR did neither affect transcriptional repression nor differentiation arrest of cells 
mediated by v-ErbA. Moreover, v-ErbB signalling did not appear to affect either the v­
ErbA interaction with C-NCoR or the v-ErbA-mediated repression of CA II mRNA 
levels in the presence of C-NCoR.
Using transient transfection assays in the erythroid MEL cell line we have 
shown that v-ErbA can repress transcription of the erythroid-specific CA II-HS2 
enhancer. In contrast, expression of td359-v-ErbA carrying a mutation in the helix H1, 
did not result in repression of transcription. Our data are consistent with findings from 
other groups showing that mutations in the CoR-box located at the helix 1 of LBD of 
TR abolish its transcriptional repressive activity and its ability to interact with 
corepressors (Damm et al., 1987; Damm and Evans, 1993; Chen and Evans, 1995; 
Horlein et al., 1995). However, given that CoR-box mutations also disturb interaction 
of nuclear receptors with RXR, it is possible that the region comprising the CoR-box 
serves a more architectural role (Collingwood et al., 1997; Zhang et al., 1997a; 
reviewed in Hu and Lazar, 2000). Structural studies have shown that H1 CoR-box
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residues are buried in the RAR-LBD and thus might not comprise a corepressor 
binding site (Wurtz 1996).
Using mammalian two hybrid assays we showed that both endogenous NCoR 
as well as overexpressed C-NCoR fused to VP 16 can interact with v-ErbA. These 
observations were further supported by immunoprecipitation experiments. Hence a 
dominant negative approach appeared a feasible way to demonstrate the involvement 
of NCoR/SMRT in the v-ErbA-mediated repression. However, transient co-expression 
of the C-terminal portions of NCoR and SMRT did not alleviate transcriptional 
repression of a variety of TRE/VRE-containing reporters in v-ErbA expressing cells. 
Our results suggest either that NCoR/SMRT are not involved in the v-ErbA-mediated 
repression or that NCoR-(1586-2453) or SMRT-(981-1495) were not expressed at 
high enough levels to squelch the endogenous corepressors from v-ErbA.
It is also possible that interference with v-ErbA transcriptional repression and 
transformation capacity by C-terminal parts of NCoR can only be observed on 
chromatin level. Therefore, we established an HD3 cell line stably expressing C- 
NCoR. However, HD3-dn5 cells did not display a differentiation phenotype indicative 
of alleviation of v-ErbA repressive function. In addition, CA II mRNA levels were not 
affected by overexpression of C-NCoR. These observations question the involvement 
of a corepressor complex containing NCoR in v-ErbA-mediated repression of 
transcription and oncogenicity.
Since v-ErbB signalling was reported to disturb the interaction between v-ErbA 
and SMRT (Hong et al., 1998) we also tested whether v-ErbA/C-NCoR interaction 
and regulation of CA II transcription were affected by v-ErbB. Under the conditions 
used, it appears that the presence of an active v-ErbB does not alter C-NCoR 
association with v-ErbA as probed by co-immunoprecipitation assays. Moreover, 
transcriptional regulation of CA II was not differentially affected in HD3-dn5 cells and 
HD3-vec cells by the inactivation of v-ErbB. Thus, the nature of the v-ErbA/NCoR 
interaction might be different from that of v-ErbA/SMRT, which was shown to be 
phosphorylation-dependent (Hong et al., 1998).
The findings that HD3-dn5 and HD3-vec cells are indistinguishable in terms of 
proliferation, differentiation, CA II transcription and transcriptional repression of a 
number of TRE/VRE-containing reporters suggest that C-NCoR does not functionally
Chapter 4 163
displace the endogenous NCoR/SMRT from a putative v-ErbA/NCoR complex under 
the tested conditions. A number of possible mechanisms can be invoked to interpret 
our results. Apart from the shocking possibility that NCoR is not involved in the v­
ErbA mediated repression, it seems likely that there is high redundancy between 
NCoR and other corepressors such as Alien (Dressel et al., 1999). Cell-type 
determinants or fine tuned stoichiometrical requirements may also play a critical role 
in the corepressor usage (Soderstrom et al., 1997). It is also possible that NCoR may 
just act as platform for other regulatory factors to facilitate the function of unliganded 
TR and that NCoR itself is not involved in the repression function of TR. This notion 
is consistent with findings involving negative TREs where transcriptional activation 
mediated by unliganded TR is enhanced upon interaction of TR with NCoR and 
recruitment of histone acetyl transferases (HATs). Upon ligand binding NCoR is 
displaced from TR and presence of HDACs facilitates repression through these 
negative TREs (Darling et al., 1989; Saatcioglu et al., 1993; Tagami et al., 1997; 
Sasaki et al., 1999; Tagami et al., 1999). Consistent with the notion that NCoR serves 
only architectural roles are findings showing that NCoR (or mSin3 and HDAC) 
stabilise TR homodimers bound on DNA which in turn enhances the function of 
unliganded TR (Hollenberg et al., 1996; Cohen et al., 1998; Sasaki et al., 1999; Satoh 
et al., 1999). The possibility that the levels of C-NCoR in HD3-dn5 cells might simply 
be not high enough to saturate the highly overexpressed v-ErbA in HD3 cells cannot 
be ruled out either. It is also possible that NCoR requires other domains apart from the 
C-terminal RIDs to facilitate the stabilisation of a corepressor complex. If so, it is not 
unlikely that C-NCoR did not function as a dominant negative NCoR because C- 
NCoR may have lower affinity for v-ErbA than NCoR and thus it is not able to replace 
the endogenous corepressor from v-ErbA bound to chromatin. Finally we should 
seriously consider that in HD3 cells v-ErbA is not the only factor that regulates 
transcription of CA II gene.
Concluding, our results show that a C-terminal part of NCoR, comprising only 
the two receptor-interaction domains, does not functionally interfere with a putative v- 
ErbA/NCoR repressive complex. These results are puzzling because we could show 
that C-NCoR interacts with v-ErbA and other class II nuclear receptors. Further
164 Chapter 4
experiments will be required to unravel the mechanism of transcriptional repression by 
v-ErbA in vivo.
Materials and methods
Cell culture and transfection assays
A derivative of the AEV-transformed cell line HD, namely HD3-EpoR 
expressing the murine erythropoietin receptor was grown in CFU-E medium (Dolznig 
et al., 1995). Differentiation was induced in differentiation medium containing 5 U/ml 
human recombinant Epo and 0.0004 U/ml insulin (Dolznig et al., 1995). The tyrosine 
kinase inhibitor PD 153035 (5 ^M) was added to inhibit signalling from the v-ErbB 
oncoprotein (Fry et al., 1994). Chicken embryo fibroblasts (CEF) were grown in 
EBM+H (EAGLE (Gibco-BRL), 25 mM Hepes pH7.3, supplemented with 8% FCS, 
2% chicken serum, 100 U/ml penicillin and 100 ^g/ml streptomycin) (Graf and Beug, 
1983). MEL cells were a kind gift from Philipsen and were grown in DMEM (Gibco- 
BRL) supplemented with 10% fetal calf serum, penicillin-streptomycin and non­
essential amino-acids (Philipsen et al., 1990).
Transient transfection assays in CEF cells or HD3 cells (wild-type or 
derivatives) were performed with the calcium phosphate method (Barettino et al.,
1993) or the DEAE-dextran method (Choi and Engel, 1988), respectively. In a typical
5 7
experiment 3.10 CEF cells or 10 HD3 cells were transfected with 5 ^g of reporter 
construct together with 1 ^g of EF1a-Luc or EF1a-CAT as internal control plus the 
indicated amounts of expression vectors or pSG7 or pOGI to keep the same amount of 
transfected DNA in all samples, and harvested after 48 hours. CAT and luciferase 
activities were measured as described previously (Barettino et al., 1993).
CEF cells stable transfected were made as described in (Damm et al., 1987)
6
with pCRNCM-LoxP1-dn-NCoR or LoxP1-pCRNCM empty-vector. Briefly, 10 cells 
in medium without serums were transfected with 7 ^g of expression vector DNA and 1 
^g of helper-virus DNA together with 20 ^g of Dosper transfection reagent 
(Boehringer Manheim). After 4-6 hrs the medium was removed and fresh EBM+H
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medium was added. After 2 days the cells were grown in medium containing G418 for 
selection. The selection stopped after all control cells were dead (5-6 days).
For HD3 cells stable transfectants, CEF (wild-type or stable transfected) cells 
were treated with mitomysin-C (10 ^g/ml) for 2 hours washed and incubated for 4 
hours in normal EBM+H medium. Washed HD3 cells were added on the CEF cells 
and cocultured for 2 days, ficol-purified and resuspended in the appropriate medium or 
selected in semi solid medium containing G418 at 2-3 ^g/ml. After death of control 
cells, the resistant cells were collected under a microscope and resuspended in S13 
medium (Beug et al., 1986).
Plasmids and antibodies
Reporter plasmids HS2-tk, tk, M1-HS2-tk were described in (Ciana et al.,
1998). F2-1x-tk and F2-3x-tk were a kind gift from Baniahmad (Baniahmad et al., 
1990). Expression vector pSG-v-erbA, pSG-c-erbA and pSG-v-erbA-td-359 were 
described in (Barettino et al., 1993; Barettino et al., 1994). Plasmids 3xUAS-tk-luc 
and Gal4-TRß were a kind gift from Heinzel (Heinzel et al., 1997). GAL4-v-erbA, 
Gal4-TRa and Gal4-RARa(135-403) were a kind gift from Baniahmad (Baniahmad et 
al., 1992). C-SMRT (aa 981-1495) and PCDNA3-NCoR-1586-2453 were kind gifts 
from Evans and Heinzel respectively (Chen and Evans, 1995; Soderstrom et al., 1997). 
To generate the PCRNCM-dnNCoR construct the 1524 C-terminal bases of NCoR 
(including the M2 epitope) were PCR amplified from pBKS-NCoR (Soderstrom et al.,
1997) with primers upper (5’ atttGCGGCCGCAGCTAACTTCATAGACGTG 
containing a Not I site) and lower (5 ’ CGCATCGATGTCGACGGCCGC) containing a 
Sal I site). The PCR product was digested with Not I and Sal I. The Sal I excised 
fragment containing His-tag and H902 epitope from pTAG/CMV-neo (Baier et al.,
1994) was subcloned into Sal I digested pLNTLb vector that contains a loxP cassette 
with HSV-tk and neo resistance (gift from Horcher M). The resulting construct was 
digested with Cla I/Not I and together with the Not I/Sal I digested PCR fragment 
containing C-terminus of NCoR with the M2 epitope was ligated into Cla I/Sal I 
digested pCRNCM vector.
To construct the PBKS-VP16-C-NCoR plasmid the pVP16 vector (Clontech) 
was PCR amplified using primers upper 5’-
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AGCGGCCGCGTCTACCATCGAGGGCCT (containing a Not I site) and lower 3’- 
CTCTGCAGCGTACTCGTCAATTCCAAG (containing a Pst I site) and digested 
with Not I and Pst I. Simultaneous ligation of pTag/CMV-neo digested with EcoR 
I/Not I, the Not I/Pst I digested PCR product and pBKS-NCoR digested with Pst I/Kpn
I into EcoR I/Kpn I cleaved pBKS yielded plasmid PBKS-VP16-C-NCoR. Ligation of 
the EcoR I/Kpn I fragment (blunt) into blunted Bgl II/Xba I digested pOGI vector 
resulted pOGI-VP16-C-NCoR.
The following antibodies were used: 1G10 monoclonal anti-gag antibody, 
polyclonal antibody against the DBD/LBD of TRa, polyclonal antibody against 2339­
2453 aa of NCoR kindly provided by Heinzel (Heinzel et al., 1997), monoclonal 
antibody M2 against the M2 epitope of flag-tagged dn-NCoR construct (Kodac), 
monoclonal antibodies against the myc epitope, TBP (SL39) (Ruppert et al., 1996), 
E1A (M73), C-SMRT and c-kit.
Photometric hemoglobin assay
Hemoglobinisation of the cells was measured as previously described (Schmidt 
et al., 1986). Briefly, 50 ^l aliquots of cultured cells were transferred onto a microtiter 
plate, washed with PBS, resuspended in 25 ^l water and frozen down. 125 ^l of a test 
solution (0.5 mg/ml O-phenylenediamine dihydrochloride in 0.1 M citrate phosphate 
buffer pH 5.0, 1 ^l /ml H2O2) were added to each thawed sample and the reaction was 
stopped after two minutes with 125 ^l 8N H2SO4. Absorbances of the samples were 
measured with an Elisa reader (SLT spectra image) at 492 nm with a reference 
wavelength at 620 nm. The results were normalised to hemoglobin content of standard 
erythrocyte lysate.
Immunoprecipitations and immunoblotting
Cell extracts were incubated with 1G10 antibody bound to protein A beads for 
3-5 hrs at 4oC in IP buffer (120 mM NaCl, 5 mM MgCl2, 20 mM Tris-HCl pH 8, 10% 
glycerol, 0.5 mM PMSF, 5 mM ß-mercaptoethanol, 0.01 ^M Aprotinin and 1 ^M 
Leupeptin). After 8 washes the beads were resuspended in laemli buffer (50 mM Tris 
pH 6.8, 100 mM ß-mercaptoethanol, 2% SDS, 0.1% bromophrnol blue, 10% glycerol) 
and loaded into a 7, 8 or 10% SDS-polyacrylamide gel. Electrophoresis was followed
Chapter 4 167
by transfer to nitrocellulose membrane and the blots were incubated overnight with the 
first antibody. Subsequently the blots were incubated with alkaline phosphatase- or 
peroxidase- conjugated secondary antibodies for 2hrs and visualised by chromogenic 
substrate (Promega) or by chemiluminescence (ECL, Amersham), respectively.
Cytosol and nuclear extracts were made as follows: cells were centrifuged and 
washed twice with PBS. Two times the packed cell volume (PCV) of buffer A (10 mM 
Hepes pH 7.9, 5mM MgCl2, 10mM NaCl, 0.1% Triton X-100, 5 mM ß- 
mercaptoethanol, 0.1 mM PMSF) was added and cells were left for 10’ on ice and 
subsequently homogenised. The homogenate was centrifuged at 1440 g for 10’ at 4oC 
and 0.1xPCV from buffer B (150 mM Hepes pH 7.9, 1.4m M NaCl, 15mM MgCl2,
0.1% Triton X-100, 5 mM ß-mercaptoethanol, 0.1 mM PMSF) was added to the 
supernatant. The pellet of the centrifugation was resuspended and homogenised in 
1xPCV of buffer C (20 mM Hepes pH 7.9, 420 mM NaCl, 5 mM MgCl2, 0.1 mM 
EDTA, 20% glycerol, 0.1% Triton X-100, 5 mM ß-mercaptoethanol, 0.1 mM PMSF). 
The homogenate and the diluted supernatant from the previous step were centrifuged 
at 100000 g for 1hr at 4oC. The supernatants were the nuclear extract and the cytosol, 
respectively.
Northern blot
Total RNA was extracted using the TRIzol™ (Gibco-BRL) method; CA II, and 
GAPDH mRNA levels were detected by northern blot analysis as previously described 
(Zenke et al., 1990).
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The v-ErbA oncoprotein is one of the two oncoproteins encoded by the avian 
erythroblastosis virus (AEV) which induces erythroleukemia in chickens. The 
transformation ability of v-ErbA has been correlated with its ability to repress 
transcription of certain erythroid stage-specific genes (reviewed in Beug et al., 1996; 
Stunnenberg et al., 1999). However, the molecular mechanisms of repression by v­
ErbA have remained largely obscure. In the studies described in this thesis, we have 
provided evidence that carbonic anhydrase II (CA II) gene is a genuine v-ErbA target 
gene as previously postulated. Subsequently, we have investigated the interplay 
between v-ErbA and other cofactors that might be involved in its repressive function.
GENERAL DISCUSSION
1. Erythroid-specific transcriptional regulation of CA II gene
Our studies have provided insight into the erythroid-specific expression of CA 
II gene. DNase I hypersensitivity assays revealed two regions in the CA II locus (HS1 
and HS2) that undergo chromatin modifications upon induction of differentiation, thus 
implicating HS1 and HS2 in transcriptional regulation of CA II (chapter 2). It is 
widely accepted that tight packing of DNA into chromatin structure is correlated with 
transcriptional repression. DNase I hypersensitivity can reveal DNA regulatory 
elements such as enhancers, promoters and locus control regions (LCRs), occupied by 
transcription factors. Due to binding of transcription factors, enhancers are able to 
overcome the negative effects of chromatin by establishing an ‘open’, accessible 
chromatin structure (reviewed in Bagga et al., 1998; Blackwood and Kadonaga, 1998; 
Bulger and Groudine, 1999; Higgs, 1998; Li et al., 1999; Maniatis et al., 1998; 
Udvardy, 1999). Thus, the identification of HS2 as DNase I hypersite was the first 
indication that it could function as a regulatory region or enhancer. Enhancers are 
DNA fragments usually spanning 60 to 300 bp containing densely arranged elements 
for regulatory factors such as Sp1, ATF, NF-kB, NF-E2, GATA and architectural 
proteins like HMG I/Y or LEF-1. Their primary function is to locally increase the 
concentration of activating factors to form the enhanceosome. The precise
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arrangement and the identity of the elements are unique for each enhancer (reviewed 
in Carey, 1998).
Sequence inspection of HS2 revealed the presence of cis-acting elements for the 
transcriptionally positive GATA-factors. GATA-sequences were first identified as cis- 
regulatory elements in the promoters of chicken globin genes (Evans et al., 1988). 
GATA-proteins are eryhroid-specific transcription factors and key regulators for the 
different stages of hematopoiesis. Transcriptional activation of most erythroid genes 
that play a role in maturation, survival and terminal differentiation of erythroid 
precursors depends on GATA-factors (reviewed in Orkin, 1992; Orkin, 1996; Orkin 
and Weiss, 1999; Shivdasani and Orkin, 1996). GATA-binding sites are found in the 
different erythroid-specific DNase I hypersensitive sites (HSs) of the ß-globin gene 
LCR and, frequently in conjunction with NF-E2-sites, are the main determinants for 
the establishment of hypersites (HSs). Although the exact mechanism of GATA- 
factor-induced chromatin remodelling is still poorly understood, it has been postulated 
that when bound to nucleosomal DNA GATA-factors induce extensive disruption of 
histone/DNA contacts (Boyes et al., 1998b). Thus, GATA-sites are directly involved 
in chromatin remodelling (Muro-Pastor et al., 1999; Pomerantz et al., 1998; 
Stamatoyannopoulos et al., 1995). In HD3 cells, HS2 gradually opens upon induction 
of differentiation (chapter 2). This is concomitant with the upregulation of GATA-1 
expression during erythroid differentiation (Yamamoto et al., 1990). A model emerges 
in which GATA-sites located in the HS2 enhancer play a role in the erythroid-specific 
expression of CA II gene. According to this model, GATA-factors are involved in the 
establishment of the ‘open’ chromatin structure of HS2. Our observations that in 
primary chicken erythroid cells, HS2 is already accessible by DNase I (chapter 2), and 
that in HD3 cells the two critical GATA-sites are occupied in both undifferentiated 
and differentiating cells are in line with this model.
Recently, it has been reported that acetylation of GATA-1 by p300/CBP 
enhances GATA-1-dependent transcription and induction of differentiation (Blobel et 
al., 1998; Boyes et al., 1998a; Hung et al., 1999). Given that the HS2 activity is 
governed by GATA-sites (chapter 3) we can speculate that GATA-1 together with 
coactivators with histone acetyltransferase (HAT) activity may contribute to the 
formation as well as to the activity of a HS2 bound enhanceosome.
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Intriguingly, the three GATA-sequences present in HS2 show differential 
function. While the two GATA-sites (I and II) located upstream of the VRE are critical 
for the HS2 enhancer activity, the contribution of GATA-motif III (downstream of the 
VRE) appears to be minimal. Recently, it has been reported that transcriptional 
activation by GATA-factors is strongly dependent on the context of the GATA- 
sequence and not only on the DNA binding affinity in vitro (Trainor et al., 2000). 
Therefore, we can speculate that the context and the position and of a GATA-sequence 
with respect to the DNA helix embracing the nucleosome dictates whether a GATA- 
sequence contributes to transcriptional activation or may have an architectural role in 
the enhanceosome assembly.
Given our observation that T3-activated TR can induce chromatin changes in 
HS2 as well as activate CA II mRNA levels, it appears that in vivo  CA II may be 
regulated by TR. It is tempting to speculate that the GATA-factors, present primarily 
in hematopoietic tissue, are required for initiating chromatin changes allowing TR to 
bind and to activate transcription in the presence of ligand. It is also possible that 
synergy between GATA-factors and liganded TR along with recruited coactivators is 
required to activate CA II expression in v ivo . How changes in the composition of HS2 
enhanceosome affect the CA II promoter activity and how promoter/enhancer 
communication is achieved remains to be investigated.
2. Repression by v-ErbA
CA II has been postulated to be a target gene for v-ErbA (Disela et al., 1991; 
Fuerstenberg et al., 1992). Immunoprecipitation of v-ErbA/DNA complexes showed 
that v-ErbA can bind to HS2 suggesting that v-ErbA may act through the HS2 to 
regulate CA II gene transcription (chapter 2). Using two unbiased approaches and 
starting with a 17 kb fragment encompassing a substantial part of the CA II locus we 
have identified a v-ErbA binding site (VRE). Taken together with in vivo  footprinting 
experiments revealing occupancy of the site it can be concluded that v-ErbA, an 
unliganded class II receptor, binds to its responsive element embedded in chromatin.
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In this thesis the mechanism by which v-ErbA represses transcription of CA II 
has been investigated. We have shown that v-ErbA neutralises the activity of factors 
bound to GATA-sites and confirmed that v-ErbA can occlude liganded TR from 
binding to its cognate DNA site in v ivo . Finally we have investigated the involvement 
of corepressors in mediating repression by v-ErbA.
2.1. Quenching the activity of factors bound to GATA-sites
In chapter 3 we have demonstrated that an important role of v-ErbA in 
repression of CA II transcription is quenching the positive action of the GATA-factors 
bound to two adjacent GATA-sites within the HS2 enhancer. How v-ErbA quenches 
the activity of GATA-factors is yet unclear. Given that a direct interaction between v­
ErbA and GATA-factors could not be detected in immunoprecipitation assays, one can 
envision the existence of proteins that act as bridging factors between v-ErbA and 
GATA-factors. Alternatively, since VRE and the two GATA-sites are adjacent, it is 
likely that v-ErbA, possibly in association with a corepressor complex, inhibit the 
interaction of GATA-factors with DNA or with coactivators such as p300/CBP by 
steric hindrances. If an HDAC-containing complex is associated with v-ErbA, it is also 
not unlikely that HDACs deacetylate GATA-factors, thus rendering them inactive. The 
possibility that v-ErbA associates and thus squelches coactivators of GATA-factors 
such as p300/CBP, is highly unlikely since v-ErbA lacks helix H12 that is crucial for 
coactivator interaction (Blanco et al., 1998; Feng et al., 1998; Masuyama et al., 1997; 
Nolte et al., 1998; Rachez et al., 2000; Ren et al., 2000; Westin et al., 1998). 
Additional studies will be needed to unravel how v-ErbA neutralises GATA-factor 
function, and whether and how v-ErbA interferes with promoter/enhancer 
communication.
We have shown that the ability of v-ErbA to neutralise the activity of GATA- 
factors is shared with unliganded TR (chapter 3). Overexpressed unliganded TR also 
causes differentiation arrest and CA II down regulation (Bauer et al., 1998). It has 
been proposed that one determinant of v-ErbA oncogenicity is its overexpression p e r  
se when compared to endogenous TR (Beug et al., 1996). It remains to be elucidated 
whether endogenous unliganded TR represses CA II expression in normal primary
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cells or whether repression is caused by other cellular proteins. Our observations 
(chapter 2) that in primary chicken erythroid cells, the HS2 enhancer is already ‘open’ 
but the locus remains silent is in line with the existence of a cellular repressor 
molecule other than v-ErbA that is bound to HS2 in the undifferentiated state. Apart 
from TR, other members of the nuclear receptor superfamily that bind to cis-acting 
motifs similar to that of v-ErbA, such as COUP-TF, LXR or Rev-ErbA, may bind to 
the HS2-VRE in undifferentiated cells (reviewed in Mangelsdorf and Evans, 1995; 
Peet et al., 1998; Waxman, 1999). Thus, it is not unlikely that overexpressed v-ErbA 
induces transformation because it constitutively mimics the function of a cellular 
repressor.
2.2. Occlusion of TR
In chapter 2 we have demonstrated that liganded TR is able to induce ‘full’ 
opening of the HS2 consistent with other studies showing that ligand-activated TR 
instigates chromatin changes in an in vivo chromatin reconstitution system (Wong et 
al., 1997). We have also shown that liganded TR can activate transcription via the HS2 
region suggesting that the HS2-VRE element can function as a TRE. Taken together 
our data suggest a more general role of TR in transcriptional regulation of CA II gene 
and reinforce the notion that TR is involved in erythroid differentiation (Disela et al., 
1991; Gandrillon et al., 1994; Schroeder et al., 1992).
In cells expressing v-ErbA and gag-TRa at equimolar levels (HD3V3 cells), the 
T3-mediated transcriptional activation of HS2 was not as high as the transcription 
obtained with a HS2-containing construct carrying a mutated VRE (M1-HS2) to which 
neither v-ErbA nor gag-TRa can bind (chapter 2). Thus, it appears that v-ErbA 
occludes liganded TR from binding to the VRE resulting in ablation of the T3-induced 
activation. Such a feature has often been correlated with the ability of v-ErbA to 
sustain cell proliferation (Damm and Evans, 1993; Forrest et al., 1990; Fuerstenberg et 
al., 1992; Sap et al., 1989; Schroeder et al., 1990; Zenke et al., 1990). Interestingly, 
while in transfection experiments the T3-mediated activation of HS2 was moderate (4- 
to 5-fold), the mRNA levels of endogenous CA II were highly enhanced (chapter 2). 
In interpreting the T3-responsiveness in transfection experiments versus endogenous
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CA II transcription, the intrinsic differences in the experimental approaches should be 
taken into consideration. Northern blot analysis of CA II mRNA levels reveals the net 
result of the action of liganded TR that may be exerted at multiple levels. It has been 
reported that TR can bring about chromatin changes by interaction with histone 
acetyltransferases (HATs) (Wong et al., 1998). The TRAP coactivator complex that 
does not contain HAT activity is presumably recruited at a subsequent step (reviewed 
in Glass and Rosenfeld, 2000). Thus, it is possible that the observed CA II mRNA 
levels represent the combinatorial or sequential effect of liganded TR with various 
coactivators. Transiently transfected DNAs do not form a normal nucleosomal 
structure (Archer et al., 1992; Bresnick et al., 1990; Cereghini and Yaniv, 1984; Innis 
and Scott, 1983; Jeong and Stein, 1994a; Jeong and Stein, 1994b; Pennie et al., 1995; 
Reeves et al., 1985; Schlake et al., 1994; Van Lint et al., 1996). Therefore, it is 
possible that in transfection assays the T3-induced activation of transcription from 
HS2 reflects only the function of coactivators without HAT activity.
From our data it is obvious that v-ErbA is able to occlude liganded TR in 
transfection assays. However off-rate experiments show that RXR-TR binds with 
higher affinity than RXR-v-ErbA to the CA II-VRE. Therefore, it is possible that 
additional mechanisms contribute to the ability of v-ErbA to antagonise TR in vivo. 
One can speculate that signalling from v-ErbB to v-ErbA might affect the affinity of v­
ErbA for the DNA element in v ivo . It is also conceivable that the more than 100-fold 
overexpression of v-ErbA as compared to TR (Disela et al., 1991) in the AEV 
transformed HD3 cells compensates for the reduced DNA affinity of v-ErbA.
In conclusion, our data corroborate the notion that v-ErbA occludes liganded 
TR thus repressing T3-activated transcription. We have additionally shown that 
occlusion depends largely on the sequence of the DNA responsive element, because 
substitution of the VRE with a canonical DR4 potentiates the T3-response (chapter 3). 
It is not unlikely that the presence of a weak TRE within the HS2 is one of the 
determinants of the proper timing of CA II expression during differentiation.
Comparing the repressive activities of v-ErbA and unliganded TR revealed an 
unexpected and intriguing observation. While unliganded TR could repress 
transcription from the heterologous tk reporter construct containing the VRE sequence, 
v-ErbA could not repress the intrinsic activity of tk promoter (chapter 3). When acting
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via the everted repeat element F2, both TR and v-ErbA significantly repressed the tk 
promoter activity, reinforcing the critical role of the sequence and the architecture of 
the element for v-ErbA function (Olson et al., 1998; Wahlstrom and Vennstrom,
1998). Thus it appears that the repressive function of v-ErbA is not equivalent to that 
of TR. It is possible that occlusion of unliganded TR by v-ErbA also contributes to the 
transformation activity of v-ErbA.
2.3. Involvement of corepressors in the v-ErbA mediated repression
Immunoprecipitation and two hybrid assays have clearly shown that v-ErbA 
can interact with the corepressor NCoR (chapter 4). Thus, it seemed feasible that 
overexpression of a N-terminally truncated NCoR (C-NCoR) comprising the receptor 
interaction domains (RIDs) and lacking silencing functions would result in 
interference with v-ErbA/NCoR interaction and in a relief of transcriptional 
repression. Surprisingly, using HD3 cells stably overexpressing C-NCoR a functional 
interference of the presumed dominant negative corepressor could not be observed. In 
addition, no differences were observed in the phenotype of the stable cell line 
expressing C-NCoR as compared to ‘empty vector’ cells, leading to the idea that 
NCoR is not crucial for the v-ErbA-mediated repression. It is tempting to speculate 
that NCoR may be a platform protein that can facilitate docking of proteins 
contributing to the repressive function of TR and v-ErbA. This model is corroborated 
by the observations that TR in the presence of ligand associates with HDACs 
repressing transcription via negative TREs, whereas unliganded TR-mediated 
activation is enhanced by NCoR and HATs (Darling et al., 1989; Saatcioglu et al., 
1993; Sasaki et al., 1999; Tagami et al., 1997; Tagami et al., 1999). It is also possible 
that the truncated C-NCoR has reduced affinity for v-ErbA as compared to full-length 
NCoR. Towards this end, v-ErbA may interact with full-length NCoR via other 
domains besides the C-terminal receptor interaction domains (RIDs), thus explaining 
the inability of C-NCoR to behave as a dominant negative NCoR. Additional studies 
are required to assess whether and under what conditions NCoR associates with v­
ErbA in v ivo .
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3. How does v-ErbA regulate CA II transcription?
Based on our and other findings I propose the following model to explain how 
CA II is transcriptionally regulated in erythroid cells and how v-ErbA interferes with 
this mechanism (Figure 1). Early in hematopoietic differentiation, the CA II locus is 
closed. At the stage of erythroid progenitor (or earlier) the two DNase I hypersites 
(HS1 and HS2) are opened. While binding of GATA-1 very likely causes HS2 
opening, the factors involved in HS1 opening remain unknown. However, HS2 
remains transcriptionally inactive. At a next step, p300/CBP associate and acetylate 
GATA-factors triggering the formation of the HS2 enhanceosome and rendering 
GATA-factors capable of activating transcription. Endogenous liganded TR might also 
play a role in the enhanceosome assembly. It is also possible that at this step 
coactivator complexes such as TRAP/SMCC are tethered to HS2 to mediate the 
transcriptional activity of the HS2-enhanceosome. For transcriptional activation of CA
II gene to occur, HS2 has to be brought in close proximity to the promoter by looping 
to locally increase the concentrations of positive transcription factors at the 
neighbourhood of the promoter and to initiate transcription.
In AEV-transformed cells, v-ErbA binds to the HS2 and prevents the activity of 
GATA-factors. Whether v-ErbA prevents their acetylation or their ability to activate 
transcription remains to be seen. By binding to HS2, v-ErbA also occludes liganded 
TR from binding. As a result of this dual activity of v-ErbA, a productive interaction 
between HS2 enhancer and the promoter cannot occur. It is also possible that v-ErbA 
interacts with and stabilises a corepressor complex, thus inhibiting the assembly of the 
HS2-enhanceosome. v-ErbA may also stabilise repressor complexes formed on the 
promoter. This hypothesis is supported by our findings that v-ErbA interacts with 
NCoR in immunoprecipitation assays in v i tro . Inhibition of HDAC activity does not 
relieve repression by HS2 in transfection assays, whereas endogenous CA II mRNA is 
avidly upregulated. Supposing that NCoR is the platform for a complex tethered by v­
ErbA, one can speculate that v-ErbA stabilises a NCoR/HDAC-containing complex 
formed at the promoter region. In the proximity of the CA II promoter there is a CpG 
island that may be methylated in the AEV transformed cells by the MeCP2 repressor 
(Antequera et al., 1990; Cameron et al., 1999; Issa et al., 1994; reviewed in Jones and 
Wolffe, 1999; Razin, 1998). Thus, it is not unreasonable to speculate that v-ErbA
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interacts and facilitates the function of the MeCP2 repressor protein present in the 
vertebrate HDAC complex (Jones et al., 1998; Nan et al., 1998). Our findings that v­
ErbA cannot convey active repression to the VRE unless it is in the context of HS2 
suggests that a combination of factors and pathways might be in place for the 
regulation of CA II transcription (Figure 1).
P300/CBP and/or TRAP
1 2  3 4
CpG-ísland Exons GATA'1 v-ErbA Exons
Figure 1 Model for regulation of CA II gene transcription by v-ErbA. v-ErbA quenches the 
activity of GATA-factors bound to the HS2 that are responsible for the erythroid-specific 
activation of CA II gene transcription. v-ErbA also occludes liganded TR from binding to the 
CA II-VRE thus preventing the assembly of the HS2 enhanceosome. In addition, v-ErbA may 
contribute to the activity of a corepressor complex formed on the promoter perhaps by being 
involved in the stabilisation/function of MeCP2 complex bound on the CpG islands of the CA 
II promoter. Whether a corepressor complex containing NCoR/SMRT and HDACs is 
involved in any of these activities of v-ErbA remains to be shown.
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4. Implications
During tumor development multiple pathways appear to be deregulated implicit 
to the fact that cells have multiple mechanisms to regulate their growth and 
differentiation and that several separate changes may be required to bypass these 
controls. Inherent to their crucial role, class II nuclear receptors are important targets 
for impairment during neoplasia and their inactivation might represent a critical step in 
multistage processes leading to carcinogenesis. The chicken v-ErbA system has long 
been and still is a paradigm, and results obtained in this system have guided studies on 
hematopoiesis as well as on malignancies in other organisms. Undoubtedly, further in 
depth investigations in the v-ErbA model system will help elucidating the general 
mechanisms leading to oncogenic transformation, and to develop drugs to stop tumor 
progression, to induce apoptosis or to trigger differentiation of tumor cells.
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SUMMARY
Thyroid hormone (T3) exhibits a vast array of profound effects on homeostasis, 
development, amphibian metamorphosis, differentiation and neoplasia. The action of 
T3 is mediated via its binding to the cognate thyroid hormone receptor (TR). TR in 
turn binds to specific DNA sequences called thyroid responsive elements (TREs). TR 
in the presence of T3 activates transcription while unliganded TR leads to repression. 
TR is expressed in many different tissues and utilises a multitude of mechanisms to 
regulate transcription. The v-ErbA oncoprotein is a mutated viral variant of TRa and 
is encoded by the Avian Erythroblastosis virus (AEV). AEV encodes for another 
oncogene, v-ErbB, which is a constitutively activated EGF receptor with tyrosine 
kinase activity. The co-operation of the two oncogenes leads to fatal erythroleukemia 
as a result of enhanced proliferation and arrest of differentiation of the AEV- 
transformed erythroblasts. Due to mutations, v-ErbA cannot bind T3 hormone and thus 
it cannot activate transcription like its cellular counterpart. It is now widely accepted 
that the contribution of v-ErbA to leukemia is due to its ability to constitutively repress 
transcription of certain erythroid genes such as carbonic anhydrase II (CA II). 
However, the molecular mechanisms employed by v-ErbA to repress transcription 
have remained largely obscure. The hypothesis that v-ErbA behaves as a constitutive 
unliganded TR is attractive but not consistent with a number of experimental 
observations.
In the studies described in this thesis we set out to assess how v-ErbA regulates 
the transcription of the CA II gene. Using DNase I hypersensitive site mapping we 
have identified two hypersite regions (designated HS1 and HS2) as prime candidate 
regions for transcriptional regulation of the CA II gene (chapter 2). HS1 is located 7 
kb upstream of the transcription start site while HS2 is located 8 kb downstream of the 
promoter within the second intron. Immunoprecipitation of v-ErbA/DNA complexes 
and in vitro footprinting experiments demonstrated that the intronic HS2 region has a 
binding site for v-ErbA. In vivo footprinting experiments showed that an unliganded 
class II nuclear receptor, v-ErbA binds to a v-ErbA responsive element (VRE) 
embedded into chromatin. Interestingly, the in vivo occupancy of the VRE by v-ErbA 
coincides with CA II repression while a loss of the VRE protection occurring upon
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induction of differentiation correlates with CA II upregulation. Using mutagenesis 
analysis and transfection experiments, we showed that HS2 behaves as a potent 
enhancer that is repressed by v-ErbA.
Detailed mutation analyses (chapter 3) demonstrated that the HS2 region 
activates transcription independent of the position and the orientation relative to the 
heterologous tk as well as the homologous CA II promoters, thus identifying HS2 as a 
bona fide  erythroid-specific enhancer. Additionally, we demonstrated that the 
enhancer activity of HS2 is governed by erythroid-specific factors that bind to two 
adjacent DNA motifs with GATA sequence located 5’ to the VRE, which constitute 
binding sites for the GATA-factors. Thus, v-ErbA appears to neutralise the positive 
activity of erythroid GATA-factors bound to the HS2. Quenching of GATA-factors is 
observed with unliganded TR as well.
In chapter 2 we showed that the chromatin architecture of HS2 can be 
modulated by liganded TR in erythroid progenitor cells that express gag-TRa to levels 
equivalent to v-ErbA (HD3V3 cells). These findings are consistent with studies 
showing that TR instigates chromatin changes upon ligand activation. We show that 
overexpressed TR binds to the HS2-VRE as an RXR-TR heterodimer in vitro and 
conveys transcriptional activation upon addition of ligand in vivo. Full activation as 
defined by a HS2-containing construct carrying a mutation in the VRE that abolishes 
v-ErbA binding, could however not be accomplished. Our data corroborate the notion 
that v-ErbA occludes liganded TR from binding to VRE resulting in ablation of the 
T3-induced activation. This feature of v-ErbA correlates very well with its observed 
oncogenic activity (chapter 3). We show in addition that occlusion of liganded TR by 
v-ErbA in vivo depends largely on the sequence of the DNA responsive element, 
suggesting that v-ErbA and TR responsive elements (VREs and TREs) are not 
necessarily the same.
Comparison of the repressive activities of v-ErbA and unliganded TR via the 
VRE element (chapter 3) uncovered an unexpected and intriguing observation. The v- 
ErbA oncoprotein is unable to repress the intrinsic tk promoter activity while 
unliganded TR can efficiently repress it. Given that repression of CA II transcription is 
important for the v-ErbA induced leukemic phenotype, this lack of repression by v- 
ErbA versus unliganded TR may be part of its oncogenic activity.
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In chapter 4 we started to address the question whether the presumed 
corepressor complex containing NCoR/SMRT and HDAC (and possibly SIN3) binds 
to v-ErbA enabling its repressive function in vivo. Using immunoprecipitation assays 
we showed that v-ErbA can indeed interact with endogenous NCoR. Because the C- 
terminus of NCoR (C-NCoR) does not comprise silencing functions but can still 
interact with nuclear receptors, it was anticipated that overexpression of C-NCoR 
would interfere with v-ErbA/NCoR interaction and ultimately would result in relief of 
transcriptional repression mediated by v-ErbA, Using HD3 cells stably overexpressing 
C-NCoR, a functional interference of the presumed dominant negative corepressor 
could however not be observed. In addition, the overall phenotype of the cells was not 
affected by overexpression of C-NCoR, suggesting that under the tested conditions 
NCoR is not crucial for the v-ErbA mediated repression. These data question the 
generally accepted but not proven model that corepressors are essential for the 
repressive functions of nuclear receptors.
Our studies have provided new insight into the mechanism of the v-ErbA- 
mediated transcriptional repression. Further in vivo investigations may shed light on 
the role of v-ErbA in leukemic transformation.
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Samenvatting
Thyroid hormoon heeft een aantal duidelijke functies gedurende homeostase, 
ontwikkeling, amfibische metamorfose, differentiatie en tumorigenese. De thyroid 
hormoon receptor (TR) komt tot expressie in een groot aantal verschillende weefsels 
wat suggereert dat het transcriptie kan reguleren via verschillende mechanismen. Het 
v-ErbA oncoproteïne is een gemuteerde virale variant van TRa en wordt gecodeerd 
door het ‘Avian Erythroblastosis Virus’(AEV). AEV codeert ook voor een ander 
oncogen, v-ErbB, een constitutief actieve EGF receptor met tyrosine-kinase activiteit. 
De samenwerking tussen deze twee oncogenen leidt tot fatale erythroleukemie als 
gevolg van een verhoogde proliferatie en een differentiatieblok van de AEV 
getransformeerde erythroblasten. Als gevolg van een aantal mutaties kan v-ErbA 
thyroid hormoon (T3) niet meer binden en kan het daarom transcriptie niet meer 
activeren, zoals zijn cellulaire tegenhanger wel kan. Het wordt nu alom geaccepteerd 
dat de bijdrage van v-ErbA aan leukemie het gevolg is van het vermogen van v-ErbA 
om constitutief de expressie van bepaalde erythroïde genen te onderdrukken, zoals 
carbonic anhydrase II (CA II). De mechanismen van transcriptionele repressie door v­
ErbA zijn tot nu toe grotendeels onduidelijk gebleven. De hypothese dat v-ErbA zich 
gedraagt als een constitutieve receptor zonder hormoonbinding is aantrekkelijk maar 
niet consistent met een aantal experimentele observaties.
In de studies die worden beschreven in dit proefschrift hebben we geprobeerd 
vast te stellen hoe v-ErbA transcriptie van het CAII gen reguleert. Gebruikmakend van 
‘DNaseI hypersensitive site mapping’ hebben we twee DNaseI hypersensitieve regios 
(HS1 en HS2) geïdentificeerd als belangrijkste kandidaten voor de regulatie van CAII 
transcriptie (Hoofdstuk 2). HS1 is 7 kb bovenstrooms van de CAII 
transcriptiestartplaats gelokaliseerd, HS2 8 kb benedenstrooms van de promoter in het 
tweede intron. Een combinatie van immunoprecipitaties van v-ErbA/DNA complexen 
en in vitro  footprint experimenten toonden aan dat de HS2 regio een bindingsplaats is 
voor v-ErbA. In vivo  footprint experimenten lieten zien dat een klasse II nucleaire 
receptor zonder hormoon, v-ErbA, bindt aan een ‘v-ErbA responsive element’ (VRE) 
in het chromatine. De in vivo  binding van v-ErbA valt samen met repressie van het 
CAII gen, terwijl het verlies van protectie van de VRE na inductie van differentiatie
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samenvalt met CAII activering. Gebruik makend van mutagenese- en transfectie- 
experimenten konden we aantonen dat de HS2 zich gedraagt als een sterke enhancer 
waarvan v-ErbA de activiteit onderdrukt.
Gedetailleerde mutatie analyse (Hoofdstuk 3) demonstreerde dat de HS2-regio 
transcriptie kan activeren onafhankelijk van de positie en de oriëntatie t.o.v. de 
heterologe tk promoter en de homologe CAII promoter, wat aantoont dat HS2 als een 
bonafide erythroid-specifieke enhancer kan functioneren. Daarnaast toonden we ook 
aan dat de enhancer activiteit van de HS2 wordt veroorzaakt door erythroid-specifieke 
factoren die binden aan twee GATA-factor bindingsplaatsen die aan de 5’- kant van de 
VRE grenzen. v-ErbA lijkt de positieve activiteit van deze erythroid-specifeke GATA- 
factoren te neutraliseren. Ook TR zonder hormoon is in staat tot neutralisatie van de 
activiteit van deze GATA factoren.
In Hoofdstuk 2 tonen we aan dat de chromatine architectuur van de HS2 
gemoduleerd kan worden door hormoongebonden TR in erythroïde voorloper cellen 
die gag-TRa even hoog tot expressie brengen als v-ErbA (HD3-V3 cellen). Deze 
resultaten zijn in overeenstemming met een aantal studies die laten zien dat TR 
chromatine veranderingen induceert na activering door hormoon. We toonden ook aan 
dat TR dat tot overexpressie wordt gebracht aan de HS2-VRE bindt als een RXR-TR 
heterodimeer en transcriptie kan activeren na de toevoeging van hormoon. Maximale 
activering, zoals bij een HS2 bevattend construct met een mutatie in de VRE waardoor 
v-ErbA niet meer kan binden, kon echter niet worden bereikt. Onze data dragen bij aan 
de hypothese dat v-ErbA hormoon-geactiveerde TR van de VRE kan verdringen wat 
resulteert in inhibitie van thyroid hormoon geïnduceerde activering. Deze eigenschap 
van v-ErbA correleert goed met zijn oncogene capaciteit (Hoofdstuk 3). We toonden 
ook aan dat competitie van v-ErbA en TR voor een bindingsplaats in vivo  grotendeels 
afhankelijk is van de nucleotidevolgorde van het bindingselement, wat suggereert dat 
v-ErbA en TR ‘responsive elements’ (VRE en TRE) niet noodzakelijkerwijs dezelfde 
elementen zijn.
Het vergelijken van de repressie door v-ErbA en niet-hormoongebonden TR op 
een VRE element (Hoofdstuk 3) toonde een onverwachte en interessante eigenschap 
aan. Het v-ErbA oncoproteïne is niet in staat om de tk promoteractiviteit te 
represseren, terwijl TR zonder hormoon dit wel kan. Gegeven het feit dat repressie van
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CAII transcriptie belangrijk is voor het v-ErbA geïnduceerde fenotype, suggereert dit 
dat dit onvermogen tot repressie door v-ErbA ten opzichte van TR deel kan zijn van 
zijn oncogene activiteit.
In Hoofdstuk 4 zijn we begonnen de vraag te beantwoorden of het corepressor 
complex dat NCoR/SMRT en HDAC (en mogelijk SIN3) bevat, v-ErbA bindt en 
repressie door dit eiwit mogelijk maakt in vivo. In immunoprecipitaties lieten we zien 
dat v-ErbA inderdaad endogeen NCoR kan binden. Omdat de C-terminus van NCoR 
(C-NCoR) geen ‘silencing’-functies heeft maar nog steeds nucleaire receptoren kan 
binden, werd verwacht dat overexpressie van C-NCoR zou interfereren met endogene 
v-ErbA/NCoR interacties wat uiteindelijk zou resulteren in derepressie door v-ErbA. 
Een dominant-negatieve functie voor C-NCoR in cellen die dit eiwit stabiel tot 
expressie brengen kon echter niet worden aangetoond. Daarnaast was het fenotype van 
de cellen onveranderd door overexpressie van C-NCoR, wat suggereert dat onder de 
geteste condities NCoR niet essentieel is voor v-ErbA geïnduceerde repressie. Deze 
data trekken het algemeen geaccepteerd maar niet bewezen model in twijfel dat 
corepressoren essentieel zijn voor repressie door nucleaire hormoonreceptoren.
Onze studies hebben nieuwe inzichten verschaft op het gebied van v-ErbA 
geïnduceerde transcriptionele repressie. Verder in vivo  onderzoek kan mogelijk meer 
duidelijkheid brengen in de rol van v-ErbA in het ontstaan van leukemie.
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